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1. Summary 
Clostridium difficile is a Gram-positive, anaerobic, endospore-forming bacterium that produces 
several virulence factors, most prominently the secreted protein toxins Toxin A (TcdA) and 
Toxin B (TcdB). Clostridium difficile infections (CDI) are often hospital acquired and antibiotic-
associated. Treatment of CDI currently involves taking broad-spectrum antibiotics, e.g. 
vancomycin. Due to the extremely high relapse rate of CDI after antibiotic treatment, the 
emergence of new highly virulent C. difficile strains and the threatening antibiotic resistance, 
the need for new therapeutic treatment methods for CDI is more urgent than ever before. To 
develop new therapeutics, a detailed knowledge of the molecular processes inside the 
pathogen as well as a comprehensive structural and functional knowledge of its virulence 
factors and proteins involved in infection is essential. Aim of this thesis was therefore the 
structural characterization of the main virulence factor TcdB and of proteins that are involved 
in basic cellular processes, i.e. growth and sporulation, of Clostridium difficile. 
The main virulence factor of Clostridium difficile, TcdB, belongs to the family of large clostridial 
toxins (LCTs) and consists of four functional domains, which mediate the mechanism of action. 
Via its receptor binding domain, the toxin binds to the host cell surface and is internalized via 
endocytosis. Acidification of the endosome causes conformational changes in the TcdB 
intermediate translocation domain, whereupon hydrophobic parts of this domain insert into the 
endosomal membrane and form a pore. Through this pore, the N-terminal glucosyltransferase 
domain is transferred into the host cell cytosol, where it inactivates host GTPases by 
glucosylation. Upon inactivation of these GTPases, several downstream signaling processes 
are disturbed, which can lead to inflammation response and cell death. 
Other research groups have already published several structures of individual TcdB domains, 
e.g. the autoprotease and the glucosyltransferase domain. However, crystal structures of the 
translocation domain and of full-length TcdB were still missing. The aim of this project was a 
structural characterization of the translocation domain and full-length TcdB to get insights into 
the atomic structure and the translocation process of the virulence factor. Several constructs 
including full-length TcdB as well as truncated TcdB fragments were cloned for purification and 
crystallization experiments. However, protein crystallization of these constructs was not 
successful. In parallel, SAXS (small angle X-ray scattering) experiments of some TcdB 
constructs were performed to reveal the overall shape of the TcdB translocation domain. The 
calculated SAXS envelope shows high similarity to the TcdA translocation domain. This 
reveals that, besides their high sequence similarity, TcdA and TcdB share also a high structural 
similarity. 
A second project of this thesis involved the functional and structural characterization of 
Clostridium difficile proteins that are essential for growth or sporulation of the pathogen in vitro 
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(Dembek et al., 2015). Five functionally and structurally uncharacterized proteins (CD1067, 
CD1219, CD1823, CD2589 and CD2752) were selected with the objective of finding novel 
protein folds and potential drug targets for CDI treatment. Several constructs of all five proteins 
were cloned, expressed in E. coli and purified. Pure protein samples were used for 
crystallization experiments.  
SAXS experiments revealed that CD1219 is present as a dimer in solution. The crystal 
structure of dimeric CD1219 could be determined by SeMet-SAD (single wavelength 
anomalous diffraction) to 1.8 Å resolution and reveals that the monomer of CD1219 consists 
of two domains. The large C-terminal domain shows structural similarities to P-loop GTPases 
and includes several secondary structure motifs and conserved residues that are essential for 
GTP binding. Its small N-terminal domain shares an OB-fold, which is characteristic for 
oligonucleotide-binding proteins, such as IF1s and cold-shock proteins. Nevertheless, further 
biochemical experiments are necessary to confirm DNA-/RNA- binding to the small N-terminal 
domain and GTP-binding to the large C-terminal domain of CD1219.  
The crystal structure of CD1823 was solved by molecular replacement to 1.9 Å using the 
crystal structure of the H2O2 stress response protein YaaA from E. coli as a model. CD1823 
shows a compact protein structure without characteristic conserved secondary structure 
motifs. Comparison with homologous proteins and analysis of the operon architecture of 
CD1823 reveals that the protein could be involved in peroxide stress response. SAXS analysis 
showed that it is monomeric in solution, but the structural analysis of CD1823 revealed no 
obvious hypotheses concerning its molecular function. Hence, further experiments are 
necessary to reveal the function of CD1823. 
The crystal structures of the other three selected proteins (CD1067, CD2589, CD2752) could 
not be determined in this thesis due to challenges during protein purification, deficient crystal 
growth or insufficient diffraction quality of the protein crystals. Various attempts such as buffer 
optimization by TDSA (thermal denaturation shift assay), crystal optimization using grid 
screens or SER (surface entropy reduction) yielded only slight improvements. 
Another part of this thesis dealt with the structural characterization of the diffocin proteins of 
Clostridium difficile. The diffocin particle is a contractile, bacteriophage-tail like bacteriocin. It 
consists of an outer contractile sheath and an inner non-contractile tube. Upon SOS-response, 
the diffocin particles are released by bacterial lysis, whereupon they can attack other C. difficile 
strains in the environment. After binding to the host cell, the diffocin sheath is contracted and 
the tube is pushed through the host cell membrane, which creates a small pore. This pore 
formation results in disturbance of the membrane potential, upon which the bacterial host cell 
is killed. 
Both diffocin sheath and tube are built of multiple copies of one single protein, the sheath 
protein CD1363 and the tube protein CD1364. In this thesis, the crystal structures of both 
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proteins were determined to 1.9 and 1.5 Å resolution, respectively. Both proteins show high 
structural similarity to other bacteriophage-like proteins, e.g. the pyocin proteins of 
Pseudomonas aeruginosa. Based on homology of these related proteins, a model of the 
diffocin particle was created in this thesis. 
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2. Introduction 
2.1. The pathogenic bacterium Clostridium difficile 
Clostridium difficile is an anaerobic, Gram-positive, spore-forming bacterium that is widespread 
in nature and was first described in 1935 as an “actively motile, heavy-bodied rod with 
elongated subterminal or nearly terminal spores” (Hall & 
O’Toole, 1935). It can be found in the soil but is also present 
in the intestine of animals and humans. There, it can cause 
life-threatening infections, making it a huge hazard for the 
population. In 2011, 29.000 deaths associated with 
Clostridium difficile infections were registered in the USA 
(Center for Disease Control, U.S.). It is assumed that more 
than 65.000 CDI cases exist in Germany per year (Lübbert 
et al., 2016). In the last years new epidemic C. difficile 
strains were detected in North America and Europe, which 
show increased toxicity and mortality (Kuijper et al., 2006).  
Most Clostridium difficile infections (CDI) are hospital-acquired or antibiotic-associated. Due to 
its spore-forming ability, the pathogen can survive on hospital surfaces for a long time, as 
C. difficile spores are extremely resistant to heat- or alcohol-based standard disinfectant 
treatments (Paredes-Sabja et al., 2014). Furthermore, the spores and the bacterium can be 
transferred via the oral-fecal route between clinical staff and patients, which is a problem 
especially for elderly people (Martin et al., 2016). As people > 65 years are more often in 
contact with hospital areas and the microbiome and physical condition changes upon age, they 
are more often infected with C. difficile than younger people (Jump, 2013). 
Apart from long-term hospital stays, antibiotic treatments are an additional risk factor for CDI. 
Usually, the pathogen is outcompeted by other bacteria in the human gut. After disturbance of 
the microbiota, especially after treatment with broad-spectrum antibiotics (e.g. clindamycin), 
the majority of the human microflora is wiped out. Ingested spores can germinate and due to 
its resistance to antibiotics, C. difficile can colonize the human colon. The bacterium multiplies 
and releases its main virulence factors, the protein toxins, which cause major tissue damage 
and are the origin of the disease symptoms (Wilson, 1993). 
Symptoms of C. difficile associated infections can range from mild diarrhea and fever to even 
life-threatening infections with a high death rate, such as toxic megacolon or 
pseudomembranous colitis (PMC) (Kuijper et al., 2006). PMC is characterized by plaques (so-
called pseudomembranes) in the mucosa of the colon (Bartlett et al., 1978). 
 
Figure 1: Electron microscopic 
image of Clostridium difficile (M. 
Rohde/HZI, M. Jahn/TU 
Braunschweig) 
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Due to the emergence of new highly virulent strains, the usually high antibiotic resistance of 
C. difficile and the high relapse rate of C. difficile-associated infections, there is an urgent need 
for new treatment methods (Smits et al., 2016). 
 
2.2. Virulence factors of Clostridium difficile 
The main virulence factors of C. difficile are the two secreted protein toxins, TcdA and TcdB. 
They belong to the family of large clostridial toxins (LCT) and are the causative agents of CDI 
(Awad et al., 2014). More details about the protein toxins of Clostridium difficile can be found 
in chapter 6.1. 
Besides the homologous protein toxins, the pathogen possesses several further virulence 
factors. As it colonizes the gut of animals and humans, many different virulence factors are 
involved in adhesion to host cells and colonization processes. Among these are flagella 
(Delmee et al., 1990), which facilitate the accelerated and directed movement of the bacterium 
to the host cell and to the site of infection, as well as S-layer proteins (Karjalainen et al., 2001) 
and adhesins (Waligora et al., 2001), which enable adhesion to host-cell surfaces and 
colonization of the host. 
 
2.3. Sporulation of Clostridium difficile 
Anaerobic bacteria such as C. difficile usually cannot survive in an aerobic environment 
outside the host because they cannot tolerate the oxygenic environment. Also, in the host 
stomach the bacterium has to cope with a hostile environment due to the low pH. A route to 
endure these extreme conditions is to form resistant spores, which enable the bacterium to 
survive in these environments for a long time (Paredes-Sabja, et al., 2014). It could be shown 
that C. difficile strains that are unable to form spores are also not able to survive in an 
environment outside the host (Deakin et al., 2012). Furthermore, spores are resistant to 
antibiotics and attacks from the immune system (Ali et al., 2011). Thus, the spores of 
Clostridium difficile are considered to be the infectious form of the pathogen. 
It is assumed that different environmental factors trigger sporulation in Clostridium difficile, 
such as starvation or quorum sensing (Higgins & Dworkin, 2012). In most Clostridium species, 
the regulation of sporulation involves phosphorylation of Spo0A, the master regulator of 
sporulation, by histidine kinases (Steiner et al., 2011). C. difficile spores are usually 
incorporated into the host via the oral-fecal route. They germinate in the host gut in presence 
of primary bile acids (e.g. taurocholate, cholate). This process is further supported by L-glycine 
(Sorg et al., 2008 and Wheeldon et al., 2011), which is recognized by the receptor CspC 
(Francis et al., 2013). The spore coat is then degraded due to proteolysis by serine proteases 
(Adams et al., 2013). This leads to the release of calcium dipicolinic acid, resulting in complete 
core hydration, outgrowth of vegetative cells and colonization of the host intestine (Paredes-
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Sabja et al., 2014; Bhattacharjee et al., 2015). The vegetative cells can then produce toxins, 
the prominent virulence factors of Clostridium difficile. However, the exact mechanism and 
regulation of spore formation, germination and interaction with the host is still unknown. 
 
2.4. Treatment of Clostridium difficile-associated infections 
The standard therapy of C. difficile infections usually involves the administration of broad-
spectrum antibiotics (e.g. metronidazole, vancomycin), but the relapse rate of CDI after taking 
these antibiotics is around 20% (Eyre et al., 2012). The infections reoccur usually 1-3 weeks 
after the antibiotic administration was stopped, but relapse after a few months has also been 
observed (Choi et al., 2011). The particular reasons for the recurrence of CDI are not known 
(Fekety et al., 1997), but risk factors for CDI recurrence are e.g. high age of patients 
(McFarland et al., 1999), use of fluorochinolones (Cadena et al., 2010), proton-pump inhibitors 
and a low level of serum albumin (Kim et al., 2010). 
However, some new additional therapeutic treatment methods currently gain more and more 
popularity. One alternative to broad-spectrum antibiotics is the more specific antibiotic 
fidaxomicin (Vaishnavi, 2015). Furthermore, neutralizing human monoclonal antibodies are 
already in phase III clinical studies. Bezlotoxumab, a monoclonal TcdB-neutralizing antibody, 
has already been approved by the FDA (Food and Drug Administration) to support antibiotic 
treatment of CDI, in order to prevent recurrence of infection (Wilcox et al., 2017). By binding 
to the CROPs region of TcdB, Bezlotoxumab prevents toxin binding to host cell surfaces and 
neutralizes toxicity in vitro (Orth et al., 2014). Another promising therapy option is fecal 
microbiota transplantation. This technique involves the infusion of the stool of a healthy person 
in the gastrointestinal tract of a patient suffering from CDI. The disturbed microflora of the 
patient is regenerated by the microflora of a healthy person by defeating the pathogen. 
Unfortunately, long-term studies of this relatively new technique are currently not available and 
only few hospitals support this procedure (Lee et al., 2015; Kelly & Tebas, 2018). 
Treatment of CDI might also involve small-molecule inhibitors (Slater et al., 2013). A few 
inhibitors are on their way and have already been FDA-approved. Among those is Ebselen, a 
compound that blocks the autoprotease domain of TcdB. A study shows reduced tissue 
damage in a mouse infection model upon infection with C. difficile and treatment with Ebselen 
(Bender et al., 2015). The compound further leads to inactivation of NADPH oxidase 1 activity 
(Smith et al., 2012), which reduces the toxin-induced production of reactive oxygen species. 
Another promising compound is the antioxidant N‑acetylcysteine, which prevents TcdB-
induced tissue damage in a colonic explant model (Farrow et al., 2013). 
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3. Research Objectives 
Clostridium difficile is a pathogen that can cause life-threatening infections. Therapy of these 
infections is currently extremely problematic due to the ease of spread of the bacterium, its 
antibiotic resistance and the recurrence of infections after antibiotic treatment. Therefore, the 
need for new therapeutic treatment methods is very urgent. To develop new drugs, it is 
essential to obtain a detailed understanding of the molecular processes inside the pathogen 
and the mechanisms and structures of its virulence factors. To enlighten the details of 
molecular processes of C. difficile, one has to analyze the structure and function of essential 
proteins that are involved in central metabolic pathways. The aim of this thesis is therefore to 
characterize virulence factors, essential proteins and the diffocin proteins of Clostridium difficile 
structurally. The crystal structures can then be used to derive initial ideas about the molecular 
function of the respective proteins and can be considered as a basis for the development of 
new therapeutic treatment methods for CDI. 
1. Structural analysis of TcdB 
The secreted protein toxin TcdB is one of the main virulence factors of Clostridium 
difficile. The crystal structures of some domains of TcdB have already been published, 
but the crystal structure of full-length TcdB and of its intermediate translocation domain 
were unknown at the outset of this thesis. To get a detailed insight into the translocation 
process and pore formation of the toxin, it is essential to determine the structure of its 
intermediate translocation domain. The crystal structure of full-length TcdB and its 
translocation domain could pave the way for designing new drugs that target the 
translocation domain specifically in order to inhibit toxin translocation and therefore 
prevent infection of the host. Consequently, one aim of this thesis was to determine the 
crystal structure of the intermediate TcdB domain by crystallographic methods, either 
with the full-length toxin or with fragments containing the entire intermediate domain or 
parts of this domain. 
2. Structural and functional studies of proteins involved in growth or sporulation of 
Clostridium difficile 
Structural and functional analysis of uncharacterized proteins that are involved in 
central metabolic processes can aid the identification of new potential drug targets. A 
recently published genome-wide study using transposon mutants identified several 
proteins that are involved in growth or sporulation of Clostridium difficile in vitro 
(Dembek et al., 2015). Since several of these proteins are structurally uncharacterized, 
they do most probably not belong to a common, well-characterized protein family. A 
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detailed structural characterization of these proteins could hence lead to identification 
of new potential drug targets for CDI therapy. Some of these uncharacterized proteins 
have therefore been selected for this thesis with the aim to characterize the proteins by 
crystallographic methods. 
3. Structure determination of diffocin proteins 
Diffocin particles are high-molecular weight bacteriocins that specifically kill other 
C. difficile strains in the environment of the diffocin-producing bacterium. Based on their 
architecture, diffocin particles share similarities to bacteriophage tails. They are 
assembled by several structural components and consist of a tail, which is composed 
of a contractile sheath and an inner rigid tube. The diffocin target specificity is 
determined by the receptor binding proteins. By engineering diffocins, one can direct 
the particles to target individual strains. Therefore, they are treated as a potential novel 
therapy for CDI. A structural characterization of the diffocin proteins can ease the 
process of diffocin engineering for therapeutic purposes. As structural data for the 
diffocin proteins have not been available at the beginning of this thesis, they should be 
characterized by crystallographic methods in this thesis. 
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4. Principles of X-ray crystallography 
Protein X-ray crystallography was used for structure determination of proteins involved in 
disease and infection processes of Clostridium difficile in this thesis. The structural analysis of 
a protein can also help to derive ideas about its potential function and to get a detailed insight 
into its molecular mechanism. X-ray crystallography is therefore an important tool for the 
structural as well as the functional characterization of proteins. 
 
4.1. Crystallization of proteins 
To determine the three-dimensional structure of a protein by X-ray crystallography, the protein 
has to be crystallized. Protein crystallization is achieved by transition of the protein sample 
from the liquid into the crystalline phase. This transition is described by a so-called phase 
diagram, which is exemplarily shown in Fig. 2 (Asherie, 2004). The phase diagram is a two-
dimensional plot of the protein concentration against precipitant concentration. It can be 
divided in three parts: the stable, metastable and unstable zone. In the stable zone, the protein 
is present in soluble form in solution. No crystal growth will take place. By transition above the 
solubility curve (blue line in Fig. 2), the protein reaches the metastable zone. This is typically 
achieved by incubation of the protein with precipitant solution, as this decreases the protein 
solubility. In the metastable region, spontaneous crystal growth can occur due to phase 
separation and spontaneous formation of nuclei. In the nucleation zone, supersaturation of the 
protein sample is high enough for crystal growth and spontaneous nucleation can take place. 
In the unstable region, also called precipitation zone, supersaturation (e.g. due to high 
precipitant concentration) of the sample leads to protein precipitation (Rupp, 2015). 
 
Figure 2: Schematic overview of protein crystallization. (A) A crystallographic phase diagram illustrates the state of 
the protein sample as a function of precipitant and protein concentration. The different zones (stable, metastable 
and unstable) are separated by a blue and red line, respectively. The blue line illustrates the solubility line and 
describes the transition of the protein from the soluble into the metastable zone. This transition is essential for 
nucleation and crystal formation. (B) Different methods of protein crystallization-set ups are depicted: hanging-drop 
and sitting-drop vapor diffusion, microbatch under oil and microdialysis. The figure is adapted from Rupp, 2009. 
Reproduced with permission from Biomolecular Crystallography by Bernhard Rupp, © 2009-2014 Garland 
Science/Taylor & Francis LLC.  
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Therefore, it is important to determine a suitable composition of precipitant solution and an 
appropriate crystallization setup for controlled crystal growth. Protein crystallization is 
influenced by several further parameters. An essential requirement for protein crystallization is 
a high sample purity and in most cases a high protein concentration (5 - 30 mg/ml). 
Temperature, pH, reservoir composition and concentration can also affect crystal growth. 
There are several different crystallization setups for protein crystallization. In this study, the 
sitting-drop vapor-diffusion method was used. Protein and reservoir (precipitant) solution are 
usually mixed in a 1:1 ratio and incubated in a chamber above the precipitant-containing 
reservoir solution as a “sitting drop”. As the protein drop contains less precipitant solution 
compared to the reservoir, water diffuses from the protein drop into the reservoir solution in a 
closed system to compensate this imbalance. Hence, the protein and precipitant concentration 
in the drop increase and transition of the protein from the soluble into the metastable phase is 
initiated (Rupp, 2009). 
As it is dependent on many different parameters, protein crystallization is an unpredictable 
process. It can sometimes take weeks or months, but does not have to be successful at all. It 
is therefore important to monitor the crystallization setup continuously over time until crystal 
growth is observed. 
 
4.2. Diffraction of X-rays and data collection 
Once single protein crystals of suitable size (50 - 500 µm) are obtained, diffraction experiments 
can be performed. Prior to data collection, cryoprotection of the crystal is important to avoid 
ice formation, which can result in destruction of the crystal arrangement and can lead to loss 
of diffraction quality (Haas & Rossmann, 1970; Garman, 2003). The use of cryoprotectants, 
such as glycerol or 2,3-butanediol, is usually dependent on the reservoir composition and the 
amount of cryoprotectant solution has to be determined for each crystal individually. However, 
some crystallization conditions do not require the use of additional cryoprotectants, as latter 
are already included in the reservoir solution. The crystals can then be fished directly from the 
crystallization screen using nylon loops and need to be flash-cooled in liquid nitrogen 
immediately. 
After cryoprotection and harvesting, the crystal is mounted in the X-ray beam on a goniometer 
in front of the X-ray source. A schematic experimental setup is illustrated in Fig. 3. It usually 
includes an X-ray source for generation of a focused X-ray beam of specific wavelength and a 
goniometer head for crystal mounting. A cryocooling system with a nitrogen gas stream at 
100 K protects the crystal from radiation damage upon formation of radicals during data 
collection. The detector, which is required for collection of the diffraction pattern, and a beam 
stop, which prevents the detector from damage by non-diffracted X-rays, are located behind 
the goniometer (Rhodes, 2006). 
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Figure 3: Experimental setup of an X-ray diffraction experiment. The X-ray source produces a focused X-ray beam 
of a certain wavelength that hits the crystal, which is mounted on a goniometer head. The diffracted X-rays are 
recorded on a detector. A beam stop is essential to prevent damage of the detector by non-diffracted intense X-
rays. 
 
X-rays of a certain wavelength are used for protein X-ray diffraction experiments. The 
resolution of a protein structure is determined by the minimal distance between two points that 
can be clearly separated from each other and is dependent on the wavelength of the used 
light. As the bond length between two atoms is usually in the range of a few Å, X-rays with a 
wavelength of ~ 0.1 - 100 Å are used for X-ray crystallography to resolve a protein structure at 
the molecular level (Rupp, 2009). 
As X-rays are only weakly diffracted by a single protein molecule, the diffraction signal has to 
be amplified. This is achieved by the use of a protein crystal, which includes identical copies 
of the protein in a regular periodic arrangement. When the X-rays hit the protein crystal, they 
are scattered by the electrons of the protein atoms, which are located on the lattice planes of 
the crystal. It is therefore assumed that the incoming X-rays are reflected at these planes 
(Fig. 4). Diffraction of the X-rays can be described by Bragg’s law (equation 1; Bragg, 1913). 
 
Figure 4: Schematic illustration of Bragg’s law. Two incident X-rays are reflected at the crystal planes with the 
distance dhkl by the angle θ. Constructive interference occurs, when dhkl is an integer of the wavelength λ. 
 
 ∙   2 ∙ sin 
 (1) 
In this equation, n is an integer, λ is the wavelength of the incoming electromagnetic wave, d 
is the distance between the planes in the crystal and θ is the diffraction angle of the X-ray. 
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When d is a positive integer of the wavelength λ, diffraction can be observed. This 
phenomenon is also called constructive interference. The scattered waves interfere 
constructively and the sum of their reflections is recorded on the detector. The waves that 
interfere destructively are cancelled out. This leads to a distinct diffraction pattern that consists 
of many single spots, the reflections. It contains information about the unit cell and spacegroup 
of the protein crystal. The intensity of the reflections gives information about the electron 
envelope of the protein. 
The diffraction pattern that is visible on the detector can be explained by transcribing Bragg’s 
law into the reciprocal space, which is inversely proportional to the real space. For this purpose, 
an Ewald sphere has to be calculated (Ewald, 1913). This is a three-dimensional sphere with 
the radius r = 1/λ centered on the crystal and is exemplarily illustrated in Fig. 5. The origin of 
the reciprocal crystal lattice is located in the intersection of the Ewald sphere with the direct 
X-ray beam. Bragg’s law is true for each lattice point that is located on the surface of the Ewald 
sphere. This indicates constructive interference and the respective point will be visible as a 
reflection on the detector. Due to rotation of the crystal during data collection, various lattice 
points will lie on the Ewald sphere and produce reflections on the detector. The diffraction 
pattern is therefore a direct projection of the three-dimensional reciprocal crystal lattice. Each 
diffraction point is described by its intensity, the Miller indices h, k, l of the reciprocal crystal 
lattice and is dependent on the diffraction angle θ (Foadi & Evans, 2008). 
 
Figure 5: Schematic representation of the Ewald sphere. The construction of an Ewald sphere (sphere with radius 
1/λ around the crystal) explains the diffraction pattern on the detector. In this figure, the protein crystal is depicted 
as a green cube, incident X-rays are diffracted by the crystal (red arrows). The reciprocal crystal lattice is illustrated 
by black dashed lines, the lattice points as green dots. Whenever a lattice point lies on the Ewald sphere (red dot), 
Bragg’s law is satisfied and this point is visible as a reflection on the detector due to constructive interference. 
Reproduced with permission from Biomolecular Crystallography by Bernhard Rupp, © 2009-2014 Garland 
Science/Taylor & Francis LLC. 
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4.3. Data processing and structure determination 
The diffraction pattern of the protein crystal is recorded on the detector during the diffraction 
experiment. The positions and intensities of the reflections have to be determined to calculate 
the desired electron density ρ(r), which is essential for structure determination. 
The processing of the dataset starts with indexing of the reflections. During this step, the unit 
cell parameters and the space group of the protein crystal are determined. Therefore, one 
needs to extract the reflection positions, as well as experimental data such as detector 
distance, wavelength and beam position from the dataset. Crystal orientation and possible 
spacegroups are proposed and the Miller indices for each reflection are assigned to describe 
the correct position of each reflection (Powell, 2017).  
The asymmetric unit (AU) is the smallest element that describes a crystal. By rotation and 
translation of the AU, the unit cell is created, which is characterized by one of the 14 Bravais 
lattices (Fig. 6). The lattice symmetry of the crystal is in turn defined by one of the 65 possible 
spacegroups. They describe the respective symmetry operators that are applied to construct 
the unit cell (Rupp, 2009). 
Figure 6: Organization of protein molecules in a crystal. (A) The unit cell is described by the unit lattice, which is 
filled with a protein motif. A crystal contains several copies of this unit cell that are arranged in the crystal lattice. 
(B) Overview of the six primitive three-dimensional crystal lattice types that are described by the vectors a, b, c 
and the angles α, β, γ. (C) Overview of the eight centered three-dimensional crystal lattice types, which result in 
14 possible Bravais-lattices in total together with the six primitive types. Reproduced with permission from 
Biomolecular Crystallography by Bernhard Rupp, © 2009-2014 Garland Science/Taylor & Francis LLC. 
 
During integration, the second step of data processing, the intensity of a specific region is 
measured in contrast to the background. Due to the crystal symmetry, one reflection will be 
measured several times concerning the different crystal orientations during rotation of the 
crystal in the beam. The next step of data processing is the reduction step. Thereby, the 
dataset is reduced to only one single intensity value per reflection. The following scaling step 
yields an averaged intensity value for each reflection, considering crystal morphology and 
beam intensity (Powell, 2017). 
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The electron density can then be calculated using the following equation: 
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 (2) 
In equation 2, V is the unit cell volume, Fhkl is the structure factor amplitude for each reflection 
and αhkl its associated phase. The electron density can hence only be calculated when 
amplitude and phase of each reflection are known. The amplitudes can be derived directly from 
the experimentally measured intensities Ihkl, as the intensities are proportional to the structure 
factor amplitudes (I = |Fhkl|2). However, the phase information is lost during the diffraction 
experiment. This is the so-called phase problem of X-ray crystallography (Rupp, 2009).  
Several methods can be used to solve the phase problem. Phases can for example be 
determined by Molecular Replacement (MR). For this method, one needs a protein model that 
shares a high sequence similarity with the uncharacterized protein. It is assumed that proteins 
that share at least 30% sequence identity adopt a similar fold. The structure of a similar protein 
can hence be used as a search model to solve the structure of a protein with unknown structure 
by MR. The phases of the search model will thereby give an estimation of the phases of the 
unknown protein. For MR, a dataset of the native protein crystal is collected and the unit cell 
is determined by processing the dataset analogous to the above description of data 
processing. The structure of the known protein is then placed in the unit cell of the unknown 
protein by rotational and translational search. Once in the correct position and orientation, 
phases of the known structure and intensities of the unknown structure are combined to 
calculate the electron density for the unknown protein structure (Evans & McCoy, 2007).  
When no suitable MR model is available for structure determination by MR, phases can also 
be determined experimentally. For experimental phasing, heavy atoms are introduced into the 
protein by expression of SeMet-labeled protein or by soaking heavy atoms, e.g. mercury or 
gold, into the protein crystal. In this study, Se-SAD was used for experimental phasing. SAD 
is short for “single-wavelength anomalous diffraction”. For this method, heavy atoms that 
absorb X-rays at a specific wavelength (absorption edge) are used, as the intensity and phase 
of the diffracted X-rays are influenced in the presence of an anomalous scatterer. In detail, the 
atomic scattering factor f is impacted by the two additional components f’ and f’’ in the presence 
of heavy atoms. 
(  () + ∆(, + -∆(′′ (3) 
In equation 3, fn is the normal scattering factor of the native protein, which is dependent on the 
diffraction angle, but independent of the wavelength. ∆f’ is the dispersive component, which 
describes the reduction of the measured intensities at different wavelengths. ∆f’’ is the 
imaginary component, which shows a 90° phase shift compared to the normal and dispersive 
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component. In contrast to the normal component, the two factors f’ and f’’ are dependent on 
the wavelength that is used for the diffraction experiment. The influence of the anomalous 
scattering factors on the native scattering factor are illustrated in Fig. 7B. This anomalous 
difference is used to locate the heavy atoms in the unit cell by Patterson functions. 
 
Figure 7: Impact of an anomalous scatterer on the structure factor amplitude and its use for the determination of the 
phase problem. (A) FPA is the structure factor of the anomalous derivative of the protein, FA that of the anomalous 
scatterer and FP that of the native protein. The amplitude of FPA is measured experimentally and the position of the 
anomalous scatterers can be determined by Patterson functions. Two possibilities for the phase angle of the protein 
are thus possible, indicated by red circles in the right panel. (B) Illustration of Friedel’s law. When Friedel’s law is 
true, two structure factors FP and F-P are real functions and have the same amplitude, but inverse phases (left panel). 
FPA is therefore equal to its Friedel pair F-PA. In the presence of an anomalous scatterer, Friedel’s law is not true. 
The phases of the scattering factors f’ and f’’ are changed, as the imaginary component f’’ of the scattering factor 
shows a phase shift of 90° (middle panel). FPA is hence not equal to F-PA anymore (right panel). Reproduced with 
permission from Biomolecular Crystallography by Bernhard Rupp, © 2009-2014 Garland Science/Taylor & Francis 
LLC. 
The structure factors contain information of all atoms that are present in the crystal. The 
structure factor of a protein crystal that contains heavy atoms (PA) is thus described by the 
sum of the structure factors of the protein atoms (P) and heavy atoms (A), FPA = FP + FA. 
According to Friedel’s law, the structure factor Fhkl and its Friedel mate F-h-k-l have the same 
amplitude, but opposite phases. In the presence of an anomalous scatterer, Friedel’s law is 
not true anymore, as the Friedel pairs have different amplitudes and different 
phases (Fhkl ≠ F-h-k-l). Fig. 7 illustrates the impact of an anomalous scatterer (heavy atom) on 
the structure factors (Rupp, 2009). In Fig. 7B, the structure factor for the native protein (FP) is 
shown in black, that of the anomalous protein derivative (FPA) in blue and the structure factor 
of the heavy atom (FA) in red. For the native protein, Friedel’s law is true and the Friedel pair 
FPA and F-PA show the same amplitude and inverse phases (mirrored at the real axis), as 
illustrated in the left panel of Fig. 7B. For the anomalous protein derivative (right panel of 
Fig. 7B), the scattering is influenced by the heavy atoms, which were introduced into the native 
protein, resulting in a phase shift and breakdown of Friedel’s law. The structure factor 
amplitudes for the Friedel pair are hence not equal anymore (indicated by different lengths of 
the vectors FPA and F-PA). By combining the information of the measured amplitudes and the 
location of the anomalous scatterer in the protein, two phase solutions are possible (highlighted 
by red circles in Fig. 7A), but only one of the two possible phase angles is correct. Iterative 
cycles of density modification techniques such as solvent flattening can then be used to 
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determine the correct phase angle and to solve the phase problem. The correct phase solution 
is also indicated by decreasing R-values during refinement. 
 
4.4. Model building, refinement and validation of the solved structure 
Once an electron density map is calculated, the amino acid chain can be built into the electron 
density map by automated or manual model building. An initial model is built concerning 
different parameters, such as secondary structure constraints, length and angle of chemical 
bonds and distances between neighboring backbones and side chains. Depending on the 
resolution of the structure, specific details of the amino acid side chains can be visualized in 
the electron density map. The better the resolution, the more details can be built, e.g. different 
amino acid rotamers. Water molecules or ligands can also be visualized in the electron density 
map with increasing resolution (Rhodes, 2006).  
After each model building step, a refinement of the model against the experimental data is 
performed using an algorithm. The theoretical structure factors of the model (Fcalc) are 
calculated and compared to the experimentally measured structure factors (Fobs). During model 
building, the difference between these structure factors should be minimized to yield a good fit 
of model data and experimental data. The quality of this fit is described by R-factors, which 
illustrate the correlation between model (Fcalc) and experimental data (Fobs). Two R-factors are 
usually considered: Rwork and Rfree (Brünger, 1992).  
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Rwork directly correlates the model with the experimental data, while Rfree is calculated excluding 
5% of the reflections to avoid overfitting of the data. Both R-factors should decrease during 
refinement to indicate that the previous step of model building was successful. When the 
process of model building is finished, both R-factors should not change anymore during 
refinement and should not differ by more than 5% (Brünger, 1992). 
The quality of the final structure is usually validated by different parameters and plots. The 
Ramachandran plot illustrates the statistical distribution of peptide torsion angles φ and ψ that 
cluster in specific regions for the respective secondary structure motifs that are present in the 
protein structure. Amino acids that show unusual peptide bond torsion angles are clustered in 
so-called “unallowed” regions of this plot (Ramakrishnan & Ramachandran, 1965).  
Bond lengths and angles are compared to empirical values and are described by the r.m.s.d. 
from the empirical values. They should not exceed a certain threshold. Another parameter that 
can be used for quality analysis is the MolProbity score. It is an overall score for the evaluation 
of the structure quality, as it combines several criteria for quality analysis (e.g. rotamer outliers, 
torsion-angle analysis etc.) in one single score (Davis et al., 2004). 
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5. Materials and Methods 
5.1. Chemicals, solutions and materials 
5.1.1. Chemicals 
Unless stated differently, all chemicals were purchased at the highest purity available (p.a., 
pro analysi) from the companies AppliChem (Darmstadt, Germany), Fluka (Seelze, Germany), 
Merck (Darmstadt, Germany), Qiagen (Hilden, Germany), Roth (Karlsruhe, Germany), Sigma-
Aldrich (Taufkirchen, Germany) and ThermoFisher Scientific Inc. (Waltham, Massachusetts, 
USA). 
 
5.1.2. Buffers, media and stock solutions 
Buffers and stock solutions were prepared in ddH2O and filter sterilized before use; buffers for 
protein preparation were additionally degassed before use. Media were autoclaved. Antibiotics 
were used at concentrations of 100 µg/ml ampicillin, 34 µg/ml chloramphenicol and 5 µg/ml 
tetracycline.  
Solutions for agarose gel electrophoresis: 
50x TAE buffer 242 g Tris, 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA pH 8.5 
in 1 L ddH2O 
0.8% agarose solution 2 g agarose in 250 ml 1x TAE buffer 
DNA standard GeneRuler DNA Ladder Mix, Thermo Scientific 
DNA sample buffer 20% Ficoll 400, 0.25% bromophenol blue, 0.25% xylenecyanol 
 
Media: 
LB agar 10 g/L NaCl, 10 g/L bacto tryptone, 5 g/L yeast extract, 15 g/L 
agar 
LB medium 10 g/L NaCl, 10 g/L bacto tryptone, 5 g/L yeast extract 
TB medium 12 g/L bacto tryptone, 24 g/L yeast extract, 0.4% (w/v) glycerol, 
170 mM KH2PO4, 720 mM K2HPO4 
SOC agar 20 g/L bacto tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM 
KCl, 10 mM MgCl2, pH 7.5, 15 g/L agar 
SOC medium 20 g/L bacto tryptone, 5 g/L yeast extract, 0.5 g/L NaCl, 2.5 mM 
KCl, 10 mM MgCl2, pH 7.5 
5x M9 salts 64 g/L Na2HPO4 x 7 H2O, 15 g/L KH2PO4, 5 g/L NH4Cl, 2.5 g/L 
NaCl in 1 L ddH2O 
M9 Minimal medium 780 ml autoclaved ddH2O, 200 ml 5x M9 salts, 20 ml 20% α-D-
glucose, 1 ml 2 M MgSO4, 100 µl 1 M CaCl2 
Autoinduction medium TB-medium, 0.01% lactose, 2 mM MgSO4 
 
18  5 Materials and Methods 
Buffers for protein purification: 
Strep-TcdB543-2366(C698A)-His6 
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 500 mM imidazole 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
Strep-Trap Buffer A 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
Strep-Trap Buffer B 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 5 mM Desthiobiotin 
SEC buffer 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
 
 
TcdB800-1834 
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 10 mM imidazole 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 500 mM imidazole 
MBP affinity Buffer A 20 mM Tris/HCl pH 8.0, 500 mM NaCl 
MBP affinity Buffer B 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 10 mM maltose 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 500 mM NaCl 
IEX Buffer A 20 mM Tris/HCl pH 8.0, 20 mM NaCl 
IEX Buffer B 20 mM Tris/HCl pH 8.0, 1 M NaCl 
SEC buffer 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 10% glycerol 
 
 
native CD1219  
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 500 mM imidazole 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
IEX Buffer A 20 mM Tris/HCl pH 8.0, 20 mM NaCl 
IEX Buffer B 20 mM Tris/HCl pH 8.0, 1 M NaCl 
SEC buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
 
 
SeMet-CD1219  
SeMet-CD2589 
 
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 1 mM DTT 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 1 mM DTT, 500 mM imidazole 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 2 mM DTT 
IEX Buffer A 20 mM Tris/HCl pH 8.0, 10 mM NaCl, 2 mM DTT 
IEX Buffer B 20 mM Tris/HCl pH 8.0, 1 M NaCl, 2 mM DTT 
SEC buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 2 mM DTT 
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 native CD1823   
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 300 mM NaCl 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 300 mM NaCl, 500 mM imidazole 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
SEC buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
 
 
native CD1363 
native CD1364  
 
MBP affinity 
chromatography 
Buffer A 
20 mM HEPES pH 7.5, 300 mM NaCl 
MBP affinity 
chromatography 
Buffer B 
20 mM HEPES pH 7.5, 300 mM NaCl, 10 mM maltose 
Dialysis Buffer 20 mM HEPES pH 7.5, 150 mM NaCl 
Ni(II)-IMAC Buffer A 20 mM HEPES pH 7.5, 150 mM NaCl 
Ni(II)-IMAC Buffer B 20 mM HEPES pH 7.5, 300 mM NaCl, 500 mM imidazole 
SEC buffer 20 mM HEPES pH 7.5, 150 mM NaCl 
 
 
native CD2589-SER1  
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 500 mM NaCl 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 500 mM imidazole 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
IEX Buffer A 20 mM Tris/HCl pH 8.0, 15 mM NaCl 
IEX Buffer B 20 mM Tris/HCl pH 8.0, 1 M NaCl 
SEC buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
 
 
native CD2752   
Ni(II)-IMAC Buffer A 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 2 mM DTT 
Ni(II)-IMAC Buffer B 20 mM Tris/HCl pH 8.0, 500 mM NaCl, 500 mM imidazole, 2 mM DTT 
Dialysis Buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 2 mM DTT 
SEC buffer 20 mM Tris/HCl pH 8.0, 150 mM NaCl, 2 mM DTT 
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Solutions for SDS-PAGE: 
4x stacking gel buffer 0.5 M Tris/HCl pH 6.8, 0.4% (w/v) SDS 
Stacking gel (5%) 1x stacking gel buffer, 5% (w/v) acrylamide (from 
30% (w/v) stock solution: 37.5:1), 0.1% (w/v) APS, 
0.001% (v/v) TEMED 
4x resolving gel buffer 1.5 M Tris/HCl pH 8.8, 0.4% (w/v) SDS 
Resolving gel (15%) 1x resolving gel buffer, 15% (w/v) acrylamide (from 
30% (w/v) stock solution: 37.5:1), 200 μL 10% APS, 
0.001% (v/v) TEMED 
8x SDS-PAGE sample 
buffer 
2.2 ml 100 mM Tris/HCl pH 6.8, 10% (w/v) SDS, 4 ml (v/v) 
100% glycerol, 800 µl β-Me, 0.05% bromophenol blue 
Running buffer 25 mM Tris/HCl, 192 mM glycine, 0.1% (w/v) SDS 
Protein standard Protein Marker I, 14.4-116 kDa, VWR 
PageRuler™ Plus Prestained Protein Ladder, 10-250 kDa, 
ThermoFisher Scientific 
 
 
5.1.3.  Oligonucleotides and DNA templates 
All oligonucleotides used in this study were designed using the program OligoCalc (Kibbe, 
2007) and were purchased from MWG Eurofins Genomics (Munich, Germany). Sequences of 
the open reading frames (ORFs) were picked from the UniProt (The UniProt Consortium, 2017) 
database. A detailed list of oligonucleotides used in this study can be found in 
table 31 – table 37 in the supplement.  
Different DNA templates were used for gene amplification and cloning in this study. Some 
templates were purchased as synthetic DNA constructs codon-optimized for expression in 
E. coli. Other constructs were cloned based on genomic Clostridium difficile DNA, a kind gift 
from Prof. Dr. Ralf Gerhard (MHH, Hannover, Germany). Some TcdB constructs were created 
based on the plasmid pHIS1522-TcdB543-2366 (kind gift from Prof. Dr. Ralf Gerhard, MHH, 
Hannover) as DNA template. Other TcdB fragments were cloned based on TcdB-DNA Codon-
optimized for expression in E. coli, which was ordered at GenScript (Piscataway, USA). 
Synthetic DNA templates ordered at Life Technologies GmbH (Darmstadt, Germany) were 
used for amplification of the uncharacterized proteins essential for growth or sporulation of 
Clostridium difficile. All diffocin proteins were amplified from genomic Clostridium difficile DNA. 
 
5.1.4.  Plasmids and constructs 
All plasmids and constructs that were used or generated in this study are listed in table 38 in 
the supplement. 
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5.1.5.  Microorganisms 
Different E. coli strains were used for amplification of constructs and heterologous protein 
expression in this thesis, respectively. All strains are listed in table 1. 
Table 1: Overview of all microorganisms used in this study. 
Bacterial strain Genotype/Origin Antibiotic 
resistance 
Used for 
Bacillus megaterium Prof. Dr. Ralf Gerhard, MHH, Hannover Tetracycline Protein 
expression 
(TcdB) 
E. coli Omnimax F´ {proAB lacIq lacZΔM15 Tn10(TetR ) 
Δ(ccdAB)} mcrA Δ(mrr hsdRMS-mcrBC) 
Φ80(lacZ)ΔM15 Δ(lacZYA-argF)U169 
endA1 recA1 supE44 thi-1 gyrA96 relA1 
tonA panD 
Tetracycline Cloning / 
amplification 
of plasmids 
E. coli TOP10 F– mcrA Δ(mrr-hsdRMS-mcrBC) 
Φ80lacZΔM15ΔlacX74 recA1 araD139 
Δ(ara leu) 7697 galU galKrpsL (StrR) 
endA1 nupG 
Streptomycin Cloning / 
amplification 
of plasmids 
E. coli XL1 blue F´ proAB lacIqZΔM15 Tn10 Tetr/ recA1 
endA1 gyrA96thi-1 hsdR17 supE44 relA1 
lac 
Tetracycline Cloning / 
amplification 
of plasmids 
E. coli 
Rosetta2(DE3) 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pRARE2 (CamR) 
Chloramphenicol Protein 
expression 
E. coli BL21 
CodonPlus(DE3)-RIL 
F– ompT hsdS(rB– mB–) dcm+ Tetr gal 
λ(DE3) endA Hte [argU ileYleuW Camr] 
Chloramphenicol Protein 
expression 
  
 
5.1.6.  Enzymes 
All restriction enzymes used for cloning in this study (BamHI, DpnI, HindIII, KpnI, NdeI, XhoI), 
as well as Antarctic Phosphatase, T4 DNA Polymerase, Recombinase A and T4 DNA Ligase 
were purchased from New England Biolabs (Ipswich, MA, U.S.A.). Phusion DNA Polymerase 
was ordered at ThermoFisher (Waltham, Massachusetts, USA), Taq Polymerase at VWR 
(Darmstadt, Germany) and KAPAHiFi Polymerase at Peqlab (Erlangen, Germany).  
TEV protease was produced in the laboratory from plasmid pHR-MBP_TEV (DPF, MPI 
Dortmund) as His6-MBP-TEV fusion protein and was purified via Ni(II)-immobilized metal ion 
affinity chromatography (Ni(II)-IMAC). PreScission protease was expressed from plasmid 
pET28(+) and was used after purification by Ni(II)-IMAC and size exclusion chromatography. 
Sumo protease was produced from plasmid pXX-Sumo and was purified by Ni(II)-IMAC and 
size exclusion chromatography. 
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5.1.7.  Columns for protein purification 
All columns that were used for protein purification in this study are listed in table 2. 
Table 2: Overview of columns that were used for protein purification in this study. 
HisTrapTM HP 5 mL column GE Healthcare, Munich, Germany 
HiTrapTM TALON® crude 5 mL column GE Healthcare, Munich, Germany 
HiTrapTM Q FF 5 mL column GE Healthcare, Munich, Germany 
StrepTrapTM HP 5 mL column GE Healthcare, Munich, Germany 
Strep 10 mL column (column material: Strep-Tactin® 
Superflow®, IBA GmbH, Göttingen, Germany) 
prepared by Peer Lukat, HZI, 
Braunschweig, Germany 
MBPTrapTM HP 5 mL column GE Healthcare, Munich, Germany 
HiLoad™75 16/60 Superdex™75 prepgrade GE Healthcare, Munich, Germany 
HiLoad™75 26/60 Superdex™75 prepgrade GE Healthcare, Munich, Germany 
HiLoad™200 16/60 Superdex™200 prepgrade GE Healthcare, Munich, Germany 
HiLoad™200 26/60 Superdex™200 prepgrade GE Healthcare, Munich, Germany 
Superose® 6 10/300 GL GE Healthcare, Munich, Germany 
Superdex™ 75 10/300 GL GE Healthcare, Munich, Germany 
Superdex™ 200 10/300 GL GE Healthcare, Munich, Germany 
 
 
5.1.8.  Kits 
All commercially available molecular biology kits and crystallographic kits that were used in 
this study are summarized in table 3. 
Table 3: Overview of molecular biology kits and crystallography screens used in this study. 
Molecular Biology Kits 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit Qiagen, Hilden, Germany 
QIAprep Spin Miniprep Kit Qiagen, Hilden, Germany 
 
Crystallographic Kits / Screens 
IndexTM Hampton Research, Aliso Viejo, USA 
JCSG+, JCSG Core I, II, III and IV Qiagen, Hilden, Germany 
MIDASTM Molecular Dimensions, Suffolk, U.K. 
Morpheus® Molecular Dimensions, Suffolk, U.K. 
Protein Complex Suite Qiagen, Hilden, Germany 
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5.2. Cloning 
In this study, two different methods were used for cloning: traditional cloning using restriction 
enzymes as well as sequence-and-ligation-independent cloning (SLIC). 
 
5.2.1.  Traditional cloning 
5.2.1.1. Polymerase chain reaction 
Polymerase chain reactions (PCR) were conducted for amplification of target DNA. For this 
purpose, genomic Clostridium difficile DNA (CD630, Prof. Dr. Ralf Gerhard, MHH, Hannover, 
Germany), as well as synthetic DNA codon-optimized for expression in E. coli were used as 
DNA templates. In this study, Phusion DNA polymerase and KAPAHifi DNA polymerase were 
used for PCR experiments. Taq DNA polymerase was used for colony PCR (cPCR). A pipetting 
scheme for the respective PCR reactions and corresponding PCR programs are shown in 
table 4 and table 5. After addition of DNA polymerase to the PCR mixture, PCR programs were 
started immediately. 30 cycles of denaturation, annealing and elongation were used for 
standard PCR. 
Table 4: Pipetting scheme for PCR reactions.  
 Phusion Polymerase KAPAHifi Polymerase Taq Polymerase 
final 
concentration 
Template DNA* x µl x µl 1 µl ca. 100 ng 
Primer fwd 2.5 µl 0.5 µl 0.5 µl 2-5 µM 
Primer rev 2.5 µl 0.5 µl 0.5 µl 2-5 µM 
dNTPs 1 µl 0.75 µl - 200-300 µM 
Buffer 10 µl GC buffer 5 µl GC buffer - 1x 
ddH2O to 50 µl to 25 µl 5.5 µl  
Polymerase 1 µl 0.5 µl 7.5 µl RedTaq Mastermix  
* For genomic DNA as template more DNA is required. For cPCR one bacterial colony was resuspended in 10 µl 
sterile ddH2O and used as DNA template for cPCR. 
 
 
Table 5: Overview of PCR programs. 
  
Phusion Polymerase KAPAHifi Polymerase Taq Polymerase 
  
T (°C) t (s) T (°C) t (s) T (°C) t (s) 
 Initial denaturation 98 180 95 180 95 300 
30x 
Denaturation 98 10 98 20 95 30 
Annealing Tm – 5 °C 30 Tm – 5 °C 15 Tm – 5 °C 60 
Elongation 72 30 s / kb 72 60 s / kb 72 60 s / kb 
 Final elongation 72 600 72 60 s / kb 72 300 
 Storage 8 ∞ 8 ∞ 8 ∞ 
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Samples were mixed with 10x DNA sample buffer after PCR and were analyzed using agarose 
gel electrophoresis, according to 5.2.1.2. 
 
5.2.1.2. Agarose gel electrophoresis 
After PCR, the PCR products were analyzed on an agarose gel. According to the gel size, 
approximately 2-6 µl Roti® GelStain (Carl Roth GmbH, Karlsruhe, Germany) were added to a 
0.8% agarose gel. After addition of 1 µl 10x DNA sample buffer to 9 µl DNA sample, samples 
were loaded on the gel. Gels were run at 100 V for 60 min and inspected under UV light after 
the run. By comparing the DNA fragments to a DNA standard, the success of the respective 
PCR reaction or DNA digest was analyzed. After successful PCR, the remaining PCR product 
that was not loaded on the gel was purified using a PCR purification kit. In the presence of 
several bands visible on the agarose gel, the respective fragment of desired size was cut out 
using a scalpel and purified using a gel extraction kit according to the manual of the 
manufacturer. 
 
5.2.1.3. DNA restriction 
To create suitable 3’ overhangs for ligation, PCR products and plasmids were digested using 
restriction enzymes. For plasmid digestion, it was necessary to add Antarctic Phosphatase for 
dephosphorylation of the 5’ ends of the plasmid DNA and prevention of plasmid religation. The 
pipetting scheme for DNA restriction of PCR products and plasmid DNA is shown in table 6. 
Table 6: Pipetting scheme for restriction digest of PCR products and vector DNA. 
 PCR products Plasmid DNA 
Template DNA x µl (ca. 1 µg) x µl (ca 2 µg) 
Restriction enzyme I 1 µl 1 µl 
Restriction enzyme II 1 µl 1 µl 
10x NEB buffer* 5 µl 5 µl 
Antarctic Phosphatase - 1 µl 
10x buffer for Antarctic Phosphatase - 5 µl 
ddH2O to 50 µl to 50 µl 
* CutSmart buffer was used for all high fidelity (HF) restriction enzymes. For standard enzymes (no HF) buffers 
were used as proposed by the manual of the manufacturer. 
 
DNA was digested for 2 h at 37 °C, followed by enzyme inactivation for 20 min at 65 °C. After 
digestion, the DNA samples were purified using a PCR purification kit according to the manual 
of the manufacturer. DNA concentrations were determined using a NanoDrop 1000 (VWR, 
Darmstadt, Germany). The UV absorption was measured at 600 nm and it was assumed that 
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a UV absorption of 1 equals 50 ng/µl double stranded DNA. DNA concentrations were then 
calculated accordingly.  
 
5.2.1.4. Ligation 
After restriction digest, PCR products and vectors were ligated using T4 DNA ligase. An 
insert:vector ratio of 3:1 was used for ligation reactions. The pipetting scheme for ligation 
reactions is shown in table 7. 
Table 7: Pipetting scheme for ligation reactions using T4 DNA ligase. 
 Ligase reaction 
Insert 6 µl 
Vector 2 µl 
T4 DNA ligase 1 µl 
10x buffer for ligase 1 µl 
 
Ligation reactions were incubated for 12-16 h at 16 °C, followed by inactivation of T4 DNA 
ligase for 20 min at 65 °C. Ligated plasmids were immediately transformed into competent 
E. coli cells (chapter 5.4). 
Analysis of cloning success was done by DNA sequencing. Therefore, circular DNA was 
extracted from E. coli cells (XL1blue or TOP10) by a plasmid MiniPrep Kit according to the 
protocol of the manufacturer. Samples were sequenced either inhouse at the Genome 
Analytics Facility (GMAK) at HZI (Braunschweig, Germany) or by MWG Eurofins Genomics 
(Ebersberg, Germany) according to the respective protocols. ClustalOmega (Sievers et al., 
2011) was used to analyze sequencing results by pairwise sequence alignments with insert 
DNA. 
 
5.2.2. Sequence-and-ligation-independent cloning 
Besides traditional cloning using restriction enzymes, sequence-and-ligation-independent 
cloning (SLIC) was used in this study. Therefore, oligonucleotides for PCR of the respective 
inserts were designed with overhangs complementary to the respective plasmid DNA used for 
cloning. This ensures annealing of single-stranded overhangs of PCR product and vector. For 
amplification of insert DNA, Phusion Flash PCR Mastermix (ThermoFisher Scientific, Waltham, 
Massachusetts, USA) was used. Cloning was performed as indicated in the respective 
manuals of the manufacturers and according to the protocols established at DPF (Dortmund, 
Germany). A pipetting scheme for SLIC-PCR reactions is shown in table 8. The standard PCR 
program for PCR using Phusion Flash Mastermix is summarized in table 9. 
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Table 8: Pipetting scheme for PCR reactions using Phusion Flash Mastermix for SLIC. 
 Volume final concentration 
2x Phusion Flash Mastermix 15 µl 1x 
Template DNA 2 µl 10 ng 
Primer fwd 2 µl 0.5 µM 
Primer rev 2 µl 0.5 µM 
5 M betaine 6 µl 1 M 
ddH2O 3 µl  
 
Table 9: Standard PCR program used for SLIC in this study. 
 Step T (°C) t (s) 
 Initial denaturation 98 120 
30x 
Denaturation 98 10 
Annealing Tm – 5 °C 10 
Elongation 72 45 s / kbp 
 Final elongation 72 420 
 Storage 8 ∞ 
 
Immediately after PCR, a DpnI digest was performed to remove excessive template DNA. 1 µl 
DpnI and 3.4 µl 10x CutSmart buffer were added to the 30 µl PCR reaction and incubated for 
1 h at 37 °C. After addition of 15.6 µl sterile ddH2O, reactions were purified using a PCR 
purification kit according to the manual of the manufacturer. A small amount of digested PCR 
product was run on a 0.8% test agarose gel to check the success of the respective PCR 
reactions. Plasmids were digested by KpnI and HindIII for 2 h at 37 °C in CutSmart buffer. To 
create single-stranded overhangs, vector and insert DNA were treated with T4 DNA 
polymerase (SLIC mix 1) individually without adding dNTPs. A vector:insert ratio of 1:1 was 
used. The pipetting scheme for SLIC mix 1 is shown in table 10. 
Table 10: Pipetting scheme for SLIC mix 1. 
Component Volume Stock concentration Final concentration 
T4 DNA polymerase 3.3 µl 0.03 U/µl 0.1 U/reaction 
NEB buffer 2 2 µl 10x 1x 
ddH2O sterile 14.7 µl – x   
vector / insert x µl  25 ng vector 
 
Each reaction was incubated for 10 min at 22 °C and stopped by addition of 2 µl 10 mM dCTP, 
which blocks the exonuclease activity of T4 DNA polymerase. For the recombination reaction 
(SLIC mix 2), insert and vector DNA with single-stranded complementary overhangs were 
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incubated with recombinase A to ensure ligation of insert and plasmid. The pipetting scheme 
for the recombination reaction is shown in table 11. 
Table 11: Pipetting scheme for SLIC Mix 2 (recombination reaction) used for SLIC in this study. 
 Volume Stock concentration Final concentration 
T4 DNA ligase buffer 2 µl 10x 1x 
RecA 1 µl 40 ng/µl 2 ng/µl 
Vector SLIC Mix 1 8.5 µl   
PCR SLIC Mix 1 8.5 µl   
 
SLIC Mix 2 reactions were incubated for maximal 30 min at 37 °C and immediately 
transformed into highly competent E. coli Omnimax cells. Positive clones were identified by 
colony PCR and DNA sequencing. 
 
5.2.3. Site-directed mutagenesis / Surface entropy reduction 
To introduce specific changes in the DNA sequence, a slightly modified protocol of 
QuickChange® II site-directed mutagenesis (Stratagene) was used. In this study, site-directed 
mutagenesis was used to delete frameshift mutations, to introduce a mutation for inactivation 
of a protein and for generation of surface entropy reduction (SER) mutants. For this purpose, 
specific oligonucleotides were created, which contain the desired mutation in the middle of the 
oligonucleotide sequence. Forward and reverse primer have to be complementary to each 
other. The PCR pipetting scheme for site-directed mutagenesis using KAPAHifiTM DNA 
polymerase and the PCR protocol are summarized in table 4 and table 5. 16 cycles of 
denaturation, annealing and extension were used for mutation of a single amino acid, 18 cycles 
were used for multiple amino acid deletions or insertions. 
  
5.3. Preparation of chemically competent E. coli cells 
Chemically competent E. coli cells were used for molecular biology experiments and protein 
expression. Rubidium competent E. coli cells were prepared by Claudia Hanko (HZI, 
Braunschweig, Germany) according to established standard protocols. Cells were flash-frozen 
in liquid nitrogen and stored at -80 °C. 
 
5.4.  Heat shock transformation of E. coli cells 
For plasmid preparation and protein production, plasmids were transformed into competent 
E. coli cells by heat shock transformation. 50 µl competent cells were mixed with 100 ng 
plasmid DNA and incubated on ice for 30 min. Heat shock was performed for 1 min at 42 °C 
and cells were incubated on ice for further 5 min. 1 ml pre-warmed LB medium was added and 
28  5 Materials and Methods 
the mixture was incubated for 45-60 min under shaking at 37 °C. 100 µl were plated on LB-
agar plates containing respective antibiotics and stored in a 37 °C incubator overnight. 
 
5.5.  Test expression 
To determine suitable conditions for protein expression, a test expression was performed for 
most constructs. Several E. coli strains (E. coli BL21 CodonPlus(DE3)RIL, 
E. coli Rosetta2 (DE3)), as well as different media (LB, TB, autoinduction) in combination with 
various expression temperatures were tested. Plasmids were transformed in competent E. coli 
expression strains for protein production. A single colony was inoculated in 50 ml LB medium 
containing respective antibiotics and was incubated over night at 37 °C in the shaking 
incubator. This overnight culture was used to inoculate a 100 ml culture on the next day to an 
OD600 ~ 0.05. Cells were incubated at 37 °C in a shaking incubator. When OD600 reached 0.8, 
1 ml culture (sample before induction) was pelleted. Protein expression was induced in the rest 
of the cell culture by addition of 1 mM IPTG. The cells were incubated over night at the 
respective expression temperature. At different time points after induction (1 h, 3 h, overnight) 
OD600 was measured and samples were taken to analyze protein production on an SDS PAGE. 
The samples after induction were normalized to the respective OD600 before induction to 
analyze the time-dependent protein expression. 
For cell lysis, the samples collected 1 h and 3 h after induction were treated with BugBuster® 
(Merck, Darmstadt, Germany) according to the protocol of the manufacturer. The samples 
collected after overnight protein expression were not treated with BugBuster but were lysed by 
sonication. Therefore, 10 ml samples of each culture were pelleted. The cell pellets were 
resuspended in 1-2 ml buffer (usually 20 mM Tris/HCl pH 8.0, 300 mM NaCl) and disrupted by 
sonication (2x 10 sec pulse with 10 sec break between each pulse), followed by 30 min 
centrifugation at 13.000 rpm. Samples of supernatant and pellet were stored for SDS PAGE. 
For test expression of proteins fused to a His6-tag, 25 µl Ni-NTA superflow beads (Qiagen, 
Hilden, Germany) were added to the supernatant fraction. The mixture was incubated at 4 °C 
and washed several times by alternating steps of centrifugation (1.500 rpm, 1 min, 4 °C) and 
resuspension of the beads in 25-30 µl buffer. After the final washing step, the beads were 
resuspended in 25 µl buffer and a sample was retained for SDS PAGE. Various samples of 
supernatant, pellet and beads and respective time points were then loaded on an SDS-PAGE 
to analyze the soluble production of proteins. 
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5.6. Protein production 
5.6.1. Protein expression in Bacillus megaterium 
Some TcdB constructs (Strep-TcdB543-2366-His6 and Strep-TcdB543-2366(C698A)-His6) 
were expressed in Bacillus megaterium. Transformation of both constructs in Bacillus 
megaterium protoplasts was done by Prof. Dr. Ralf Gerhard (MHH, Hannover, Germany). Cells 
were plated on LB-agar including tetracycline. A single colony was used to inoculate overnight 
cultures (50 ml LB medium + 5 µg/µl tetracycline). For glycerol stock preparation, 500 µl 
overnight culture were mixed with 500 µl glycerol. The mixture was immediately fresh frozen 
in liquid nitrogen and stored at -80 °C. These glycerol stocks were used for inoculation of 
overnight cultures during the rest of this study. Therefore, a small amount of the glycerol stock 
was added to 50 ml LB medium including tetracycline using a pipette tip. The culture was 
incubated over night at 37 °C under vigorous shaking and this overnight culture was used for 
inoculation of 1 L cultures the next day. 8x 1 L LB medium including tetracycline was inoculated 
with the overnight culture to OD600 ~ 0.05. The large cultures were incubated at 175 rpm at 
37 °C. When cells reached an optical density OD600 ~ 0.4, protein expression was induced by 
addition of 0.5% α-D-xylose. After shaking at 175 rpm for additional four hours, cells were 
harvested at 4 °C, 7000 rpm for 30 min. The cell pellets were flash frozen in liquid nitrogen and 
stored at -80 °C until further usage. 
 
5.6.2. Protein expression in E. coli 
5.6.2.1. Standard expression (T7 promoter) 
In this study, genes were cloned in an expression vector behind a T7 promoter. The encoded 
protein is only expressed in the presence of T7 polymerase. Therefore, plasmids were 
transformed in E. coli strains, which contain T7 polymerase. This polymerase is controlled by 
the lac promoter. In the absence of lactose or presence of glucose (catabolite repression), the 
lac repressor is bound to the lac promoter and prevents expression of the recombinant protein. 
By adding lactose or the lactose analogue IPTG to the medium, protein expression is induced, 
as lactose induces the dissociation of the lac repressor (Studier et al., 1990). 
For protein production, expression constructs were freshly transformed in competent E. coli 
cells. Overnight cultures (LB medium including respective antibiotics) were inoculated with a 
single colony and grown over night at 37 °C under vigorous shaking. Large cultures (1 L 
medium containing respective antibiotics) were inoculated with overnight cultures to an OD600 
of 0.05. The cultures were grown to an optical density OD600 of 0.8 - 1.0 at 37 °C under 
vigorous shaking. Protein expression was induced by addition of 1 mM isopropyl-thio-β-D-
galactopyranosid (IPTG). Cells were incubated at 20 °C overnight and harvested by 
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centrifugation at 4 °C and 7.000 rpm for 20 min. Pellets were flash-frozen in liquid nitrogen and 
stored at -80 °C until further usage. 
Expression conditions for proteins that were expressed and purified in this study are 
summarized in table 39 in the supplement. 
 
5.6.2.2. Expression of selenomethionine-labeled proteins 
Selenomethionine (SeMet)-labeled proteins were used for structure determination by SeMet-
SAD for some proteins in this thesis. To express SeMet-labeled protein, the respective 
expression plasmid encoding the protein was freshly transformed into chemically competent 
E. coli cells. A single colony was used to inoculate an overnight culture (50 ml LB medium, 
containing respective antibiotics), which was incubated over night at 37 °C under vigorous 
shaking. The overnight cultures were pelleted the next day by centrifugation at 4.500 rpm, 4 °C 
for 30 min. The cell pellet was washed with 50 ml M9 medium two times and was finally 
resuspended in 40 ml M9 minimal medium. Large cultures (1 L M9 minimal medium, containing 
antibiotics) were inoculated with 20 ml of the washed overnight cultures and incubated at 37 °C 
in a shaking incubator. When the cells reached an OD600 ~ 0.5, amino acids were added 
(100 mg L-lysine, 100 mg L-threonine, 100 mg L-phenylalanine, 50 mg L-isoleucine, 50 mg L-
leucine, 50 mg L-valine per liter medium). After another 30 min incubation at 37 °C, 60 mg 
selenomethionine was added per liter cell culture. Protein expression was induced by adding 
the respective amount of IPTG that was essential for native protein expression. Expression of 
SeMet-labeled protein was performed analogous to native protein expression. The cells were 
harvested at 4 °C, 7.000 rpm for 30 min, pellets were flash-frozen in liquid nitrogen and stored 
at -80 °C until further usage. 
 
5.6.2.3. Autoinduction 
In a T7 expression system, protein expression is typically induced by addition of IPTG. Using 
a defined autoinduction medium, no addition of IPTG is needed. One can control protein 
expression by adding a defined amount of glucose and lactose to ensure protein expression 
during the late log phase. Glucose will ensure the binding of the lac repressor to the lac 
promoter. Lactose will then ensure the removal of the repressor and induce protein expression. 
In the presence of both glucose and lactose in the medium, bacteria will first use all glucose 
for their metabolism because lactose is not the preferred carbohydrate source for E. coli. The 
protein expression will hence be turned on when all glucose in the medium was consumed by 
the bacteria. Therefore, one advantage of autoinduction is that there is no need to monitor the 
progress of protein expression and manual induction of protein expression by adding IPTG is 
not necessary (Studier, 2005). 
5 Materials and Methods  31 
For autoinduction, the expression plasmid was transformed in the respective E. coli cells. A 
single colony was used to inoculate an overnight culture (50 ml TB medium containing 
respective antibiotics, 1% glucose and 2 mM MgSO4). The overnight cultures were grown 
overnight at 37 °C under shaking. Large cultures (1 L TB medium containing respective 
antibiotics, 0.01% lactose and 2 mM MgSO4) were inoculated with the overnight cultures to an 
OD600 of 0.5. Cells were incubated at 37 °C in a shaking incubator for 4 h. Temperature was 
then decreased to 25 °C and cells were incubated for further 20 - 24 h. Cells were harvested 
by centrifugation for 25 min at 4 °C and 6.500 rpm. Cell pellets were flash-frozen in liquid 
nitrogen and stored at -80 °C until further usage. 
 
5.7. Protein purification 
5.7.1. Cell disruption 
The relevant amount of cell pellet stored at -80 °C was thawed on ice. The pellet was 
resuspended in the appropriate volume of resuspension buffer. DNase A (1 mg/ml stock) and 
protease inhibitor (cOmplete™ Mini Protease Inhibitor Cocktail, Roche, Mannheim, Germany) 
were added prior to cell disruption. The cell pellet was homogenized by stirring on a magnetic 
stirrer at 4 °C. Cells were disrupted by 30 min sonication (1 s pulse and 10 s break between 
each pulse) using a Bandelin Sonopuls sonicator (BANDELIN electronic GmbH & Co. KG, 
Berlin, Germany). After sonication, cell debris and insoluble proteins were removed from the 
soluble protein fraction by centrifugation at 4 °C and 16.000 rpm for 1 h. Samples for SDS-
PAGE were collected from the supernatant and pellet fraction after centrifugation to analyze 
the success of soluble protein expression. 
 
5.7.2. Ni(II) Immobilized metal ion affinity chromatography 
Ni(II)-Immobilized metal ion affinity chromatography (Ni(II)-IMAC) was performed using a 5 mL 
HisTrapTM HP column attached to an ÄktaPurifier FPLC system, which had been washed with 
degassed ddH2O and the respective buffers. The column was also washed with ddH2O and 
equilibrated with buffer A. The soluble protein fraction was loaded onto the column using a 
sample pump with a flow of 1 - 3 ml/min and a maximal pressure of 0.3 MPa. Unbound proteins 
were washed off with buffer A and unspecifically bound proteins were eluted by washing the 
column with 3% buffer B (15 mM imidazole). A linear gradient from 3 - 100% buffer B 
(15 - 500 mM imidazole) over ca. 15 CV (column volumes) was used for protein elution. 2 mL 
fractions were collected and particular samples were analyzed by SDS-PAGE. 
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5.7.3. Further affinity chromatography methods 
Proteins carrying a His6-MBP tag were purified using MBP-affinity chromatography. The 
procedure was performed analogous to Ni(II)-IMAC (chapter 5.7.2). The protein solution was 
loaded onto 1 – 3 MBPTrapTM HP 5 mL columns in series and elution was achieved by 
washing the column with 100% buffer B (10 mM maltose). 
Proteins with a Strep-tag were purified using Strep-affinity chromatography analogous to MBP-
affinity chromatography. Protein solution was loaded on a 10 mL column packed with Strep-
Tactin® Superflow® and the target protein was eluted by 100% buffer B containing 5 mM D-
desthiobiotin. 
 
5.7.4. Dialysis and tag cleavage 
After affinity chromatography, fractions containing the target protein were pooled. To cleave 
off the affinity tag, the appropriate amount of the respective protease was added. 1 mg Sumo 
protease was used to cleave 100 mg target protein, TEV- and S3C-protease were used in a 
1:30 molar protein:protease ratio. The protein solution was dialyzed over night at 4 °C under 
continuous stirring against 2 L dialysis buffer using SnakeSkinTM dialysis membrane with a 
3500 MWCO (ThermoFisher Scientific, Waltham, Massachusetts, USA).  
 
5.7.5. Reverse Ni(II) immobilized metal ion affinity chromatography 
After tag cleavage and dialysis overnight, precipitated protein was separated from the soluble 
fraction by centrifugation at 4.500 rpm 4 °C for 30 min. The supernatant was loaded on a 5 mL 
HisTrapTM HP column after centrifugation and another Ni(II)-IMAC run was performed 
according to 5.7.2 to separate the cleaved protein from the tag, protease und uncleaved 
protein. Cleaved protein should not be able to bind to the column anymore and should hence 
elute in the flowthrough. The cleaved His6-tag, the His-tagged protease and uncleaved protein 
should instead bind to the column and elute during a linear gradient to 100% buffer B 
containing 500 mM imidazole. Protein containing fractions were collected and analyzed by 
SDS-PAGE. Depending on the purity of the target protein, it was subjected to another step of 
chromatography (e.g. ion exchange chromatography) to yield higher purity or was directly used 
for final size exclusion chromatography. 
 
5.7.6. Ion exchange chromatography (IEC) 
Depending on the pI value of the target protein, anion or cation exchange chromatography was 
performed. Before IEC, the respective buffer was exchanged to a low-salt buffer (containing 
maximal 20 mM NaCl). The protein solution was loaded onto a 5 mL ion exchange column, 
which was equilibrated with buffer A. Unbound protein was washed off with buffer A and a 
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linear gradient from 0 - 100% buffer B (0 - 1 M NaCl) over 150 ml was applied for protein 
elution. 2 mL fractions were collected and protein-containing samples were analyzed by SDS-
PAGE. Fractions containing the target protein were pooled and concentrated prior to final size 
exclusion chromatography. 
 
5.7.7. Size exclusion chromatography 
Before final size exclusion chromatography, the target protein was concentrated using 
Vivaspin® concentrators (Sartorius AG, Göttingen, Germany) with an appropriate MWCO 
according to the size of the protein (chapter 5.7.10). Size exclusion chromatography columns 
were washed with one column volume degassed water and equilibrated with at least one 
column volume size exclusion chromatography buffer. The concentrated protein was then 
injected manually onto the size exclusion chromatography column using a sample loop. The 
size exclusion chromatography run was performed using a flow and maximal pressure 
recommended by the column manufacturer for the respective column. Samples of eluted 
proteins were analyzed using SDS-PAGE, fractions with pure target protein were pooled and 
concentrated. The protein was either directly used for crystallization screens or flash frozen in 
liquid nitrogen and stored at -80 °C until further usage. 
 
5.7.8. Purification protocols 
Unless stated differentially, all proteins used in this study were purified using a 3- or 4-step 
purification protocol. A summary of all proteins purified in this study with the according 
chromatography steps and final buffer is shown in table 12. 
Table 12: Summary of all proteins purified in this study. 
Protein (Construct) Purification Protocol Final buffer 
TcdB 543-2366 (C698A) 
(pHIS1522-TcdB 543-2366 (C698A)) 
Strep-affinity chromatography 
no tag cleavage 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
300 mM NaCl 
TcdB800-1834 
(pOPINM-TcdB800-1834) 
Ni(II)-IMAC 
MBP-affinity chromatography 
tag cleavage by S3C protease 
reverse Ni(II)-IMAC 
IEX 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
300 mM NaCl, 
10% glycerol 
CD1363 
(pOPINM-CD1363) 
MBP-affinity chromatography 
tag cleavage by S3C-protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM HEPES pH 7.5, 
100 mM NaCl, 
3 mM β-Me 
CD1363 SeMet 
(pOPINM-CD1363) 
MBP-affinity chromatography 
tag cleavage by S3C-protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM HEPES pH 7.5, 
100 mM NaCl, 
3 mM DTT 
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CD1364 
(pOPINM-CD1364) 
MBP-affinity chromatography 
tag cleavage by S3C-protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM HEPES pH 7.5, 
100 mM NaCl, 
3 mM β-Me 
CD1219 
(pET-Sumo-CD1219) 
Ni(II)-IMAC 
tag cleavage by Sumo protease 
reverse Ni(II)-IMAC 
IEX 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
150 mM NaCl 
CD1219 SeMet 
(pET-Sumo-CD1219) 
Ni(II)-IMAC 
tag cleavage by Sumo protease 
reverse Ni(II)-IMAC 
IEX 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
150 mM NaCl, 
2 mM DTT 
CD1823 
(p10$-CD1823) 
Ni(II)-IMAC 
tag cleavage by Sumo protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
150 mM NaCl 
CD2589 
(pET-Sumo-CD2589) 
Ni(II)-IMAC 
tag cleavage by Sumo protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
150 mM NaCl 
CD2752 
(pET-Sumo-CD2752) 
Ni(II)-IMAC 
tag cleavage by Sumo protease 
reverse Ni(II)-IMAC 
size exclusion chromatography 
20 mM Tris/HCl pH 8.0, 
150 mM NaCl, 
2 mM DTT 
 
 
5.7.9. SDS-PAGE 
The success of soluble protein expression and purification was analyzed using Sodium-
Dodecyl-Sulfate Gel Electrophoresis (SDS-PAGE). Gels were prepared using standard 
protocols (Laemmli, 1970) and consisted of a 5% polyacrylamide stacking gel and 10%, 15% 
or 18% polyacrylamide resolving gels, respectively. Protein samples were diluted with buffer 
to an appropriate protein amount, 8X protein sample buffer was added and the samples were 
denatured at 95 °C for 5 min. After short centrifugation at 13.000 rpm, samples were run on a 
gel at 150 V for ca. 40 - 60 min in running buffer. Afterwards the gel was stained with 
InstantBlueTM (Expedeon, Cambridgeshire, UK) staining solution for 15 min on a shaker and 
was washed with water afterwards. 
 
5.7.10. Concentration of protein samples 
Protein samples have to be concentrated before size exclusion chromatography and 
crystallization. Therefore, Vivaspin® concentrators (Sartorius AG, Göttingen, Germany) with 
an appropriate MWCO depending on the protein size were used in this study. The concentrator 
membrane was washed with buffer prior to use by centrifugation at 4.000 rpm for 5 min. After 
buffer removal, the protein sample was loaded in the concentrator. The protein sample was 
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concentrated by centrifugation at 4 °C and 4.000 rpm until the desired protein volume was 
reached. 
 
5.7.11.  Determination of protein concentration 
Protein concentrations were determined using a NanoDrop 1000 (VWR, Darmstadt, Germany) 
spectrophotometer. The theoretical molecular weight und extinction coefficient of the protein 
(table 13) were calculated based on the amino acid sequence using EXPASY ProtParam 
(Gasteiger et al., 2003). The absorption of the protein sample was measured at 280 nm. The 
protein concentration was calculated using the Lambert-Beer’s law (equation 5). 
 
;  < ∙  ∙ =>? (5) 
In this equation, A is the absorption of the protein solution at 280 nm, c is protein concentration 
in M, d is path length in cm and ε280 is the extinction coefficient at 280 nm in M-1cm-1. 
Table 13: Overview of theoretical molecular weight and extinction coefficient of all proteins purified in this study. 
Protein Molecular weight (kDa) Extinction coefficient (M-1cm-1) 
Strep-TcdB543-2366-His6 210.1 225430 
TcdB800-1834 116.3 92600 
CD1363 39.2 20525 
CD1364 16.0 23950 
CD1067 44.8 8900 
CD1219 39.5 23840 
CD1823 29.2 27850 
CD2589 34.3 20400 
CD2752 25.6 21890 
 
 
5.8. Protein crystallization and structure determination 
5.8.1.  Initial crystallization screens 
Screening for crystallization conditions was performed using the sitting drop vapor-diffusion 
technique in a 96 well INTELLI-PLATE® (Art Robbins Instruments, Sunnyvale, USA). Plates 
were set up using the Honeybee 961 (Zinsser Analytic GmbH, Frankfurt, Germany) dispensing 
robot. Drops consisted of 0.2 µl protein solution and 0.2 µl reservoir solution, the reservoir 
volume was 70 µl. Different commercially available screens (chapter 5.1.8) in combination with 
various protein concentrations (20 mg/ml, 15 mg/ml, 10 mg/ml, 5 mg/ml) were used for initial 
screening. All crystallization plates were set up at 20 °C. Crystallization plates were stored in 
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an automated imaging system (Formulatrix) and were imaged regularly. Images were 
inspected and analyzed manually via the Rockmaker software (Formulatrix). 
 
5.8.2.  Crystal optimization 
Some initial crystallization hits were optimized using grid or random screens. Optimization of 
crystallization conditions is necessary when crystals are e.g. too small for fishing or resolution 
is insufficient for data collection. In a grid screen, one crystallization condition is optimized by 
changing one parameter in each row or column of the screen, respectively, e.g. protein 
concentration, buffer pH, concentration of salt or precipitant, etc. The Formulator system 
(Formulatrix) was used to prepare random screens. Thereby, ingredients of several initial 
crystallization hits are randomly combined to find new crystallization conditions, which are not 
covered by using commercially available screens. Plates for crystal optimization were set up 
according to 5.8.1 using the Honeybee robot. 
 
5.8.3.  Data collection 
Unless stated differently, crystals were cryoprotected using 10% 2,3-butanediol added to the 
mother liquor. The crystals were fished with nylon loops and were flash-frozen in liquid 
nitrogen. Screening for crystal diffraction was performed inhouse (HZI, Braunschweig, 
Germany) at 100 K. Test images were collected using a wavelength of λ = 1.54 Å (Cu-Kα edge) 
and a Rigaku Saturn 944+ CCD detector. High-resolution datasets, as well as anomalous data, 
were collected at SLS (Swiss Light Source, Villigen, Switzerland; Müller et al., 2012), DESY 
(Deutsches Elektronen Synchrotron, Hamburg, Germany; Burkhardt et al., 2016) and BESSY 
(Berliner Elektronenspeicherring-Gesellschaft für Synchrotronstrahlung m. b. H., Berlin, 
Germany; Müller et al., 2015). Datasets that were used for structure determination in this study 
are listed in table 14. 
Table 14: Data collection strategies for protein crystals used in this study. 
Protein Beamline Detector Wavelength λ (Å) Images Oscillation (°) 
native CD1219  PXII, SLS PILATUS 6M 1.000 3600 0.1 
SeMet-CD1219  PXII, SLS PILATUS 6M 0.978 7200 0.1 
native CD1823  P11, DESY PILATUS 6M 1.033 3600 0.1 
SeMet-CD1363  PXIII, SLS PILATUS 6M 0.979 7200 0.1 
native CD1364  BL14.1, BESSY PILATUS 6M 0.918 3600 0.1 
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5.8.4.  Data processing and structure determination 
Data were integrated using XDS (Kabsch, 2010) and scaled using Aimless (Evans, 2006). 
Molecular Replacement was performed using Phaser from the Phenix (Adams et al., 2011) 
software. SeMet-SAD data were analyzed using the ShelX software (Sheldrick, 2008) and 
Autosol (Adams et al., 2010) for data processing. After structure solution, the model was built 
manually and refined in iterative cycles. COOT (Emsley & Cowtan, 2004; Emsley et al., 2010) 
was used for model building and phenix.refine (Afonine et al., 2012) for refinement. Final 
structures were validated using MolProbity (Chen et al., 2009) and figures were prepared using 
PyMOL (DeLano, 2002) and Chimera (Pettersen et al., 2004). 
 
5.8.5. Limited proteolysis 
To find more stable protein fragments for protein crystallization, limited proteolysis experiments 
were performed using Proti-AceTM and Proti-AceTM 2 Kit (Hampton Research). The protein 
solution was diluted to 10 mg/ml in 20 mM Tris/HCl pH 8.0, 150 mM NaCl. Proteases were 
diluted to 0.01 mg/ml with 10 mM HEPES pH 7.5, 500 mM NaCl. 10 µl protein was mixed with 
10 µl protease and incubated at 37 °C. After 1 h, 2 h and 16 h, protein digestion was stopped 
by addition of 5 µl 8X SDS sample buffer to 8 µl digested protein sample. 10 µl were run on a 
15% SDS-PAGE for analysis of protein digestion by the individual proteases. 
 
5.9. Small angle X-ray scattering 
5.9.1.  Principles of Small angle X-ray scattering 
Small angle X-ray scattering (SAXS) is an analytical method that is used for the structural 
analysis of proteins in solution at low resolution. It uses the same principle as X-ray 
crystallography: a protein sample is exposed to a focused X-ray beam, X-rays are diffracted 
by the protein sample and the scattered X-rays are recorded by a detector. In contrast to X-ray 
crystallography, the experiments are performed in solution and not in the crystalline state. Due 
to the random orientation of proteins in solution, structural information is lost during these 
experiments, which leads to a resolution of approximately 10 - 20 Å. Hence, one can get insight 
into the overall shape and the oligomeric state of the macromolecule in solution, but resolution 
is not high enough to determine the protein structure. SAXS is thus often used in combination 
with high-resolution techniques for structure determination, such as X-ray crystallography 
(Putnam et al., 2013). As SAXS is a contrast method, it is essential to measure a buffer blank. 
This blank has to be subtracted from the protein data to yield the diffraction of the protein 
sample exclusively without buffer background (Putnam et al., 2007). 
The protein solution is hit by X-rays of a certain wavelength, usually between 1 - 1.5 Å and 
intensities of the scattered X-rays are recorded by the detector at a low angle respective to the 
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incident beam (θ = 0.1 - 10°). The scattered intensities are recorded as a function of the 
scattering angle, resulting in a scattering curve. The intensity is dependent on the scattered 
vector |@⃗|, also called momentum transfer. This momentum transfer is described by the 
wavelength λ and the angle θ, where 2θ is the angle between incident and scattered beam 
(Feigin & Svergun, 1987). 
|@⃗|  4C ∙ sin 
  (6) 
 
Several important parameters can be directly derived from the scattering curve, enabling a fast 
characterization of the protein sample in regards of size, shape and oligomeric state of the 
protein. These parameters are e.g. the maximum particle diameter Dmax, molecular mass of 
the protein (MM), radius of gyration Rg and the volume of the hydrated particle Vp. The so-
called Guinier analysis of the experimental data is the most straightforward analysis to derive 
important parameters such as I0 and Rg (Guinier, 1939). Rg is the radius of gyration and 
describes the overall size of the particles. I0 is the intensity at θ = 0. The intensity Is of the 
scattered vector is described by the Guinier equation (equation 7) for globular proteins 
(s·Rg < 1.3). 
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By plotting ln(Is) against s2 in a Guinier plot, one directly gets information about Rg and I0. Rg 
can be derived from the slope and I0 from the y-axis intercept. The Guinier plot also gives an 
indication of the sample quality. A linear plot illustrates a monodisperse, globular folded sample 
(Guinier & Foumet, 1955). Non-linear plots indicate aggregation or an elongated shape of the 
protein (Fig. 8).  
 
Figure 8: Guinier Plot of a non-aggregated (left) and an aggregated protein sample (right). A Guinier Plot is a non-
linear plot of s2 against logarithmic intensities. I0 can be directly derived from the y-intercept of the plot, Rg can be 
derived from its slope. The shape of the Guinier-Plot gives an estimation of the sample quality, as a linear plot 
illustrates a high-quality and non-aggregated protein sample. 
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By comparison of I0 and protein concentrations with a standard protein (e.g. BSA), one can 
obtain an estimation of the molecular weight of the measured protein (equation 8; Smilgies & 
Folta-Stogniew, 2015; Mylonas & Svergun, 2007). 
JJK21LM)  D?,K21LM)/<K21LM) JJPL:)Q:2QD?,PL:)Q:2Q/<PL:)Q:2Q (8) 
Another important parameter used for data processing is Vp, the excluded volume of the 
hydrated particle. It can be calculated by the Porod equation (Porod, 1982) with Q as Porod 
invariant (equation 9). 
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 (9) 
The parameters Rg and I0 can also be extracted by Fourier-transformation of the scattering 
intensities. This Fourier-transformation results in the distance-distribution function p(r) (Koch 
et al., 2003; equation 10). 
V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In this function, r is the distance between two electrons in the particle. The distance-distribution 
function p(r) represents all pairwise distances in the protein in real space. The graphical shape 
of this function gives estimations about the protein shape (Fig. 9). Globular proteins usually 
have a bell-shaped distance-distribution function with a maximum at Dmax/2. An ab initio model, 
as well as a theoretical scattering curve for this model can be calculated based on the distance-
distribution function. This theoretical scattering curve is compared to the experimentally 
measured scattering curve. The theoretical model is then altered until theoretical and 
experimental scattering curves fit. One control parameter to evaluate the quality of this fit is 
the Χ-value (equation 11) (Grant et al., 2015). 
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In this equation, N is the number of experimental points. Iexp,sj and Icalc,sj are the experimentally 
measured and theoretically calculated intensities, respectively. η is a scaling factor and σsj is 
the experimental error. A SAXS model of high quality is indicated by a X-value < 5. 
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Figure 9: The distance distribution function p(r) is a Fourier-transformation of the scattered intensities of the SAXS 
sample. The shape of the function gives information about the shape of the measured protein. 
 
 
5.9.2. Experiments and data evaluation 
Protein samples for SAXS measurements were prepared by dialyzing the protein sample 
against SEC buffer. A dilution series (10 mg/ml, 5 mg/ml, 2.5 mg/ml, 1.25 mg/ml and 
0.625 mg/ml) of each protein was prepared and the dialysis buffer was used as a blank for the 
measurements. Data were collected at BM29, ESRF (European Synchrotron Radiation 
Facility, Grenoble, France; Pernot et al., 2013) using a PILATUS 1M detector, a sample 
detector distance of 2.867 m and a wavelength of λ = 0.9919.  
The experimental data of the buffer blank were subtracted from the experimental protein data 
using PRIMUS software (Konarev et al. 2003). This software was also used for normalizing, 
averaging and merging the experimental data. The program GNOM (Svergun, 1992) was used 
for evaluation of experimental parameters, such as radius of gyration Rg, zero intensity I0, 
maximum diameter Dmax of the particle and the distance-distribution function ρ(r). Using 
DAMMIF (Franke & Svergun, 2009), twenty runs of ab initio shape determination of the SAXS 
envelope were performed. A comparison of all models generated by DAMMIF was performed 
by damsel. This program also selected the most promising of all 20 models, determined and 
discarded possible outliers. An alignment of the selected models with the most promising one 
was conducted by damsup. damaver then averaged the models and computed a model map 
of the aligned and averaged models. The final SAXS model emerged after filtering the 
averaged model at a certain cut-off threshold by damfilt. Crysol (Svergun et al., 1995) was 
used to superimpose the calculated SAXS envelope and the crystal structure of the protein. 
The SAXS envelope was created using SITUS (Wriggers, 2012) and illustrated with Chimera 
(Pettersen et al., 2004) or PyMOL (DeLano, 2002). 
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5.10. CD spectroscopy 
5.10.1. Theory of CD spectroscopy 
In this study, CD (circular dichroism) spectroscopy was used to determine the secondary 
structure composition and quality of proteins in solution. Circular dichroism describes the 
phenomenon that chiral molecules can absorb left and right circularly polarized light to a 
different extent. In general, absorption of light is described by Lambert Beer’s law 
(equation 12), with I0 as intensity of the incoming light, I1 intensity of the outcoming light, ε 
extinction coefficient, c concentration of the sample and d as pathlength (Bulheller et al., 2007). 
a  bcdE? eD?DEf  = ∙ < ∙  (12) 
As chiral molecules show different extinction coefficients for left and right handed circularly 
polarized light (εL ≠ εR), ∆ε is recorded during CD spectroscopy (∆ε = εL - εR) as a function of 
the wavelength. ∆ε is then used to calculate the molar ellipticity (equation 13), which is 
monitored during CD spectroscopy. 

  <c@g ∙ =h − =G ∙ < ∙  (13) 
The absorption of light is dependent on the geometry of the optically active molecule. By 
comparing the CD-spectrum of a protein in a specific wavelength region with exemplary 
spectra of secondary structure motifs, one can get an idea about the secondary structure 
composition of the protein. The amide region (250 - 170 nm) is typically influenced by the 
peptide bond region of a protein. Specific secondary structure motifs enhance the absorption 
of light in this wavelength region and show a characteristic CD spectrum. Typically, α-helical 
proteins show two minima at 220 and 208 nm, β-sheets show a minimum at 215 nm (Fig. 10; 
Bulheller et al., 2007). Unfolded proteins usually give a minimum below 200 nm and a 
maximum around 210 - 220 nm. By measuring a CD spectrum of a protein sample, one can 
therefore directly get information of the proper folding of the protein. 
5.10.2. Experimental procedure 
Prior to spectrum collection, proteins were concentrated to 1 mg/ml in the respective size 
exclusion chromatography buffer and diluted with ddH2O to 0.1 mg/ml. The buffer was also 
diluted 1:10 with buffer for a blank measurement. CD spectra were collected at Jasco J-815 
CD spectrometer (Jasco, Gross-Umstadt, Germany) in 0.5 mm cuvettes (Hellma, Müllheim, 
Germany) from 190 – 300 nm, with 1 nm step resolution and 100 nm/min scanning speed. Ten 
spectra were measured for each protein and an averaged spectrum was calculated using 
Jasco Spec-Man-II software after buffer subtraction.  
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Figure 10: Exemplary CD spectra of secondary structure motifs. The CD spectrum of an α-helical protein is 
shown in red, the CD-spectrum of β-sheets in blue and that of random coils in magenta. Reproduced with 
permission from Biomolecular Crystallography by Bernhard Rupp, © 2009-2014 Garland Science/Taylor & 
Francis LLC. 
 
5.11. Thermal shift assay 
To identify the melting temperature of a protein and to determine the optimal buffer for protein 
purification, a thermal shift assay can be performed. The melting point of a protein in the 
respective buffer is an indicator of protein stability and differs between used buffers. More 
stable proteins unfold at higher temperatures compared to unstable proteins. Proteins in a 
suitable buffer therefore show a higher melting temperature than proteins in a buffer that is not 
suitable for protein purification and crystallization. Protein denaturation by temperature is 
monitored by observing the fluorescence of a fluorescent dye, in this case SYPRO orange. 
This dye binds to hydrophobic patches of the protein. In the native folded state, these 
hydrophobic patches are hidden inside the protein. The dye is not bound to the protein and 
therefore no (or only low) fluorescence is observed. When the protein is unfolded upon 
temperature increase, hydrophobic patches are exposed. The dye binds to these hydrophobic 
patches, which results in an increase of fluorescence. Protein unfolding can therefore be 
directly observed by measuring the fluorescence as a function of temperature (Huynh & Partch, 
2015). 
Prior to the thermal shift assay, a concentration test has to be performed to find the optimal 
experimental parameters (protein concentration, SYPRO orange concentration) for this assay. 
The SYPRO orange stock (5000X, Invitrogen) was diluted to 500x, 100x and 10x with ddH2O. 
The respective proteins were diluted to 2 mg/ml, 1 mg/ml and 0.5 mg/ml in the respective 
buffer. Different combinations of SYPRO orange and protein concentrations were tested in a 
96 well plate (MultiplateTM 96-Well Unskirted PCR plate, BIO-RAD, Hercules, USA). For this, 
5 µl of protein solution, 5 µl SYPRO orange solution and 40 µl of the respective buffer were 
5 Materials and Methods  43 
pipetted into a 96 well plate, the plate was sealed with Microseal®’B’ Adhesive Seal (BIORAD) 
foil and the measurement was performed using a CFX96TM RT-PCR device (BIO-RAD).  
After determining the best experimental parameters, the thermal shift assay was performed. 
Protein and SYPRO orange solution were diluted to the optimal concentrations, 5 µl of each 
solution were filled into 96-well plate and 40 µl buffer solution was added. Buffer screens were 
either prepared by Kevin Walkling (HZI, Braunschweig, Germany) or commercially available 
buffer or addivitive screens were used (RUBIC Additive screen, Molecular Dimensions). The 
plate was sealed with Microseal®’B’ Adhesive Seal (BIORAD) foil and was heated in 1 °C 
steps from 4 °C to 95 °C in a CFX96TM RT-PCR device (BIO-RAD). The fluorescence was 
measured using an excitation wavelength of 485 nm and emission wavelength of 575 nm. 
Melting curves were plotted and melting temperature was calculated using CFX Manager™ 
software (BIO-RAD). 
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6. Toxins of Clostridium difficile 
6.1. TcdB as one of the main virulence factors of Clostridium difficile 
Clostridium difficile produces several virulence factors, among these are its two most 
prominent ones, the secreted protein toxins Toxin A (TcdA) and Toxin B (TcdB). The 
homologous toxins belong to the family of large clostridial toxins (LCTs). This family includes 
many other toxins, e.g. α-toxin from Clostridium novyi and lethal toxin from Clostridium sordellii 
(table 15; Schirmer & Aktories, 2004). 
Table 15: Overview of toxins from the family of large clostridial toxins (LCTs). 
Toxin Molecular Weight (kDa) Strain 
Toxin A (TcdA) 308 Clostridium difficile 
Toxin B (TcdB) 270 Clostridium difficile 
Hemorrhagic toxin (TcsH) 300 Clostridium sordellii 
Lethal toxin (TcsL) 270 Clostridium sordellii 
α-toxin (Tcnα) 250 Clostridium novyi 
Large cytotoxin (TpeL) 191 Clostridium perfringens 
 
 
Figure 11: The homologous toxins TcdA and TcdB of Clostridium difficile show the same domain organization and 
mechanism of action. The top panel illustrates the domain architecture of the toxins. Respective domains are 
shown in different colors: glucosyltransferase domain (GTD) in red, autoprotease domain (APD) in blue, 
translocation domain (TLD) in yellow with its hydrophobic region in orange and the C-terminal receptor binding 
domain (CROPs domain) in green. A simplified schematic mechanism is shown in the bottom panel. After binding 
to host cell receptors, the toxin is taken up via clathrin-mediated endocytosis. Due to the acidic environment in the 
endosome, hydrophobic patches of the translocation domain are exposed and insert into the endosomal 
membrane to form a pore, through which the APD and GTD are transferred out into the cytosol. The APD cleaves 
off the GTD in the presence of InsP6 and the free GTD can then glycosylate and inactivate host cell GTPases. 
The bottom part of the figure is adapted from Pruitt & Lacy, 2012. 
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TcdA and TcdB are high molecular weight toxins (308 kDa and 270 kDa, respectively). They 
share 49% sequence identity and the same structural organization, which is illustrated in 
Fig. 11. In general, they consist of four domains that mediate the toxin mechanism of action 
(Shen, et al., 2012; Chumbler, et al., 2016): after toxin binding to the respective receptors on 
the host cell surface, the toxin is internalized via clathrin-mediated endocytosis 
(Papatheodorou et al., 2010). After acidification of the endosome, a pore is formed. The 
glucosyltransferase domain is cleaved off by the autoproteolytic domain and is transferred into 
the cytosol, where it inactivates host cell GTPases by glucosylation (Pfeifer et al., 2003). 
 
6.2. Domain architecture of TcdB 
Toxin B of Clostridium difficile consists of four domains: an N-terminal glucosyltransferase 
domain, followed by an autoprotease domain, an intermediate domain and a C-terminal 
CROPs domain (Jank & Aktories, 2008). In the following chapter, the structure, function and 
the current state of research of the individual TcdB domains will be discussed in detail. 
 
6.2.1. The C-terminal receptor binding domain 
The C-terminal domain of TcdB (aa 1834-2366) is characterized by several repetitive 
elements, the CROPs (combined repetitive oligopeptides). TcdB contains 19 short (20-23 aa) 
and 4 long (30 aa) repeats that are arranged in a repetitive manner (Fig. 13C). These CROPs 
form cell wall binding motifs and are predicted to bind to receptors on the host cell surface due 
to structural homology to other receptor binding domains of homologous toxins (Orth et al., 
2014). Nevertheless, it was recently shown by several studies that the CROPs domain is not 
the only receptor binding domain of TcdB. Truncation studies showed that a TcdB construct 
that lacks the CROPs domain can still enter host cells (Genisyuerek et al., 2011; Olling et al., 
2011). In addition, other homologous toxins are known that completely lack a CROPs domain, 
e.g. TpeL from Clostridium perfringens (Schorch et al., 2014). Thus, there must be a second 
receptor-binding domain present in TcdB upstream to the CROPs domain. A minimal fragment 
essential for cellular uptake was identified with TcdB1-1493 (Manse & Baldwin, 2015).  
Three receptors for this “additional” receptor binding domain of TcdB have been identified:  
• Poliovirus receptor-like protein 3 (PVRL3; LaFrance et al., 2015): expressed on the 
surface of human colon epithelial cells 
• Chondroitin sulfate proteoglycan 4 (CSPG4; Yuan et al., 2015): present in intestinal 
subepithelial myofibroblasts of mouse and human intestines 
46  6 Toxins of Clostridium difficile 
• Members of the Wnt receptor Frizzled protein family (Tao et al., 2016): components of 
the surface epithelium of the human colon 
Although it was shown that the CROPs domain is not essential for receptor binding, it has to 
play a major role during this first step of the toxin mechanism. One function of the CROPs 
domain could be to direct the toxin to the host cell by unspecific binding to the host cell surface, 
thereby directing the second receptor binding domain of TcdB to the specific receptors on the 
surface. Two antibodies (actoxumab, bezlotoxumab) that are directed against the CROPs 
domain of TcdA and TcdB, respectively, show a neutralizing effect of toxin cytotoxicity by 
blocking the binding of the toxin to host cell receptors (Yang et al., 2015). 
Crystal structures of TcdB CROPs fragments have been solved in complex with FAB domains 
of the neutralizing antibody bezlotoxumab (PDB-Code 4NP4; Orth et al., 2014) and with a non-
neutralizing antibody (PDB-Code 4NC2; Murase et al., 2014). Cryo-EM and SAXS studies 
revealed the overall shape of the full-length TcdB CROPs domain. The TcdB CROPs domain 
shows a horseshoe-shaped architecture, but a crystal structure of the full-length CROPs 
domain of TcdB has not been determined yet (Albesa-Jové et al., 2010; Pruitt et al., 2010). 
 
6.2.2. The intermediate translocation domain 
After receptor binding, the toxin is internalized via clathrin-mediated endocytosis. Due to the 
acidic environment in the endosome, the intermediate domain (TcdB800-1834) undergoes 
conformational changes and exposes hydrophobic parts. These regions insert into the 
endosomal membrane to form a pore (Qa’Dan et al., 2000). A low-resolution electron 
microscopy (EM)-envelope revealed the conformational changes of the translocation domain 
upon pH change during endocytosis. Upon pH decrease, it changes its conformation from a 
bilobed structure to a more elongated conformation (Pruitt et al., 2010).  
The intermediate domain of TcdB is responsible for pore formation and translocation of the 
enzymatically active part of the toxin into the host cell cytosol (Zhang et al., 2013). It contains 
a hydrophobic region (TcdB980-1107) that consists mainly of hydrophobic residues, e.g. 
isoleucine, glycine, leucine, valine. Several residues of this hydrophobic region are involved in 
pore formation of TcdB (Genisyuerek et al., 2011; Zhang et al., 2014). Zhang et al. (2013) 
identified eight residues between amino acids 1035 and 1107 that are involved in TcdB pore 
formation by mutational studies.  
Proteins that form membrane-inserting β-barrels typically contain a motif of alternating 
hydrophobic and hydrophilic parts. This motif is missing in the membrane-inserting part of 
TcdB. This indicates that the hydrophobic region of TcdB inserts into the endosomal membrane 
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via α-helical secondary structures and not as a β-barrel (Zhang et al., 2014). Due to the high 
homology of TcdB and diphtheria toxin, it can be assumed that both toxins use a similar 
mechanism of membrane insertion, as both toxins also show the same pattern of hydropathy. 
Diphtheria toxin inserts into the endosomal membrane as a double hairpin that consists of four 
α-helices, which form two connected helical hairpins, called “double-dagger”-motif (Choe et 
al., 1992; Wang et al., 2009). Besides a similar toxin mechanism and a strikingly similar 
hydrophobicity pattern between TcdB and diphtheria toxin, the eight TcdB residues that are 
involved in pore formation (Zhang et al., 2013) are conserved between TcdA and DT (Fig. 12). 
This points to the fact that both toxins use a similar way of pore-formation. It is hence possible 
that also TcdB of Clostridium difficile inserts into the endosomal membrane via helical 
secondary structure motifs similar to the double-dagger motif of diphtheria toxin. 
 
Figure 12: Sequence alignment of the TcdB regions that are involved in pore formation with the respective 
regions of TcdA from Clostridium difficile and diphtheria toxin (DT) from Corynebacterium diphtheria. Amino acids 
that were shown to be involved in pore formation of TcdB (Zhang et al., 2013) are marked with an orange asterisk. 
Conserved residues are highlighted by a black box. Residues with 70% similarity concerning physical-chemical 
properties are shown in bold letters.  
 
A crystal structure of the TcdB intermediate domain was not known at the onset of this thesis 
and hence was a major goal at that time. Furthermore, the exact molecular changes that take 
place in the intermediate domain upon pH change have been not known. A crystal structure 
and further biochemical and biophysical characterization of this domain would be necessary 
to draw conclusions about the mechanism of membrane insertion and pore formation of TcdB. 
 
6.2.3. The autoprotease domain 
After pore formation, the biologically active glucosyltransferase and autoproteolytic domain of 
TcdB are transferred out of the endosome. In the presence of eukaryotic inositol 
hexakisphosphate (InsP6) in the cytosol, the autoproteolytic domain cleaves off the 
glucosyltransferase domain (Egerer et al., 2009). 
The autoprotease domain of TcdB is homologuos to cysteine proteases of the MARTX toxin 
family (Shen et al., 2011). The catalytic triad (Asp593, His653, Cys698) coordinates a zinc ion 
that was shown to be essential for the autoproteolytic activity of TcdB (Chumbler et al., 2016). 
The binding site for InsP6 is located distal to the active site of the TcdB APD. Both sites are 
separated from each other by the secondary structure motif “β-flap”, which blocks the active 
site (Fig. 13B). Upon InsP6 binding, the “β-flap” undergoes a conformational change and the 
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active site gets accessible (Pruitt et al., 2009). The APD is then activated and can cleave off 
the GTD. 
The structure and mechanism of the TcdB APD are already well characterized due to the 
presence of crystal structures in complex with InsP6 (PDB-ID 3PEE; Shen et al., 2011) and 
with a peptide inhibitor (PDB-ID 3PA8; Puri et al., 2010). 
 
6.2.4. The N-terminal glucosyltransferase domain 
After cleavage by the APD, the N-terminal glucosyltransferase domain of TcdB can glucosylate 
and hence inactive host cell Rho-family GTPases such as RhoA, Rac1 and Cdc42 (Busch et 
al., 1998). The GTD (aa 1-543) of TcdB shows a typical glucosyltransferase type A fold with a 
central β-sheet and a common DXD motif (Asp286-Val287-Asp288; Fig. 13A). This motif is 
involved in binding the glucose-moiety of the cosubstrate UDP-glucose and coordination of a 
Mn2+ that is essential for catalytic activity of the GTD (Reinert et al., 2005). It transfers the 
glucose moiety from the cosubstrate UDP-glucose to a threonine residue (Thr35/37) of host 
cell Rho-family GTPases, whereupon these are inactivated. This inactivation of GTPases 
affects several downstream signaling processes, leading to a rearrangement of the actin 
cytoskeleton, cell rounding and apoptosis (Brito et al., 2002).  
 
Figure 13: Crystal structures of individual TcdB domains in cartoon representation. (A) The crystal structure of 
the TcdB glucosyltransferase domain (TcdB1-543; PDB-ID 2BVL, Reinert et al., 2005) is shown in dark red in 
complex with its cosubstrate UDP-glucose (shown as yellow sticks) and Mn2+ (shown as yellow sphere). 
Conserved residues (W101, DXD motif) are shown as blue sticks; the N-terminal 4-helical bundle is highlighted 
in light red. (B) The crystal structure of the autoprotease domain of TcdB (TcdB544-797; PDB-ID 3PEE, Shen et 
al., 2011) is illustrated in blue with bound InsP6 in yellow. The catalytic triad, which is essential for autoproteolytic 
activity of TcdB (C698, H653, D587), is shown in light blue, the “β-flap” motif is demonstrated in pink. (C) The 
crystal structure of a fragment of the CROPs domain of TcdB (TcdB1834-2099; PDB-ID 4NP4, Orth et al., 2014) 
is presented in light green. Two repeats are highlighted in dark green and orange, respectively. 
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6.3. Comparison of the homologous protein toxins TcdA and TcdB 
The overall sequence identity of TcdA and TcdB is around 49%. Both toxins share the same 
structural organization and can be separated into four individual domains (Jank & Aktories, 
2008). A sequence and structural alignment of the individual TcdA and TcdB domains reveals 
high similarity of three domains of toxin A and B. 
So far, no crystal structures of full-length TcdA and TcdB have been published. Only crystal 
structures of the glucosyltransferase domain, the autoprotease domain and fragments of the 
CROPs domain are solved for both toxins. For TcdA, a crystal structure of TcdA1-1838 
including the intermediate translocation domain has been published by another group during 
the progress of this thesis. This crystal structure is not available for toxin B. Nevertheless, a 
Phyre model of the TcdB translocation domain was generated in this thesis based on homology 
of the TcdB domain to the TcdA translocation domain. The structural similarity could be proved 
by SAXS analysis (chapter 6.5.3). The individual crystal structures as well as the Phyre model 
of the TcdB translocation domain and the crystal structure of the TcdA translocation domain 
will be analyzed in this chapter regarding their sequence and structural similarity. 
Table 16: Sequence and structural similarity of the individual domains of TcdA and TcdB. The sequence similarity 
was calculated using EMBOSS Needle (Needleman & Wunsch, 1970), the structural similarity was determined by 
a structural alignment performed in Coot (Emsley et al., 2010). 
Domain Number aa Sequence identity 
of TcdA and TcdB 
domains 
Structural similarity (r.m.s.d.) 
of TcdA and TcdB domains 
GTD TcdA-GTD 555 aa (PDB 3SRZ) TcdB-GTD 543 aa (PDB 2BVL) 50.6% 
1.10 Å 
(529 aligned residues) 
APD TcdA-APD 267 aa (PDB 3HO6) TcdB-APD 254 aa (PDB 3PEE) 55.2% 
1.00 Å 
(239 aligned residues) 
IMD TcdA-IMD 1021 aa (PDB 4R04) TcdB-IMD 1033 aa (Phyre model) 46.3% 
6.01 Å 
(699 aligned residues) 
CROPs TcdA-CROPs 878 aa (Phyre model) TcdB-CROPs 533 aa (Phyre model) 28.0% 
2.32 Å 
(143 aligned residues) 
 
The TcdA and TcdB glucosyltransferase domains (PDB-ID 3SRZ, Pruitt et al., 2012; PDB-ID 
2BVL, Reinert et al., 2005) share a sequence identity of 50.6% and the structures could be 
aligned with an r.m.s.d. of 1.10 Å. This indicates that the fold of both domains is almost identical 
with only minor differences in their sequence. A structure-based sequence alignment (shown 
in Fig. 81 in the supplement) shows that these differences are mainly located in loop regions 
and that the secondary structure elements as well as the active site composition of the TcdA 
and TcdB glucosyltransferase domain are highly conserved. 
Beside the glucosyltransferase domains, also the autoprotease domains of TcdA and TcdB 
(PDB-ID 3HO6, Pruitt et al., 2006; PDB-ID 3PEE, Shen et al., 2011) show a high sequence 
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and structural similarity. The sequence identity of both domains is 55.2% and both structures 
can be aligned with an r.m.s.d. of 1.00 Å, indicating an almost identical protein fold. A structure-
based sequence alignment is shown in Fig. 82 in the supplement. Patches of conserved 
residues are distributed over the whole protein structure and particularly all residues 
surrounding the active site, the InsP6 binding site and the β-flap are highly conserved. 
The only domain of TcdB that has structurally not been characterized so far is the intermediate 
translocation domain. The intermediate domain of TcdA and TcdB share a sequence identity 
of 46%. Due to their high sequence identity, it can be assumed that both domains share a 
similar protein fold. Therefore, a structural model of the TcdB translocation domain was 
calculated using Phyre2 (Kelley et al., 2015) based on the TcdA translocation domain as 
homology model. The crystal structure of the TcdA translocation domain (PDB-Code 4R04; 
Chumbler et al., 2016) and the Phyre model of the TcdB translocation domain can be aligned 
with an r.m.s.d. of 6.01 Å (Fig. 83 in the supplement). The central part of both domains can be 
aligned without striking deviations, but structural discrepancies between both domains are 
visible in the terminal regions of the domains. As the TcdA translocation domain was 
crystallized in presence of the neighboring autoprotease and glucosyltransferase domain, its 
structure could show slight differences in the orientation of its termini in contrast to a crystal 
structure without adjacent domains. The TcdB translocation domain termini could hence also 
undergo conformational changes in the presence of the neighboring domains, which might 
explain the high r.m.s.d. value upon alignment with the TcdA translocation domain. Another 
indicator for the high r.m.s.d. is the fact that a Phyre model of the TcdB translocation domain 
was used for the structural alignment. A crystal structure of this domain would be necessary 
to reveal the exact molecular structure and orientation of this domain and could result in a 
lower r.m.s.d. value. The structure-based sequence alignment of the TcdA and TcdB 
intermediate domain is shown in Fig. 14. 
In contrast to the above-mentioned highly similar domains of TcdA and TcdB, the C-terminal 
CROPs domain shows striking differences between toxin A and B (PDB-ID 2QJ6, Albesa-Jové 
et al., 2011; PDB-ID 4NP4, Orth et al., 2014). Their CROPs domains vary in their length, as 
well as in their amino acid composition. The TcdA CROPs domain is more than 300 residues 
longer than the TcdB CROPs domain and both domains share a sequence identity of only 
28%. The structural and especially the sequence differences between both homologous 
protein toxins could explain the fact that both toxins bind to different receptors on the host cell 
surface (Na et al., 2008; LaFrance et al., 2015). Low-resolution EM-studies (Pruitt et al., 2010) 
revealed that the overall shape and orientation of the TcdA CROPs domain is a long elongated 
tail protruding from the rest of the toxin structure. In contrast to this, the density for the TcdB 
CROPs domain was difficult to interpret, indicating that the TcdB CROPs domain is highly 
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flexible. This has also been shown by SAXS experiments of a TcdB fragment including the 
CROPs domain in this thesis (chapter 6.5.3.2). 
Overall, it can be summarized that full-length toxin A and toxin B share a similar structure with 
exception of their C-terminal CROPs domain. A full-length crystal structure or a SAXS 
envelope including all domains of both toxins would be essential to prove this hypothesis and 
to analyze the structural similarity of the homologous toxins of Clostridium difficile in atomic 
detail.  
 
Figure 14: Structure-based sequence alignment of the TcdA and TcdB intermediate domain. The sequence 
alignment was calculated by PromalS3D and edited by Espript. The aligned protein sequences of TcdA and TcdB 
are shown with conserved residues highlighted by a black box and similar amino acids are highlighted in bold. 
The secondary structure of the TcdA intermediate domain (PDB-ID 4R04; Chumbler et al., 2016) is depicted 
above the alignment, the secondary structure of a Phyre model of the TcdB intermediate domain is illustrated 
under the sequence alignment. α-helices are illustrated by spirals and β-sheets as arrows. The secondary 
structure elements are numbered consecutively. 
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6.4. Aim of this project 
At the beginning of this thesis, crystal structures of the intermediate domain of TcdB and full-
length TcdB were not available. For a better understanding of translocation and pore formation 
of Toxin B from Clostridium difficile, an atomic structure of its pore-forming domain is essential. 
The aim of this part of the thesis was therefore the structural analysis of the TcdB intermediate 
domain by X-ray crystallography and small angle X-ray scattering (SAXS). 
 
6.5. Structural analysis of TcdB from Clostridium difficile 
6.5.1. Establishment of a purification protocol for TcdB fragments 
Several expression constructs of the intermediate domain of TcdB were cloned from genomic 
Clostridium difficile CD630 DNA, as well as from synthetic DNA Codon-optimized for 
expression in E. coli. All TcdB constructs are summarized in table 35 - table 37 in the 
supplement. Test expression of all constructs was performed analogous to chapter 5.5, but 
expression of TcdB constructs in E. coli was problematic due to solubility problems and 
degradation of the recombinant proteins. To overcome degradation problems, expression of 
some constructs was performed in Bacillus megaterium. This bacterium is similar to 
Clostridium difficile and does not possess alkaline proteases, which could degrade 
recombinant gene products (Vary, 1994). It is therefore a suitable host for expression of 
Clostridium difficile toxins and toxin fragments (Yang et al., 2008; Burger et al., 2003). The 
construct that yielded the highest amount of soluble and stable TcdB was pHIS1522-TcdB543-
2366. This construct includes the autoprotease domain, the intermediate domain, as well as 
the CROPs domain of TcdB. It is fused to a non-cleavable N-terminal Strep- and a C-terminal 
His6-tag. Due to the intrinsic autoproteolytic activity of TcdB, the N-terminal Strep-tag was 
cleaved off during expression and purification of the construct via Strep-affinity 
chromatography was hence not possible. Therefore, the catalytically active residue Cys698 
was inactivated by mutation to an alanine residue using site-directed mutagenesis to prevent 
autocatalytic cleavage of the N-terminal Strep-tag.  
The resulting modified construct Strep-TcdB543-2366(C698A)-His6 was expressed in Bacillus 
megaterium at 37 °C in LB-medium, the detailed expression protocol is elucidated in 
chapter 5.6.1. After cell harvesting, the cell pellet was resuspended in buffer (20 mM Tris/HCl 
pH 8.0, 300 mM NaCl) supplemented with DNAse and protease inhibitor. The first purification 
step involved a Ni(II)-IMAC (binding buffer 20 mM Tris/HCl pH 8.0, 300 mM NaCl and elution 
buffer including 500 mM imidazole). The construct was eluted from the His-Trap column using 
a linear gradient from 0-500 mM imidazole. The fractions containing the TcdB construct were 
dialyzed against 20 mM Tris/HCl pH 8.0, 300 mM NaCl at 4 °C overnight to get rid of remaining 
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imidazole. Purification of the TcdB fragment involved a second affinity chromatography step 
using a Strep-Tactin column (20 mM Tris/HCl pH 8.0, 300 mM NaCl as binding buffer and 
20 mM Tris/HCl pH 8.0, 300 mM NaCl, 5 mM Desthiobiotin as elution buffer). A final size 
exclusion chromatography step was performed to remove potential aggregates using a 
S200 16/60 column in 20 mM Tris/HCl pH 8.0, 300 mM NaCl. The final protein yield was 
approximately 0.2 mg protein per liter cell culture. A schematic overview of the purification 
protocol, as well as the chromatogram of the final size exclusion chromatography step and an 
SDS-PAGE with the respective protein fractions are shown in Fig. 15. A further stable TcdB 
fragment (TcdB800-1834) could be purified in this thesis that was used for SAXS experiments 
(chapter 6.5.3.1). 
 
Figure 15: Production and purification of Strep-TcdB543-2366(C698A)-His6. The chromatogram and the 
corresponding SDS-PAGE of the final size exclusion chromatography are depicted in the bottom part of the 
scheme. A protein standard is shown in the first lane of the SDS-PAGE for comparison of the molecular weight 
of the purified construct (theoretical molecular weight ~ 210 kDa). 
 
54  6 Toxins of Clostridium difficile 
6.5.2. Crystallographic and EM-experiments of TcdB fragments 
TcdB fragments that showed sufficient purity after protein purification were used for 
crystallization experiments. Several commercially available screens in combination with 
different protein concentrations were used. Unfortunately, no crystal growth could be obtained 
for any TcdB construct during this thesis work. 
Besides protein crystallization, the construct Strep-TcdB543-2366(C698A)-His6 was also used 
for cryo-EM experiments. Initial negative stain screenings using uranyl acetate were performed 
at Prof. Dr. Thomas Marlovits’ lab (IMBA, Wien) to analyze whether the quality of the protein 
sample is suitable for following cryo-EM experiments. As the initial screenings revealed that 
many aggregates are present in the protein sample (Fig. 16), an improvement of sample quality 
should be performed prior to further cryo-EM experiments. 
 
Figure 16: Initial negative staining experiments of Strep-TcdB543-2366(C698A)-His6 with uranyl acetate (1:20 
dilution) reveal the presence of aggregates in the protein sample. 
 
6.5.3. SAXS analysis of TcdB fragments 
As both protein crystallization and initial electron microscopy experiments failed to reveal 
structural information about TcdB, SAXS experiments were performed to analyze the overall 
shape of TcdB and its oligomeric state in solution. SAXS data for two constructs (Strep-
TcdB543-2366-His6(C698A) and TcdB800-1834) were collected at BM29 ESRF (Grenoble, 
France; Pernot et al., 2013). Collection statistics are summarized in table 17. 
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Table 17: Summary of SAXS measurement parameters for TcdB constructs 
Construct Strep-TcdB543-2366 (C698A)-His6 TcdB800-1834 
Buffer 20 mM Tris/HCl pH 8.0, 
300 mM NaCl 
20 mM Tris/HCl pH 8.0, 
300 mM NaCl, 10% glycerol 
Protein concentration 0.57 mg/ml 0.5 mg/ml 
Number of experimental 
data points 1040 1040 
Dro 0.000 0.075 
Ra 1.800 1.400 
Rg 66.09 nm 43.71 nm 
Chi value 346.80 2.12 
Volume 287790 nm3 157475 nm3 
 
 
6.5.3.1. SAXS envelope of TcdB800-1834 
The construct TcdB800-1834 is composed of the intermediate translocation domain of TcdB. 
Solubility and affinity tags, which were attached to this construct for expression and purification, 
were cleaved off prior to SAXS experiments. The SAXS experiments of TcdB800-1834 were 
performed to get insights into the overall shape, conformation and orientation of the 
translocation domain of TcdB, as no crystal structure of this domain was available at the onset 
of this thesis.  
The fit of the experimental SAXS data and a theoretically calculated scattering curve for 
monomeric TcdB800-1834 is shown in Fig. 17A. A Phyre model of the TcdB translocation 
domain was generated based on homology to the TcdA translocation domain and was used 
for fitting the experimental data. A X-value of 2.12 indicates a good fit of experimental and 
theoretical data for monomeric TcdB800-1834 and indicates that the toxin fragment 
TcdB800-1834 is monomeric in solution. The Phyre model of monomeric TcdB800-1834 was 
afterwards fitted into the calculated SAXS envelope (Fig. 17B). 
 
 
 
 
 
 
56  6 Toxins of Clostridium difficile 
 
 
Figure 17: SAXS analysis of TcdB800-1834. (A) Fit of the experimental data (black dots) and a theoretical SAXS 
curve for monomeric TcdB800-1834 (orange curve). (B) Fit of a Phyre model of TcdB800-1834 (yellow cartoon 
representation) and the calculated SAXS envelope for monomeric TcdB800-1834. (C) Mapping of the 
hydrophobic region (orange), which is probably involved in pore formation, on the TcdB intermediate domain 
(yellow). 
The Phyre model of the TcdB translocation domain (TcdB800-1834) shows no homology to 
other known protein structures besides TcdA from Clostridium difficile. It consists mainly of β-
sheets. The hydrophobic region of TcdB (TcdB980-1107) (Zhang et al., 2014) that was shown 
to be probably involved in pore formation of the toxin was mapped on the Phyre model of the 
TcdB translocation domain (Fig. 17C). It shows that this hydrophobic region consists mainly of 
α-helical parts that wrap around the central β-sheets and reach from one end of the structure 
to the other. A long loop is located at the terminal part of this hydrophobic region, which is 
followed by a β-hairpin that contains the identified essential residues required for pore 
formation. It is assumed that these residues insert into the endosomal membrane (Zhang et 
al., 2014). Due to their location in the flexible loop and hairpin, their insertion into the 
endosomal membrane could be easily achieved by small conformational changes in the 
translocation domain. 
Because of the good fit of the TcdB Phyre model into the calculated SAXS envelope, it can be 
assumed that the theoretical Phyre model of the TcdB translocation domain reveals the 
conformation of the TcdB translocation domain in solution and is highly similar to the TcdA 
intermediate domain. However, only a crystal structure of the TcdB intermediate domain will 
reveal its exact molecular structure and conformation. 
 
6 Toxins of Clostridium difficile  57 
6.5.3.2. SAXS envelope of Strep-TcdB543-2366(C698A)-His6 
The orientation and shape of the TcdB translocation domain could be revealed by the SAXS 
envelope of TcdB800-1834 (chapter 6.5.3.1). To analyze its relative position with respect to 
the neighboring domains, additional SAXS experiments of the construct 
Strep-TcdB543-2366(C698A)-His6 have been performed. This fragment includes the 
autoprotease domain, the translocation and the CROPs domain of TcdB. The affinity tags used 
for purification could not be removed prior to the SAXS experiments, but due to their small size 
they should not hamper the measurements. 
Prior to the SAXS measurements, a theoretical model of TcdB was prepared using Phyre2 
(Kelley et al., 2015) based on homology to the TcdA crystal structure (PDB-ID 4R04; Chumbler 
et al., 2016). This model was also used for a fit into the calculated SAXS envelope of 
Strep-TcdB543-2366(C698A)-His6 (Fig. 18B). The fit of experimental SAXS data and the 
theoretically calculated scattering curve for the monomeric TcdB model is shown in Fig. 18A. 
A high X-value of 28.1 indicates a bad fit of experimental data and the theoretical model of 
monomeric TcdB. The individual TcdB domains were afterwards fitted separately into the 
calculated SAXS envelope (Fig. 18B). The crystal structure of the TcdB autoprotease domain 
(PDB-ID 3PEE; Shen et al., 2011) is shown in blue. For the fit of the intermediate translocation 
domain (TcdB800-1834) the calculated Phyre model (colored in yellow) was used in the same 
orientation that was revealed by the SAXS envelope of TcdB800-1834 (chapter 6.5.3.1). Due 
to the lack of a crystal structure of the full-length TcdB CROPs domain the structure of a 
CROPs fragments (PDB-ID 4NP4; Orth et al., 2004) was fitted two times into the SAXS 
envelope to model the full-length CROPs domain. Because this is only a manually modelled 
representation of the TcdB fragment, this fit of the individual TcdB domains into the SAXS 
envelope has to be interpreted with care. 
 
Figure 18: SAXS analysis of Strep-TcdB543-2366(C698A)-His6. (A) Fit of experimental data (black dots) and a 
theoretically calculated scattering curve for monomeric Strep-TcdB543-2366(C698A)-His6 (dashed blue line). 
(B) Fit of the individual TcdB domains into the calculated SAXS envelope for monomeric 
Strep-TcdB543-2366(C698A)-His6. The domains are shown in cartoon representation with the autoprotease 
domain in blue, the Phyre model of the intermediate domain in yellow and the CROPs domain in green. 
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The TcdA crystal structure (PDB-ID 4R04; Chumbler et al., 2016), which was published by 
another group during the progress of this thesis, revealed that the TcdA translocation domain 
starts at the C-terminal end of the APD domain and folds in a horseshoe-shape back to the 
APD domain. Due to high sequence similarity of TcdA and TcdB, it is assumed that the same 
is true for the TcdB structure. Therefore, it is highly possible that the TcdB CROPs domain 
starts between translocation and APD domain at the base of the APD domain. Also the EM 
envelope of TcdB (Pruitt et al., 2010) shows that the CROPs domain of TcdB is probably 
located in near proximity of the APD.  
The SAXS envelope of Strep-TcdB543-2366(C698A)-His6 indicates a high flexibility of the 
CROPs domain, as SAXS density for this domain is incomplete and only poorly resolved. It is 
usually difficult to calculate a SAXS envelope for highly flexible proteins or proteins that can 
be present in different conformational states (Putnam et al., 2007). It has already been shown 
by EM experiments (Pruitt et al., 2010) that the CROPs domain of TcdB can be present in 
different conformational states, while the rest of the protein does not change its orientation. 
Due to its high flexibility and the fact that the CROPs domain was modelled manually into the 
calculated SAXS envelope, it can be assumed that the orientation of the CROPs domain as 
illustrated in Fig. 18B will most probably not depict its actual conformation in solution. A crystal 
structure of the full-length CROPs domain or full-length TcdB would be helpful to discuss the 
orientation of the individual TcdB domains respective to each other. To summarize, the SAXS 
envelopes of TcdB fragments including the autoprotease, the intermediate and the CROPs 
domain of TcdB, which were calculated in this thesis, revealed that the TcdB intermediate 
translocation domain is highly similar to the TcdA domain regarding the overall shape of the 
domain. 
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7. Structural analysis of essential proteins 
7.1. Introduction 
7.1.1. The importance of structure determination of uncharacterized proteins 
The Protein Data Bank (PDB; Berman et al., 2000) is a database for crystal structures of 
biological macromolecules. Currently, 115.639 protein structures determined by X-ray 
crystallography are deposited in the PDB, which include only 120 protein structures of 
Clostridium difficile (status 22.02.18). As the genome of Clostridium difficile 630 encodes over 
3.700 proteins (Sebaihia et al., 2006), the amount of published structural information on these 
proteins is limited. Due to the inevitable need for new therapeutic treatment methods for CDI 
(Smits et al., 2016), the structural analysis of uncharacterized C. difficile proteins is an 
unavoidable requirement. Discovering new drug targets is only feasible, when the metabolic 
pathways and proteins involved in central processes inside the pathogen are well 
characterized (Lindsay, 2005). Structural and functional analysis of essential proteins of 
C. difficile has to go hand in hand to reveal insights into the bacterium and to uncover new 
potential drug targets.  
The aim of this project hence involved the structural and functional analysis of proteins from 
Clostridium difficile that are involved in central cellular processes. A detailed understanding of 
these proteins and the underlying mechanisms will guide the way to the development of new 
treatment methods for Clostridium difficile associated infections. Determination of novel protein 
structures is not only essential for a detailed atomic characterization but can also aid at 
functional characterization (Watson et al., 2005). A closer look at highly resolved crystal 
structures might identify potential binding cavities for protein ligands. By analysis of the 
surrounding amino acids and comparison to structurally related proteins, one could thus derive 
hypotheses about the potential molecular function (Wild et al., 2004), as conserved active site 
residues often indicate similar protein functions. Based on such findings, future biochemical 
experiments can be designed and initial in silico experiments, such as docking (Hermann et 
al., 2006), can be performed (Zhang & Kim, 2003). Nevertheless, it has to be considered that 
some proteins undergo conformational changes upon ligand binding, which makes docking 
experiments into apo-protein structures difficult and hence requires additional experiments for 
function determination (Hermann et al., 2007). 
The number of protein folds present in nature is limited (Chothia, 1976) and the amount of 
protein crystal structures available in the PDB is already extremely high. Therefore, it is likely 
that one finds a homologous protein with the same fold after solving the crystal structure of an 
uncharacterized protein. A comparison of the new structure with homologous functionally and 
structurally characterized proteins can hence give information on their potential molecular 
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function. On the other hand, analysis of structurally uncharacterized proteins is essential to 
detect novel protein folds that have not been deposited in the PDB so far (Wild et al., 2004).  
Besides a detailed structural characterization, analysis of the genomic environment of an 
uncharacterized protein can also reveal information about the function of the encoded protein, 
as proteins that are involved in the same metabolic pathway are often also located in the same 
genetic operon (Zhao et al., 2013). 
As structurally similar proteins might have different molecular functions in some cases 
(Finkelstein et al., 1993), additional experiments always have to be performed in order to prove 
a hypothetical function that was derived from the protein structure. Due to the difficulty of 
assigning a function to novel protein structures, many protein structures with unknown function 
are deposited in the PDB. 
 
7.1.2. Selection of uncharacterized essential proteins of Clostridium difficile 
The selection of uncharacterized proteins for this project was based on the work of Dembek et 
al., 2015. They identified several essential genes of the highly virulent epidemic Clostridium 
difficile strain R20291 using transposon-directed insertion site sequencing (TraDIS). Among 
these are 798 genes that are involved in spore production and 404 genes that are essential 
for growth of Clostridium difficile in vitro. Some of the encoded proteins could be functionally 
annotated due to homology to characterized proteins from related bacterial strains. Besides 
that, many proteins without annotated function have been identified that could serve as 
potential targets for this thesis. The distribution of characterized and uncharacterized proteins 
among all identified essential proteins is illustrated in Fig. 19. Only 242 of the 404 genes 
essential for growth have an annotated function. 109 genes have “putative” functions, 33 are 
annotated as hypothetical proteins and 20 genes encode uncharacterized proteins. Among the 
798 genes that influence spore production are 349 with annotated function, 334 with “putative” 
function, 96 hypothetical proteins and 19 uncharacterized proteins. The uncharacterized 
proteins are of special interest for this project in regards of finding new drug targets and novel 
protein folds.  
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Figure 19: Distribution of the genes that were identified by Dembek et al., 2015 to be essential for growth or 
sporulation of Clostridium difficile R20291 based on their annotated function.  
 
To select proteins for this part of the thesis, a BLAST search was performed first to find the 
respective homologues of the essential genes of C. difficile R20291 in the laboratory strain 
C. difficile 630. Several cut-off criteria were applied to discard proteins that are less well suited 
for structural characterization by X-ray crystallography, e.g. because of their content of 
transmembrane helices, their molecular weight or structural predictability etc. Proteins that 
were selected here contained 200 – 400 amino acids and no transmembrane helices, as these 
would hamper protein crystallization. Furthermore, their structure should not be predictable by 
common structure prediction servers. To search for structurally uncharacterized and 
unpredictable proteins, the PhyreBug server (unpublished) was developed by Dr. Joachim 
Reichelt. Using this server, whole genomes can be scanned combined with information about 
gene length, content of transmembrane helices and information about operon structure. 
Moreover, the structure prediction of the encoded protein by Phyre2 is provided. It was hence 
possible to discard proteins with known structure and high homology to structurally 
characterized proteins directly. 
The proteins that were finally selected based on the above-mentioned criteria are summarized 
in table 18. The genes encoding these proteins were synthetically codon-optimized for 
expression in E. coli and purchased from Life Technologies GmbH (Darmstadt, Germany). 
They were cloned in various expression vectors by SLIC-cloning as well as traditional cloning 
using restriction enzymes. Test expression in E. coli was performed with all constructs and the 
best condition was used for large-scale expression. Proteins were purified using affinity 
chromatography, ion exchange and size-exclusion chromatography to yield pure protein that 
was subsequently used for protein crystallization. Structural analysis was performed by X-ray 
crystallography and small angle X-ray scattering. The determined protein structures were then 
compared to published structures in the PDB to search for structurally related proteins and to 
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derive ideas about their potential function. A schematic overview of the general workflow 
together with achieved results for each protein is summarized in Fig. 54. 
Table 18: Summary of essential proteins of Clostridium difficile that were selected for this project. 
Protein Molecular Weight (kDa) Number of amino acids Theoretical pI Involved in 
CD1067 44.76 405 4.78 sporulation 
CD1219 39.51 355 5.96 growth 
CD1823 29.19 247 9.10 sporulation 
CD2589 34.26 293 4.89 growth 
CD2752 25.63 221 5.21 sporulation 
 
 
7.2. The uncharacterized protein CD1219 of Clostridium difficile 
CD630_12190 (CD1219) of Clostridium difficile is a 39.5 kDa protein with unknown function 
and structure. In 2015, Dembek et al. showed that its homologous gene CDR20291_1057 from 
C. difficile strain R20291 is essential for growth of C. difficile in vitro. Thus, it can be assumed 
that CD1219 might also be involved in central cellular processes and determination of its 
crystal structure would facilitate a detailed understanding of its structure and molecular 
function. 
 
7.2.1. Cloning, expression and purification of CD1219 
Bioinformatic analysis and secondary structure prediction of CD1219 by PSIPRED 3.3 
(McGuffin et al., 2000) revealed that the protein does not contain disordered regions at its N- 
and C-terminus, respectively. Therefore, full-length CD1219 was used for cloning experiments. 
To overcome potential expression problems, the DNA encoding CD1219 was codon-optimized 
for expression in E. coli (synthetic DNA ordered at LifeTechnologies, Darmstadt, Germany). 
Synthetic CD1219 DNA was cloned in a pET-Sumo vector by SLIC cloning, resulting in 
CD1219 fused to an N-terminal His6-Sumo tag followed by a cleavage site for Sumo-protease. 
After test expression in several E. coli strains, the fusion protein was solubly expressed in 
E. coli Rosetta2(DE3) cells in TB-medium after induction with 1 mM IPTG at 20 °C overnight. 
Native CD1219 was purified via 4-step purification (table 12). After a Ni(II)-IMAC, the 
His6-Sumo tag was cleaved by Sumo-protease overnight. To get rid of cleaved tag and 
protease, a second Ni(II)-IMAC was performed, followed by anion exchange chromatography 
and a size exclusion chromatography. The final yield of pure protein after size exclusion 
chromatography was 11 mg from 1 L cell culture. The chromatogram of the size exclusion 
chromatography of native CD1219 and the corresponding SDS-PAGE are shown in Fig. 20. 
The protein elutes as a dimer and the peak shows a small shoulder indicating that monomeric 
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CD1219 is still present in the sample. These fractions of monomeric CD1219 were hence 
discarded prior to further experiments. 
 
Figure 20: Final size exclusion chromatography of native CD1219. The elution profile of the final size exclusion 
chromatography of native CD1219 using a S200 26/60 column is shown in the left panel. The corresponding 
SDS-PAGE with eluted fractions is shown in the right figure. The blue bar represents the fractions that were 
pooled after size exclusion chromatography and were used for crystallization and SAXS experiments. A protein 
standard is shown in the left lane of the SDS-PAGE for an estimation of the molecular weight of the purified 
protein. The theoretical molecular weight of CD1219 is 39.5 kDa. 
 
7.2.2. Crystallization and structure determination of CD1219 
Initial crystallization screens (Core I-IV, Morpheus, Index, ProteinComplex) were set up with 
native CD1219 in different concentrations (20 mg/ml, 10 mg/ml, 5 mg/ml) immediately after 
purification. Crystal growth was obtained in various conditions already after 12 hours. Datasets 
of native CD1219 crystals were collected at PXII at SLS (Villigen, Switzerland; Fuchs et al., 
2014). Due to the lack of structural homologs of CD1219, molecular replacement was not 
possible for structure determination. Soaking heavy atoms into the native crystals was not 
successful due to crystal cracking. Therefore, SeMet-labeled CD1219 was produced in E. coli 
Rosetta2(DE3) analogous to the protocol in chapter 5.6.2.2. Purification of SeMet-labeled 
CD1219 was performed analogously to native CD1219. The final size exclusion 
chromatography elution profile of SeMet-labeled CD1219 and the corresponding SDS-PAGE 
is shown in Fig. 21. Crystallization screens were set up analogously to native CD12129 and 
crystals of SeMet-CD1219 appeared after 12 hours in various conditions. High-redundancy 
datasets of SeMet-CD1219 crystals were collected at PXII, SLS. Exemplary CD1219 crystals 
are shown in Fig. 22. Data collection statistics of native CD1219 and SeMet-CD1219 crystals 
are summarized in table 19. 
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Figure 21: Final size exclusion chromatography of SeMet-labeled CD1219. The elution profile of the final size 
exclusion chromatography (using a S200 26/60) is shown in the left figure. The corresponding SDS-PAGE with 
eluted protein fractions is shown in the right figure. A protein standard was loaded in the left lane of the SDS-
PAGE to estimate the molecular weight of the purified protein. The theoretical molecular weight of SeMet-labeled 
CD1219 is approximately 40 kDa. The blue bar represents the fractions that were pooled after size exclusion 
chromatography and were used for crystallization setups of SeMet-labeled CD1219. 
 
Figure 22: Exemplary crystals of native CD1219 (A) and SeMet-labeled CD1219 (B). (A) Crystal of native 
CD1219 in Morpheus Screen appeared 2 days after setup in the crystallization condition 5 mg/ml CD1219, 30% 
P550MME-P20K, 0.1 M Morpheus buffer 1 pH 6.5, 0.09 M Morpheus Nitrate-Phosphate-Sulfate. (B) Crystal of 
SeMet-labeled CD1219 in Morpheus Screen emerged 2 days after setup in the crystallization condition 5 mg/ml 
SeMet-CD1219, 30% P550MME-P20K, 0.1 M Morpheus buffer 3 pH 8.5, 0.09 M Morpheus Nitrate-Phosphate-
Sulfate. 
Table 19: Data collection statistics for a native CD1219 dataset and a SeMet dataset. 
Dataset CD1219_native CD1219_SeMet 
Wavelength (Å) / beamline 1.000 / SLS, PXII 0.978 / SLS, PXII 
Resolution range (Å) 48.29-1.80 (1.84-1.80) 48.33-1.80 (1.84-1.80) 
Space group P212121 P3121 
Unit cell parameters (Å) 
                          (°) 
56.1   102.8   141.2 
90       90        90 
104.06   104.06   130.56 
90          90         120 
Mosaicity (°) 0.20 0.05 
Total No. of measured reflections 1019887 (52958) 3080270 (171377) 
Unique reflections 76500 (4464) 76151 (4471) 
Multiplicity 13.3 (11.9) 40.4 (38.3) 
Mean I/σ(I) 18.6 (1.4) 31.7 (3.2) 
Completeness (%) 100 (100) 100 (100) 
Rmeas (%) 11.0 (202.3) 9.9 (156.8) 
Rp.i.m. (%) 4.1 (81.4) 2.2 (35.3) 
CC1/2 (%) 99.9 (53.2) 100 (85.3) 
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Native CD1219 crystallized in spacegroup P212121 with two molecules in the asymmetric unit 
(AU). Native crystals diffracted to 1.8 Å. SeMet-labeled CD1219 crystallized in spacegroup 
P3121 with two molecules in the AU. Crystals of SeMet-CD1219 also diffracted to 1.8 Å. The 
crystal structure of CD1219 was solved by single-wavelength anomalous diffraction (SAD) 
using one high-redundant SeMet dataset and Autosol for structure determination and data 
processing. An initial model of CD1219 was prepared using Autobuild. Further manual model 
building was performed with Coot and Phenix.refine was used for structure refinement. As 
native and anomalous CD1219 crystallized in different spacegroups, the final CD1219 model 
was used for molecular replacement using the native dataset of CD1219 by Phenix.phaser, 
but no differences between the structure of native and SeMet-CD1219 were visible. For the 
rest of this thesis, the native CD1219 structure was used for structural analysis. The refinement 
statistics for the structure of native CD1219 are shown in table 20 and the quality of electron 
density is exemplarily depicted in Fig. 23. 
 
Table 20: Refinement statistics of CD1219. 
Dataset CD1219_native (Refine31) 
Resolution Range (Å) 48.29 - 1.8 (1.864 - 1.8) 
Rwork (%) 16.0 (26.0) 
Rfree (%) 18.9 (30.2) 
No. of non-H atoms 6172 
Protein 5547 
Ligand 62 
Water 563 
R.m.s. deviation  
Bonds (Å) 0.008 
Angles (°) 0.87 
Average B factors (Å2)  
Protein 39 
Ligand 70 
Water 48 
Ramachandran plot  
Favored regions (%) 97.29 
Outliers (%) 0.00 
MolProbity score 1.35 
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Figure 23: 2Fo-Fc-electron density of CD1219 at sigma contour level 1.2. 
 
7.2.3. SAXS analysis of CD1219 
The oligomeric state of CD1219 in solution was analyzed by SAXS experiments. Data of native 
CD1219 were collected at BM29 ESRF (Grenoble, France; Pernot et al., 2013). Best data and 
scattering curves were obtained for 5 mg/ml CD1219 in 20 mM Tris/HCl pH 8.0, 150 mM NaCl. 
After data averaging and buffer subtraction, a SAXS envelope was calculated using DAMMIF 
and the oligomeric state of CD1219 was analyzed using the program Crysol. The experimental 
SAXS data were fitted using theoretically calculated data for monomeric and dimeric CD1219 
(Fig. 24A and B). The fit of experimental data with the theoretical curve for monomeric CD1219 
can be described by a X-value of 217.8, the fit with dimeric CD1219 shows a X-value of 8.1. 
As a lower X-value indicates a better fit of experimental and theoretical data, SAXS analysis 
of CD1219 revealed that the protein is present as a dimer in solution. These results are in line 
with size exclusion chromatography experiments. The crystal structure of dimeric CD1219 was 
fitted into the calculated SAXS envelope (Fig. 24C) and the calculated SAXS envelope 
represents the overall shape of the protein in solution. As almost all parts of the CD1219 crystal 
structure are covered by the SAXS envelope, it can be assumed that the structure of CD1219 
is identical in solution and in the crystal. 
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Figure 24: SAXS analysis of CD1219. (A) and (B) Experimental SAXS data (black dots) were fitted against 
theoretically calculated curves (blue line) for monomeric (A) and dimeric (B) CD1219. (C) The crystal structure 
of dimeric CD1219 was fitted into the calculated SAXS envelope and is shown in different orientations to illustrate 
the shape of CD1219 in solution. 
 
7.2.4. Crystal structure and domain organization of dimeric CD1219 
CD1219 is dimeric in solution (as shown by size exclusion chromatography and SAXS 
experiments). In the crystal state, two CD1219 molecules are present in the asymmetric unit, 
indicated by a Matthews coefficient of 2.58 and a solvent content of 52.26%. The crystal 
structure of dimeric CD1219 is depicted in Fig. 25A. The two chains are highlighted in marine 
and cyan, respectively. The dimer shows a butterfly shape and the monomer can be divided 
in a small N-terminal and a larger C-terminal domain that are connected via a small linker. The 
electron density for all amino acids of the CD1219 sequence was resolved in chain A, while 
density for amino acids 60-63 is missing in chain B. This indicates flexibility of this part of the 
protein. 
 
68  7 Structural analysis of essential proteins 
 
Figure 25: Crystal structure of dimeric CD1219 of Clostridium difficile. The dimer is shown in cartoon 
representation with the two chains in marine blue and cyan, respectively. (A) Exemplary interactions that stabilize 
the dimer interface. In the top right figure, two exemplary hydrogen bonds between Asn276 of chain A and Lys240 
of chain B, as well as between the backbone oxygen of Tyr224 of chain A and Asn192 of chain B are shown. In 
the bottom right figure, the two salt bridges between Arg5 and Glu76 of each chain are depicted. (B) The two 
CD1219 chains interact tightly with each other. The β-strands (colored in yellow) that connect the large and the 
small domain of one chain insert into the groove between the large and small domain of the other chain and the 
other way around. This creates a handshake-like interaction between the two monomers. (C) The two CD1219 
chains share the same secondary structure, while the small domains (colored in pink) are slightly shifted by 6.5° 
relative to each other. (D) Interaction of the small domains in the CD1219 dimer is stabilized by attractive 
electrostatic charge distribution. 
The interaction surface of the two monomers is 3687.4 Å2. The surface area of chain A and B 
is 16618 Å2 and 16942 Å2, respectively. The solvation free energy ΔiG that is gained upon 
dimer formation is -46.3 kcal/mol. The dimer is stabilized by several hydrogen bonds and salt 
bridges between the 100 interface residues of chain A and the 94 interface residues of chain B. 
No disulfide bond is involved in the CD1219 dimer formation. Exemplary salt bridges and 
hydrogen bonds that stabilize the CD1219 dimer are depicted in Fig. 25A and a summary of 
all bonds involved in dimer formation is listed in table 21 (data generated by PISA server, 
Krissinel & Henrick, 2007). The dimer is further stabilized by the tight packing of both chains. 
The two β-strands that are located in the linker region between the small and the large domain 
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of one chain insert into the groove between the large and the small domain of the other chain 
and the other way around (Fig. 25B). This creates a handshake-like interaction of both 
monomers. 
Both monomers can be aligned on top of each other with an r.m.s.d. of 1.44 Å including 352 
of 355 residues. The large domains of chain A and B can be aligned with an r.m.s.d. of 0.57 Å 
and the small domains with an r.m.s.d. of 2.05 Å. The overall architecture of both monomers 
is the same, while the small domain of chain B is slightly rotated by 6.5° relative to the small 
domain of chain A (Fig. 25C). Due to the symmetry of the CD1219 dimer, the surfaces of the 
small domains that face each other show an opposite electrostatic charge distribution. The 
CD1219 dimer is hence further stabilized due to electrostatic attraction between the small 
domains of each chain (Fig. 25D). 
Table 21: Overview of interactions between interface residues of chain A and chain B of the CD1219 dimer that 
stabilize the dimer formation. The residues of the respective chains are described by the three-letter amino acid 
code and their position in the CD1219 sequence. The atom involved in the salt bridge or hydrogen bond is indicated 
in brackets according to the typical PDB-file format. The bond distance is denoted in Å. 
                                  Salt bridges 
No. chain B residue Dist. [Å] chain A residue      
1 Arg5 [NH1] 3.65 Glu76 [OE1]      
2 Glu76 [OE1] 3.49 Arg5 [NH1]      
Hydrogen bonds 
No. chain B residue Dist. [Å] chain A residue  No. chain B residue Dist. [Å] chain A residue 
1 His0 [H2] 1.65 Thr80 [OG1]  21 His0 [O] 2.10 Thr80 [H] 
2 His0 [ND1] 3.85 Thr78 [O]  22 Met1 [O] 1.96 Lys96 [H] 
3 Met1 [H] 2.16 Lys38 [O]  23 Lys4 [O] 2.30 Ser77 [H] 
4 Lys4 [H] 2.19 Ser77 [O]  24 Ile39 [O] 1.95 Lys4 [HZ2] 
5 Lys4 [HZ2] 2.02 Ser77 [OG]  25 Glu76 [OE2] 2.16 Val6 [H] 
6 Lys4 [HZ1] 2.06 Ile39 [O]  26 Ser77 [O] 2.14 Lys4 [H] 
7 Arg 5 [HH22] 2.20 Thr78 [OG1]  27 Ser77 [OG] 2.07 Lys4 [HZ3] 
8 Val6 [H] 2.15 Glu76 [OE2]  28 Thr78 [OG1] 2.03 Arg5 [HH22] 
9 Tyr36 [HH] 1.97 Tyr90 [O]  29 Arg89 [O] 2.16 Leu157 [H] 
10 Asn52 [HD21] 2.06 Gln94 [O]  30 Tyr90 [O] 1.84 Tyr36 [HH] 
11 Asn52 [HD22] 2.03 Pro92 [O]  31 Pro92 [O] 2.05 Asn52 [HD22] 
12 Ser77 [H] 2.43 Lys4 [O]  32 Gln94 [O] 2.12 Asn52 [HD21] 
13 Leu79 [H] 2.08 Ser3 [OG]  33 Gln94 [O] 3.89 Thr54 [OG1] 
14 Thr80 [H] 2.32 His0 [O]  34 Asp153 [O] 1.95 Arg89 [HH22] 
15 Arg89 [HH12] 1.90 Ile217 [O]  35 Ala155 [O] 2.19 Arg89 [HH21] 
16 Lys96 [H] 2.09 Met1 [O]  36 Gly219 [O] 2.31 Gln103 [HE22] 
17 Leu157 [H] 2.20 Arg89 [O]  37 Tyr224 [O] 1.97 Asn192 [HD21] 
18 Asn192 [HD21] 2.06 Tyr224 [O]  38 Glu273 [O] 1.81 Lys240 [HZ2] 
19 Lys240 [HZ1] 1.91 Asn276 [OD1]  39 Asn276 [OD1] 1.96 Lys240 [HZ1] 
20 Lys240 [HZ2] 1.99 Glu273 [O]      
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The CD1219 monomer consists of two domains. The small N-terminal domain (aa 1-72) forms 
a β-barrel that is made up of five antiparallel β-strands. It is flanked by two short α-helices that 
cap the top and bottom part of the β-barrel. A short linker (48 aa), which consists of two short 
antiparallel β-strands and a short α-helix, connects the small N-terminal domain with the larger 
C-terminal domain. This large C-terminal domain (aa 121-353) is characterized by a central β-
sheet of eight parallel β-strands that are flanked by several α-helices. The domain organization 
of CD1219 is illustrated in Fig. 26C with the small N-terminal domain in pink, the short linker in 
yellow and the large C-terminal domain in blue. The colors of the respective domains will be 
retained during the following chapters. The structures of the small and the large domain are 
shown in Fig. 26A and B with the corresponding topology diagrams, respectively. 
 
 
Figure 26: Domain organization of monomeric CD1219. (A) The small domain of CD1219 is shown in cartoon 
representation (left) and as topology diagram (right). The central β-barrel is colored in pink with the flanking α-
helices in light pink. In the topology diagram, α-helices are shown as cylinders and β-sheets as arrows. The 
secondary structure motifs are numbered consecutively. (B) The large domain of CD1219 is illustrated in cartoon 
representation (left) and as two-dimensional topology diagram (right). The central β-strands are colored in blue 
and surrounding secondary structure motifs in light cyan. (C) Monomeric CD1219 consists of a small N-terminal 
domain (pink), followed by a linker (yellow) and a large C-terminal domain (blue). 
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7.2.5. Comparison of dimeric CD1219 with homologous structures 
To get an idea about the function of CD1219, its crystal structure was compared to structurally 
similar proteins. For this purpose, the protein structure alignment servers DALI (Holm, et al., 
2016) and PDBeFold (Krissinel & Henrick, 2004) were used. A structural alignment is usually 
characterized by the r.m.s.d. and the sequence identity of the aligned protein structures. The 
PDBeFold Q-score is an indication for the alignment quality, as it includes both the r.m.s.d. 
value of the structural alignment as well as the sequence identity of the aligned proteins. A 
high Q-score indicates a promising structural alignment, while a value of 1 reveals identical 
protein structures. The DALI server uses the so-called Z-score for evaluation of the structural 
alignment. This score is similar to the PDBeFold Q-score, as it also indicates the order of 
structural similarity between the aligned proteins. It ranges between 0 and 10 with 10 showing 
the highest structural similarity. A Z-score higher than 2 usually indicates that the two aligned 
proteins are significantly similar, illustrating that they share a similar protein fold. 
The search for structural homologous proteins of CD1219 was performed with dimeric 
CD1219, monomeric CD1219 and with the individual domains of CD1219, respectively. No 
structurally homologous proteins were found for the CD1219 dimer and monomer, but for the 
large and the small domain, respectively. The structures of the large and the small domain 
seem to be similar to conserved protein folds, but the combination of both domains in the 
CD1219 monomer and dimer might be unique. An analysis of the structural alignment results 
of the individual CD1219 domains can be found in 7.2.6 and 7.2.7. 
 
7.2.6. The small domain of CD1219 
The small N-terminal domain of CD1219 forms a five-stranded β-barrel with a hydrophobic 
core including Val9, Ile22, Val24, Ile43, Val49, Leu51 and Val68 (Fig. 27C). Strands β1-β4 
form the common Greek key motif with three antiparallel β-strands and the fourth β-strand 
antiparallel and adjacent to the first one (Hutchinson & Thornton, 1993). One side of the small 
domain shows a neutral electrostatic surface charge with small positively charged regions that 
are created by the positively charged amino acids Lys4, Arg32 and Lys38 (Fig. 27A). This side 
of the small domain is directed to the cleft between the small and large domain and is hence 
not directly accessible. In addition, the aromatic amino acids of the small domain (Tyr34, Tyr36, 
Tyr65 and Phe67) are also accommodated on this side of the protein. On the opposite side of 
this domain, the surface shows a predominantly negative charge due to the presence of 
negatively charged amino acids Glu10, Ser11, Asn25, Glu29, Asn44, Asp47, Glu48 and Asn71 
(Fig. 27B). This negatively charged surface of the small domain faces away from the rest of 
the CD1219 molecule and is hence accessible to potential binding partners. 
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Figure 27: Amino acid distribution and electrostatic surface charge of the small N-terminal domain of CD1219. 
The crystal structure of the N-terminal domain of CD1219 is shown in cartoon representation with amino acid 
side chains as grey sticks. Representation (B) is a 180° turned representation of (A) and the orientation in (C) 
depicts the view from the top onto the β-barrel. The bottom panel of each figure illustrates the electrostatic surface 
charge distribution of the respective cartoon representation in the panel above. 
 
The crystal structure of the small N-terminal domain of CD1219 was submitted to the structural 
alignment servers DALI (Holm & Laakso, 2016) and PDBeFold (Krissinel & Henrick, 2004) 
analogous to chapter 7.2.5. The results of this structural homology search are summarized in 
table 22.  
The small domain of CD1219 shows an OB-fold (oligonucleotide/oligosaccharide binding), 
which is common among DNA-/RNA-binding proteins (Theobald et al., 2003). The structural 
homology search (table 22) revealed a high similarity between the small N-terminal domain of 
CD1219 and DNA-/RNA-binding proteins, e.g. IF1s and Csps. Despite a low sequence 
similarity among OB-fold members, they all share a common protein fold characterized by a 
central β-barrel. The loops, which connect the central β-strands, are variable in their length 
and can contain further small secondary structure elements. In most cases, they are between 
70 and 150 amino acids long and they can serve as “recognition domains” in larger proteins 
(Flynn & Zou, 2010). Several residues are conserved among OB-fold proteins, e.g. a glycine 
residue in the first half of β1 and a further glycine residue at the beginning of β4, probably 
mediating the termination of the preceding α-helix. In most cases, the ligand-binding site is 
located on strands β2 and β3 and can be additionally increased by the neighboring loops 
between β1-β2, β3-α, α-β4 and β4-β5 (Theobald et al., 2003).  
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Table 22: Summary of the structural alignment search of the small domain of CD1219 using PDBeFold and DALI. 
Letters in brackets behind the PDB-Code indicate the protein chain that was used for the structural alignment. 
Proteins are listed with decreasing Q- and Z-score, respectively. 
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Depending on their function and binding mode, OB-fold proteins can be grouped into different 
categories: proteins that bind specific regions of single-stranded nucleic acids, proteins that 
bind nucleic acids without strong sequence-specificity and proteins that bind non-helical 
nucleic acids. The function of OB-fold proteins is diverse, as they are involved in various 
processes, e.g. DNA replication, transcription, translation, cold shock response, etc., but most 
of them bind single stranded nucleic acids (ssDNA/ssRNA) (Arcus, 2002). 
The structural homology search of the small domain of CD1219 revealed striking structural 
similarity to IF1s. IF1 is the smallest of the three translation initiation factors (IF1, IF2, IF3) that 
are essential for the formation of the translation initiation complex. They ensure the correct 
assembly and enhance the specificity of the complex (Hatzopoulos et al., 2010). IF1 binds to 
the A-site of the 30S subunit of the ribosome and guarantees the selection of the correct start 
codon. A crystal structure of IF1 from Thermus thermophilus in complex with the 30S ribosome 
(PDB-ID 1HR0; Carter et al., 2001) showed that IF1 binds to a cleft on the surface of the 30S 
subunit. Upon hydrogen bonding of IF1 and the ribosomal backbone, the RNA undergoes 
striking conformational changes. Two adenine residues are flipped out and bind to conserved 
arginine residues of IF1. This interaction is stabilized by further conserved IF1 residues and 
several hydrogen bonds and electrostatic interactions in this region (Carter et al., 2001). 
To illustrate the similarities between the small domain of CD1219 and IF1s, a structure-based 
sequence alignment with different bacterial IF1s is shown in Fig. 28A. It reveals that the overall 
structure and topology of IF1s and the small CD1219 domain are highly similar. The only 
exception is the presence of the small helix α2 between strands β4 and β5 of CD1219 that 
can’t be found in the selected IF1s and an extended loop between β1 and β2 of CD1219. To 
illustrate these structural similarities and differences, a structural alignment of the small N-
terminal domain of CD1219 from Clostridium difficile and full-length IF1 from Streptococcus 
pneumoniae (PDB-ID 4QL5; Stogios et al., 2014, unpublished) is shown in Fig. 28B. Both 
structures can be aligned with an r.m.s.d. of 2.05 Å over 59 of 71 residues and share a 
sequence identity of 19.3%. 
The structure-based sequence alignment illustrates that several residues of CD1219 and IF1s, 
e.g. a glycine residue at the beginning of β1, β3 and β4, are conserved. These glycine residues 
can induce a break in the secondary structure motifs, as they are usually located at the end or 
beginning of a β-strand or α-helix. However, the residues of IF1 that are involved in nucleotide 
binding, e.g. Lys39, Arg41, Arg46 (marked in red in Fig. 28A) are not conserved in CD1219. 
This indicates that, although CD1219 and IF1s share an OB-fold, they might use a different 
ligand, a different way of ligand binding or might possess a different function at all. 
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To map the RNA-binding mode of IF1s on CD1219, the RNA molecule bound to IF1 of Thermus 
thermophilus (PDB-ID 1HR0; Carter et al., 2001) was aligned onto the structure of the small 
domain of CD1219 (Fig. 29). As illustrated by the structure-based sequence alignment 
(Fig. 28A), the residues of IF1 (Lys39, Arg41, Arg46) that are involved in RNA binding are not 
present in the small domain of CD1219. Furthermore, the RNA molecule clashes with some 
regions of CD1219. A comparison of the electrostatic surface of the RNA binding region of IF1 
and CD1219 also reveals differences between both proteins. The RNA binding surface of IF1 
is positively charged (Fig. 29C), whereas the surface of the small domain of CD1219 is 
predominantly negatively charged (Fig. 27). Although the part of CD1219 that was aligned onto 
the positively charged RNA binding surface of IF1 shows small positively charged patches, 
these patches are located in the region that points away from the solvent environment. These 
differences between IF1 and CD1219 indicate that either other parts of the small domain of 
CD1219 are involved in nucleic acid binding or conformational changes of CD1219 have to 
take place upon potential DNA-/RNA binding. 
 
 
 
 
 
Figure 28: (A) Structure-based sequence alignment of the small N-terminal domain of CD1219 from Clostridium 
difficile and bacterial IF-1s from Escherichia coli (PDB-ID 1AH9; Sette et al., 1997), Thermus thermophilus (PDB-
ID 1HR0; Carter et al., 2001), Mycobacterium tuberculosis (PDB-ID 3I4O; Hatzopoulos & Mueller-Dieckmann, 
2010) and Streptococcus pneumoniae (PDB-ID 4QL5; Stogios et al., 2014, unpublished). Secondary structure 
motifs of CD1219 from Clostridium difficile and IF-1 from Streptococcus pneumoniae are depicted above and 
under the sequence alignment, respectively. β-strands are illustrated as grey arrows, α-helices are shown as 
grey spirals. The secondary structure motifs are numbered consecutively. Conserved amino acids are indicated 
by bold letters. Amino acids that are conserved in all shown bacterial species are highlighted by black boxes. 
Amino acids of IF1 that are involved in RNA binding are shown in red. (B) Structural alignment of the N-terminal 
domain of CD1219 from Clostridium difficile (pink) and IF-1 from Streptococcus pneumonia (light pink). Both 
structures are shown in cartoon representation. Residues involved in DNA binding of IF1 are shown as sticks. 
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Figure 29: (A) Electrostatic surface of IF1 (PDB-ID 1HR0; Carter et al., 2001) bound to 30S ribosomal RNA from 
Thermus thermophilus. Residues that are involved in RNA binding are shown as sticks. (B) The 30S ribosomal 
RNA from Thermus thermophilus was aligned to the small domain of CD1219 from Clostridium difficile. The 
surface of the small domain of CD1219 in the same orientation of IF1 in (A) was colored according to its 
electrostatic charge distribution (calculated with APBS) and the aligned residues of the 30S RNA from Thermus 
thermophilus are shown as sticks.  
 
Besides IF1s, the small N-terminal domain of CD1219 shows striking structural similarity to 
“cold-shock” proteins (table 22). These proteins are expressed upon temperature decrease 
and enable bacteria to survive under stress conditions. Under these conditions, the rate of 
transcription and translation is downregulated and enzyme activity, proper protein folding and 
ribosome assembly is disturbed. Cold-shock proteins thereby serve as chaperons to 
counteract these harmful conditions and ensure translation initiation by destabilizing secondary 
structures of mRNA (Chaikam & Karlson, 2010). Csps are small (65-70 aa) proteins that bind 
single-stranded nucleic acids. They contain a so-called cold shock domain (CSD), which is 
highly conserved among Csps from all kingdoms and is involved in nucleic acid binding 
(Graumann & Marahiel, 1996). It contains the RNA binding sequence motifs RNP1 and RNP2 
(ribonucleoprotein motifs) (Schindelin et al., 1993), which are mainly composed of basic and 
aromatic residues located primarily in β-strands β1 and β2. These motifs can bind regions of 
six to seven nucleotides of single-stranded nucleic acids with high specificity. Although the 
sequence and structure conservation among bacterial Csps is extremely high, they show 
different thermal stabilities based on the electrostatic surface charge distribution (Carvajal et 
al., 2017). 
The structural alignment of the small domain of CD1219 and a Csp from Bacillus caldolyticus 
(PDB-ID 1CSJ, Bressanelli et al., 1999) is exemplarily shown in Fig. 30B. Both structures can 
be aligned with an r.m.s.d. of 2.89 Å over 32 of 65 residues and show a sequence identity of 
12%. They share the same topology with CD1219 possessing an additional short α-helix (α2) 
between strands β4 and β5. Binding of the Csp to single-stranded nucleic acids is mediated 
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by the two RNP motifs. They are indicated by red boxes in the sequence alignment and are 
conserved among a variety of RNA binding proteins. The RNP motifs are located in strands β2 
and β3, respectively, and consist mainly of aromatic and basic residues, resulting in a positively 
charged electrostatic surface that enables binding to the negatively charged phosphate 
backbone of nucleic acids. The aromatic residues are essential for binding single-stranded 
nucleic acids, as they mediate the binding to nucleic acids by base stacking (Chaikam & 
Karlson, 2009). This was shown by mutational studies in E. coli Csp, where the two 
phenylalanine residues Phe16 and Phe58 were mutated to alanine residues. This mutation 
resulted in a dramatic reduction of the Csp binding affinity for ssRNA (Brennan & Platt, 1991). 
The structure-based sequence alignment in Fig. 30A shows that these Csp residues that are 
involved in nucleic-acid binding are not conserved in the small N-terminal domain of CD1219. 
The positive surface charge attributed to the aromatic and basic residues of Csp from Bacillus 
caldolyticus is concentrated on one side of the protein, indicating that this side is the region 
involved in binding to ss-nucleic acids. In contrast, the positive electrostatic surface charge of 
the small domain of CD1219 is distributed over a larger surface area (Fig. 31). 
 
Figure 30: (A) Structure-based sequence alignment of the small N-terminal domain of CD1219 and bacterial Cold-
shock proteins (Csp) from Bacillus subtilis (PDB-ID 1CSQ, Bressanelli et al., 1999), Escherichia coli (PDB-ID 1MJC, 
Schindelin et al., 1994), Listeria monocytogenes (PDB-ID 2LXJ, Lee et al., 2013) and Bacillus caldolyticus (PDB-ID 
5JX4, Carvajal et al., 2017). Secondary structure motifs of CD1219 from Clostridium difficile and Csp from Bacillus 
caldolyticus are depicted above and under the sequence alignment, respectively. β-strands are illustrated as grey 
arrows, α-helices are shown as grey spirals. The secondary structure motifs are numbered consecutively. Conserved 
amino acids are indicated by bold letters. Amino acids that are conserved among all shown bacterial species are 
highlighted by black boxes. Red boxes indicate the RNA-binding motifs RNP1 and RNP2, respectively. (B) 
Exemplary structural alignment of the N-terminal domain of CD1219 from Clostridium difficile (pink) and Csp from 
Bacillus caldolyticus (light green). Both structures are shown in cartoon representation. 
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Figure 31: (A) Residues involved in single-stranded nucleic acid binding of Csp from Bacillus caldolyticus and 
respective aligned residues of the small domain of CD1219 from Clostridium difficile in (C). The Csp crystal 
structure (PDB-Code 5JX4) is shown in light green, the amino acid side chains that are involved in nucleic acid 
binding are shown as green sticks. The crystal structure of the small CD1219 domain is shown in pink. (B) The 
electrostatic surface representation of the Csp structure in the same orientation as the crystal structure in (A) 
was calculated with APBS (Baker et al., 2001). (D) The electrostatic surface of the small domain of CD1219 of 
Clostridium difficile after alignment to Csp of Bacillus caldolyticus shows differences in the charge distribution of 
both proteins. 
 
To sum up, despite low sequence identity, the small N-terminal domain of CD1219 from 
Clostridium difficile shows striking structural similarity to OB-fold nucleic-acid binding proteins 
such as IF1s and Csps. Although they share the same fold, CD1219 lacks the conserved 
residues that are responsible for DNA-/RNA-binding in IF1s and Csps. Based on the crystal 
structure of CD1219, a nucleic-acid binding region could not be clearly defined. The nucleic-
acid binding of OB-fold proteins usually takes place in the β2-β3 region of the central β-barrel 
(Lee et al., 2013). These β-strands are located at the outside of dimeric CD1219 and not in the 
dimer interface. Usually a positively charged surface is necessary to bind the negatively 
charged nucleic acid backbone. The β2-β3 region of the CD1219 OB-fold shows positively 
charged patches including lysine and arginine residues. These patches are not concentrated 
in one specific region of the small domain of CD1219 in contrast to IF1s and Csps. This 
indicates that either conformational changes would be necessary upon DNA-/RNA-binding to 
CD1219 or that CD1219 would use a binding mechanism that is different from that of IF1s and 
Csps, if the small domain of CD1219 is indeed able to bind nucleic acids.  
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The above-mentioned similarities between the small domain of CD1219 and OB-fold proteins 
allow a construction of a hypothetical nucleic acid binding model. The nucleic acid could either 
bind separately on both sides to the small domains of the CD1219 dimer or it could bind to 
both small domains simultaneously and thus wrap around the CD1219 dimer (Fig. 32). It was 
shown that several OB-fold proteins undergo conformational changes upon nucleic acid 
binding. Furthermore, it is possible that the nucleic acid itself changes its conformation upon 
binding to OB-fold proteins, as was shown for IF1s. This conformational change could be 
necessary in nature to distinguish between the bound and unbound form of the protein 
(Williamson, 2000). OB-fold proteins can be monomeric (e.g. IF1s), but can also be present as 
dimers (Csp from Bacillus caldolyticus, Carvajal et al., 2017) or higher oligomers (nucleotidase 
from Methanocaldococcus jannaschii, Zhang et al., 2003). In this case, dimerization of the 
nucleic acid-binding domain is often used to increase the affinity and/or specificity of single-
stranded nucleic acid binding. 
Due to its structural similarity to nucleic acid-binding proteins and its structural arrangement, 
the small N-terminal domain CD1219 could indeed function as a nucleotide-binding domain. 
As no hypotheses about the mechanism and substrate could be derived from the crystal 
structure of the small domain of CD1219, further experiments are necessary to prove the 
potential binding of nucleic acids to CD1219.  
 
Figure 32: Potential models of nucleic acid binding to the small N-terminal domain of CD1219. The CD1219 
dimer is shown in cartoon representation in blue with the small N-terminal domains in pink. The nucleic acid is 
shown as orange cartoon representation. One nucleic acid molecule can either bind to both small CD1219 
domains simultaneously (A) or to each small domain separately (B). 
 
Although the small domain of CD1219 shows an OB-fold, it does not necessarily have to be 
involved in nucleic acid binding. The largest subfamily of OB-fold proteins is the nucleic-acid 
binding protein family, but in contrast to this some OB-fold proteins are known that mediate 
interaction of proteins or assembly of protein complexes (Theobald et al., 2003; Lynn et al., 
2010). A recently published structure illustrates that the cell-puncturing complex of 
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bacteriophage T4 also includes an OB-fold protein (Arcus, 2002). The OB-fold part probably 
mediates the contact between the individual protein components of this complex. To elucidate 
the exact molecular function of the small domain of CD1219, whether it is involved in nucleic 
acid binding or protein-protein interaction, further experiments are essential. 
 
7.2.7. The large domain of CD1219 as a potential GTPase 
The crystal structure and the corresponding topology diagram of the large C-terminal domain 
of CD1219 of Clostridium difficile is shown in Fig. 26B. It shows an equal distribution of 
negative and positive charge on its surface, while the solvent-exposed part of this domain is 
predominantly negatively charged (Fig. 33). 
 
 
Figure 33: Electrostatic surface of the large C-terminal domain of CD1219. The dimer of CD1219 is shown in 
cartoon representation with the large domain of one chain colored according to its electrostatic charge 
distribution. The surface of the large domain is shown from the top in (B). 
 
Analogous to the small N-terminal domain (chapter 7.2.6), a structural homology search was 
performed with the large C-terminal domain of CD1219 from Clostridium difficile using DALI 
and PDBeFold. The results are summarized in table 23. Among the proteins that showed the 
best structural alignment to the large domain of CD1219 are mainly P-loop NTPases that 
belong to the SIMIBI class of NTPases (Leipe et al., 2002). The best structural alignment of 
the large domain of CD1219 was obtained for the plasmid partitioning protein ParA from 
Escherichia coli (PDB-ID 5U1G, Zhang & Schumacher, 2017), the signal recognition particle 
receptor FtsY from Arabidopsis thaliana (PDB-ID 2OG2, Chandrasekar et al., 2007) and the 
cell division protein MinD from Archaeoglobus fulgidus (PDB-ID 1HYQ, Cordell & Lowe, 2001) 
with Z-scores of 9.5, 8.6 and 7.8, respectively.  
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Table 23: Summary of the structural alignments of the large C-terminal domain of CD1219 from Clostridium difficile 
with homologous proteins using PDBeFold and DALI. Letters in brackets behind the PDB-Code indicate the protein 
chain that was used for the alignment. Proteins are ordered with decreasing Q- and Z-score, respectively. 
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P-loop GTPases share a conserved protein fold that is characterized by a central β-sheet 
composed of seven (mainly) parallel β-strands that are each flanked by an α-helix. They are 
characterized by several conserved residues and secondary structure motifs (Saraste et al., 
1990). To compare the topology of selected P-loop GTPases with the large domain of CD1219, 
the structures were aligned respective to the central β-sheet. The strands involved in the 
central β-sheet were numbered from 1-7 consecutively, discounting further interspersed β-
strands that are not involved in the central β-sheet. A comparison of the topology and overall 
structure of some P-loop GTPases selected from table 23 and the large C-terminal domain of 
CD1219 is shown in Fig. 34. A structure-based sequence alignment of these selected P-loop 
GTPases and the large domain of CD1219 is shown in Fig. 35. 
One prominent structural feature involved in nucleotide binding in all GTPases is the so-called 
P-loop, also called Walker A motif. It is usually located as a flexible loop between strand β1 
and the following α-helix α1 (indicated as a red line in the topology diagrams in Fig. 34 and as 
a red box in the sequence alignment in Fig. 35). The typical P-loop amino acid sequence 
(GXXXXGK) is conserved among most GTPases and is characterized by several glycine 
residues (Saraste et al., 1990). It is involved in correctly positioning the triphosphate part of 
the bound nucleotide. Another conserved feature of P-loop GTPases is the [NT]KXD motif, 
which determines the guanosine specificity of the GTPase (Bourne et al., 1991). 
The alignment of the large domain of CD1219 from Clostridium difficile with the selected P-
loop GTPases shows that a flexible glycine-rich P-loop cannot be found between β1 and α1 of 
CD1219 (Fig. 34). However, a similar glycine-rich loop with the amino acid sequence 
GXGXXGXGXXXGXT is present between strand β5 and helix α4 of CD1219. In the CD1219 
crystal structure, this loop is involved in the coordination of a bound phosphate molecule and 
could hence be described as a “P-loop” involved in potential nucleotide binding. 
Another common feature of P-loop GTPases is the Walker B motif, usually located distal to the 
Walker A motif. The Walker B motif commonly involves a conserved aspartate or glutamate 
residue that is located at the end of a β-strand and coordinates a water-bridged magnesium 
ion (Walker et al., 1982). This conserved aspartate residue (D153; marked in red in the 
sequence alignment in Fig. 35) can also be found in the large domain of CD1219 and is located 
at the end of strand β2. In contrast to most GTPases, this conserved aspartate residue is not 
involved in magnesium binding in the crystal structure of CD1219.  
In general, the P-loop GTPase family can be subdivided in two groups: TRAFAC and SIMIBI 
GTPases (Leipe et al., 2002). TRAFAC is short for translation factor-related class of GTPases 
and involves translation factors, heterotrimeric G proteins, dynamins etc. The SIMIBI class 
includes signal recognition particle-associated GTPases and various enzymes involved in 
metabolism. It was named after its three largest subgroups: signal recognition GTPases, the 
MinD and BioD (dethiobiotin synthetase) superfamily (Leipe et al., 2002). The main structural 
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difference between TRAFAC and SIMIBI GTPases is the arrangement of the β-strands that 
form the central β-sheet. In SIMIBI GTPases, all β-strands are arranged parallel to each other. 
In TRAFAC GTPases, the β-strand flanking the Walker B-containing strand is antiparallel to 
the others. On basis of their amino acid sequence, both GTPase classes show differences 
concerning certain conserved residues. E.g., in the TRAFAC class, a highly conserved 
threonine or serine residue is present in the loop between β2 and β3, besides a conserved 
serine residue in β7 that is not conserved among SIMIBI GTPases. 
The overall topology of the C-terminal domain of CD1219 from Clostridium difficile and P-loop 
SIMIBI GTPases is strikingly similar, as both contain a central seven-stranded parallel β-sheet 
with flanking α-helices. The main difference is the additional short β-sheet β3* in CD1219 
between β3 and β4 that is not present in other SIMIBI GTPases. Further short α-helices and 
β-sheets in the loop regions following β5 and β7 are present in the CD1219 structure that can’t 
be found in the other selected GTPases. Furthermore, the large domain of CD1219 lacks the 
above-mentioned conserved residues that are characteristic for the TRAFAC class of 
GTPases. 
Moreover, the SIMIBI class is characterized by a further conserved aspartate residue at the 
beginning of β4 (part of the Walker B motif), which exact function is unknown. This aspartate 
residue is also present in the CD1219 structure and is indicated in red in the sequence 
alignment in Fig. 35. The P-loop sequence of SIMIBI GTPases includes a third conserved 
glycine residue (GXXGXGK), similar to the P-loop sequence of CD1219 (Leipe et al., 2002). 
The only difference between CD1219 and traditional P-loop GTPases is the position of the 
P-loop. The [NT]KXD motif conserved among GTPases is generally located in the loop 
following β6 and shows strong variability in SIMIBI GTPases. This conserved motif is not 
present in the loop following β6 in CD1219, but a similar motif if located following strand β8 in 
the large domain of CD1219 (sequence alignment in Fig. 35). Another factor indicating that 
CD1219 might belong to the SIMIBI class of GTPases is the fact that it is dimeric in solution, 
as most SIMIBI GTPases are present as dimers in nature (Leipe et al., 2002). 
As the core structure of CD1219 is strikingly similar to P-loop SIMIBI GTPases and due to the 
presence of several conserved residues and structural motifs of P-loop SIMIBI GTPases, the 
large domain of CD1219 could most probably be a SIMIBI GTPase. As some of the structural 
motifs that are essential for GTP binding are not located in the same region as in other 
GTPases, the GTP binding region of CD1219 is probably located in a different region of the 
protein as in homologous traditional GTPases. 
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Figure 34: Comparison of selected P-loop NTPases. The topology diagrams and the overall structure of selected 
P-loop NTPases are shown. Selected proteins are described by annotated protein name, species name and 
PDB-Code in the left panel. The corresponding topology diagram is shown in the middle column. β-strands are 
shown as arrows with the arrowhead on the C-terminal side and are numbered from 1-8. The central β-sheet is 
colored in dark blue, additional β-sheets are highlighted in light blue. α-helices are shown as cylinders. Helices 
above the plane of the central β-sheet are colored in dark grey, helices below the β-sheet plane are illustrated in 
light grey. The N-terminus is indicated by a hollow circle, the C-terminus by a filled black circle. The P-loop is 
shown as a red line, further conserved structural motifs and residues are highlighted in red. Dashed lines indicate 
secondary structure motifs that were left out in the topology diagram for clarity. 
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Figure 35: Structure-based sequence alignment of the large C-terminal domain of CD1219 from Clostridium 
difficile with selected SIMIBI GTPases. The alignment was created with PromalS3D and edited with Espript. Bold 
characters indicate conserved amino acid residues. Residues in red indicate conserved amino acids involved in 
nucleotide binding. The secondary structure of CD1219 is shown above the alignment with arrows indicating β-
strands and spirals illustrating α-helices. The secondary structure of the exemplary GTPase HypB from 
Methanocaldococcus jannaschii is shown under the alignment. Red boxes indicate the conserved P-loop region, 
yellow and green boxes show the modified DXXD and TXXD motifs, respectively. 
 
To study potential GTP-binding to the large domain of CD1219 of Clostridium difficile, the 
binding mode of GTP to the homologous GTPase HypB was analyzed. The binding of the 
substrate analogue GSP to the GTPase HypB from Methanocaldococcus jannaschii (PDB-ID 
2HF8, Gasper et al., 2006) is illustrated in Fig. 36A. The conserved secondary structure 
elements and amino acids that are involved in GSP binding are highlighted in respective colors 
analogous to the sequence alignment in Fig. 35. By aligning the large domain of CD1219 on 
HypB, it can be clearly shown that the bound GSP molecule clashes with secondary structure 
elements, especially helix α1, of CD1219 (Fig. 36B). Compared to HypB, α1 of CD1219 is 
longer than the aligned helix α1 in HypB. The clashes of the aligned GSP and CD1219 indicate 
that either the nucleotide-binding site of CD1219 is located in a different position as compared 
to HypB or that CD1219 has to undergo significant conformational changes upon nucleotide 
binding. The different positions of the P-loop and location of the conserved aspartate residue 
in HypB and CD1219 are illustrated in Fig. 36C.  
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Figure 36: (A) GSP bound to HypB from Methanocaldococcus jannaschii (PDB-ID 2HF8, Gasper et al., 2006). 
HypB is shown as cartoon representation in light green with the conserved P-loop in red, ENVG-motif in yellow 
and NKID-motif in dark green. Residues that are involved in GSP binding are shown as sticks, the Mg ion as 
green sphere. (B) The large domain of CD1219 after alignment to HypB with the aligned GSP molecule from 
HypB. The P-loop is shown and the conserved aspartate residue Asp153 are shown in red. (C) Alignment of 
CD1219 (blue) and HypB (green). P-loops are shown in red and conserved aspartate residues of CD1219 and 
HypB are highlighted in blue and green, respectively. 
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As discussed above, the location of the conserved secondary structure motifs that are 
characteristic for P-loop GTPases are different in the large CD1219 domain compared to 
traditional GTPases. Extensive literature search revealed that this permutation of conserved 
secondary structure motifs can also be found in other proteins (Anand et al., 2006). This group 
of proteins is called circularly permuted P-loop GTPases (cpGTPases) and includes amongst 
others YjeQ from Escherichia coli (Daigle et al., 2002), YloQ from Bacillus subtilis (Levdikov et 
al., 2004), YlqF from Thermotoga maritima (Kim et al. 2008) and YqeH from Geobacillus 
stearothermophilus (Sudhamsu et al., 2008). This circular permutation of secondary structure 
motifs affects GTP binding and hydrolysis and can lead to disturbance of the conformational 
stability of the protein. Therefore, many cpGTPases carry an additional N-terminal domain to 
stabilize the protein and the GTP binding region (Anand et al., 2006). This additional N-terminal 
domain is often involved in RNA binding. It is hence possible that RNA binding regulates GTP 
binding or the other way around. Furthermore, many cpGTPases contain a further stabilizing 
domain at the C-terminus. cpGTPases can hence be divided into different protein domains. A 
central GTPase domain and adjacent terminal stabilizing domains (Levdikov et al., 2004). 
Phylogenetic analysis revealed a close evolutionary relationship between cpGTPases and 
bacterial ribosome-binding GTPases (Anand et al., 2006). The division into individual domains 
varies among individual cpGTPases, therefore no general architecture and domain 
composition of cpGTPases can be stated. The cpGTPases YjeQ and YloQ from Bacillus 
subtilis carry e.g. an N-terminal RNA-binding domain with a conserved OB-fold, an 
intermediate GTPase domain and a C-terminal Zinc-finger domain. In contrast to these 
cpGTPases, YlqF of Bacillus subtilis consists only of the central GTPase domain and an 
additional helical C-terminal domain but lacks an N-terminal stabilizing domain.  
According to their three-dimensional structure and topology, these selected cpGTPases can 
be grouped into the TRAFAC class of GTPases (Leipe et al., 2002). They contain typical 
sequence motifs required for GTP binding, i.e. the P-loop/Walker A motif GxxxxGKS/T (G1), 
the Walker B motif DxxG (G3) and the N/TKxD motif (G4). Regular GTPases include the motifs 
in the G1-G3-G4 order in their primary amino acid sequence (Fig. 35). In cpGTPases, these 
motifs are circularly permuted and are arranged in the order G4-(G5)-G1-(G2)-G3. Although 
they have a permuted order of secondary structure elements compared to conventional 
GTPases, the three-dimensional structure of cpGTPases and conventional GTPases is highly 
similar. A sequence-based structural alignment of cpGTPases is shown in Fig. 37 and 
conserved GTPase motifs are highlighted in the respective colors analogous to the alignment 
of traditional P-loop GTPases in Fig. 35. 
cpGTPases are important proteins for the respective bacteria, as they are essential for viability 
or growth of the bacterium, see YlqF and YqeH from Bacillus subtilis (Morimoto et al., 2002). 
However, the exact molecular function of most cpGTPases has not been discovered, yet. 
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Figure 37: Structure-based sequence alignment of selected cpGTPases with highlighted motifs and residues 
involved in GTP binding. The alignment of YqeH from Geobacillus stearothermophilus (PDB-ID 3EC1, Sudhamsu 
et al., 2008), YqlF from Bacillus subtilis (PDB-ID 1PUJ, Kim et al., 2008), YjeQ from Aquifex aeolicus (PDB-ID 
2YV5, Wang et al., 2008, unpublished) and YloQ from Bacillus subtilis (PDB-ID 1T9H, Levidkov et al., 2004) is 
shown with bold letters indicating conserved residues. Motifs involved in GTP binding are colored, with G1 (P-
loop, GxxxxGKSS) in red, G2 (T) in green, G3 (DxxG) in green, G4 (N/TKxD) in yellow and G5 (SAK/L) in purple. 
The secondary structure elements of YqeH are shown above the alignment, these of YloQ under the alignment 
with β-strands as arrows and α-helices as spirals. The secondary structure elements are numbered 
consecutively. 
 
Concerning their domain architecture, CD1219 from Clostridium difficile and the cpGTPase 
YloQ from Bacillus subtilis (PDB-ID 1T9H, Levidkov et al., 2004) are highly similar. Both 
proteins contain an N-terminal OB-fold domain, followed by a short linker, a GTPase-like 
domain and a helical C-terminal domain. For YloQ it was shown that the central nucleotide-
binding domain binds GTP (Cladiere et al., 2006). Due to homology to GTPases, it can be 
assumed that also CD1219 binds GTP, but its exact molecular function and GTP-binding ability 
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has yet to be confirmed. The C-terminal domain of YloQ was identified as a Zn-finger domain 
that coordinates a Zn2+ ion (Levdikov et al., 2004). In the case of CD1219, no Zn2+ ion is bound 
to this helical C-terminal domain. The function of the C-terminal extension in CD1219 could be 
a stabilizing effect on the rest of the protein that is essential due to the permutation of the 
GTPase motifs, similar to other cpGTPases. A comparison of the three-dimensional structure 
and topology of CD1219 and YloQ is shown in Fig. 38. 
A detailed comparison of the topology of CD1219 and YloQ shows some striking similarities, 
but also differences between both proteins. The OB-fold of both proteins is highly similar. Both 
N-terminal domains (colored in pink in Fig. 38) consist of a β-barrel that is composed of five 
antiparallel β-strands. This N-terminal domain of CD1219 involves two additional short α-
helices that are not present in YloQ. The OB-fold domain is linked to the central GTPase 
domain by a short linker (colored in yellow in Fig. 38) that consists of two short antiparallel β-
strands in both proteins and an additional short α-helix in CD1219. The central GTPase domain 
(colored in blue in Fig. 38) of YloQ is composed of 6 β-strands (5 parallel and one antiparallel 
strand), flanked by α-helices on each side. CD1219, on the other hand, contains a central 8-
stranded parallel β-sheet in the core domain. Due to the presence of one antiparallel β-strand 
in its GTPase domain, YloQ is classified as a TRAFAC GTPase and CD1219, on the other 
side, shares homology with SIMIBI GTPases. The C-terminal domain of YloQ (colored in cyan 
in Fig. 38) consists of four α-helices that bind a Zn-ion. The C-terminal domain of CD1219 
involves two additional short β-strands inserted between the helices. The C-terminally bound 
Zn2+ ion of YloQ and the conserved Cys and His residues present in Zn finger domains are not 
present in CD1219. This indicates that the C-terminal domain of CD1219 does not possess 
Zn-binding affinity as compared to YloQ, but rather has a stabilizing effect on the rest of the 
protein. 
Due to several structural and sequence similarities between CD1219 and cpGTPases, it can 
be assumed that CD1219 is a cpGTPase. The major difference between CD1219 and 
cpGTPases is the topology of the central GTPase-like domain of CD1219. Most cpGTPases 
belong to the TRAFAC class of GTPases, whereas CD1219 has to be classified into the SIMIBI 
class of GTPases due to the lack of one antiparallel β-strand that is conserved among TRAFAC 
GTPases. 
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Figure 38: Comparison of the three-dimensional structure and topology of YloQ from Bacillus subtilis (PDB-ID 
1T9H, Levdikov et al., 2004) (A and B) and CD1219 from Clostridium difficile (C and D). The topology diagrams 
are shown in A and C. β-strands are illustrated as arrows, α-helices as cylinders. Topology diagrams and crystal 
structures are colored accordingly. The crystal structures of both proteins are shown in cartoon representation 
in B and D. The C-terminal OB-fold domain is colored in pink, the linker domain in yellow, the GTPase domain 
in dark blue and the C-terminal helical domain in cyan. 
 
The comparison of the homologous cpGTPases YloQ from Bacillus subtilis and YqeH from 
Bacillus anthracis illustrates the conformational changes that take place upon GTP binding. 
YqeH was crystallized with a bound GTP analogon (PDB-ID 3EC1, Sudhamsu et al., 2008) 
and YloQ in the absence of GTP (PDB-ID 1T9H, Levidkov et al., 2004). An alignment of both 
proteins shows that conformational changes, especially in the GTP binding region, occur upon 
GTP binding. It is therefore possible that also CD1219 undergoes conformational changes 
upon nucleotide binding. The secondary structure motifs of CD1219 that are possibly involved 
in nucleotide binding are characterized by high B-factors (Fig. 39B). This usually indicates a 
high flexibility and motility of the respective region and could enable potential conformational 
changes in these regions upon nucleotide binding. 
In the crystal structure of CD1219, a phosphate molecule is bound to each chain (Fig. 39A). 
The phosphate molecule is coordinated by hydrogen bonds involving the backbone residues 
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of the P-loop motif (T220 and G221), as well as side chains of residues of the ERHQG motif 
(R259 and H260) and H265. The coordination by several hydrogen bonds indicates a tight 
binding of the phosphate molecule. In conventional GTPases, the P-loop motif is involved in 
coordinating the triphosphate moiety of GTP similar to the phosphate molecule in CD1219.  
 
Figure 39: Conserved residues and secondary structure motifs involved in potential GTP binding in dimeric 
CD1219 (A) and the potential binding region in detail (C). CD1219 is shown in cartoon representation with chain 
A in dark blue and chain B in light blue. The TIYD motif is colored in yellow, the ERHQG motif in green, the 
potential P-loop in red, the bound phosphate molecule in orange, the conserved residue Thr132 in green and 
Asp153 and Asp207 in cyan. The structure is colored according to B-factors in (B) with red and thickened ribbon 
indicating high B-factors and blue highlighting low B-factors. (D) shows the Ligplot representation of the bound 
phosphate molecule in chain A of the crystal structure of CD1219 with the phosphate molecule colored in orange 
and amino acid residues in blue with carbon atoms in black, nitrogen atoms in blue and oxygen atoms in red. 
The length of the hydrogen bonds (colored in dashed green lines) coordinating the bound phosphate molecule 
is specified in Å. 
 
This indicates that a GTP molecule could bind to CD1219 with the triphosphate part 
coordinated similar to the bound phosphate molecule. Analysis of the potential binding 
region with KVFinder (Oliveira et al., 2014) reveals a binding cavity present in the crystal 
structure of CD1219 with a volume of ~420 Å3 that is large enough for binding GTP 
(Fig. 40A). A GTP molecule was docked into this cavity using AutoDockVina (Trott & Olson, 
2010). The best docking hits were analyzed manually with Pymol and the most reasonable 
orientation of GTP docked into the CD1219 cavity is shown in Fig. 40. Similar to the bound 
phosphate molecule in the CD1219 crystal structure, the triphosphate moiety of GTP is 
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coordinated by hydrogen bonds involving several backbone residues and side chains of the 
P-loop and the ERHQG motif of CD1219. The nucleotide base of the docked GTP molecule 
is only coordinated by hydrogen bonds involving the side chain of Thr227 and the backbone 
chain of Gly225. This indicates that the docked GTP molecule is tightly bound via its 
triphosphate moiety, but only loosely coordinated via its nucleotide base. As docking only 
reflects a theoretical conformation of the respective ligand and does not consider potential 
conformational changes of the ligand or the macromolecule, potential binding of GTP to 
CD1219 has to be confirmed by determination of a CD1219 crystal structure in complex with 
GTP or a GTP analogue. 
 
Figure 40: Potential binding of GTP to CD1219. (A) shows the binding cavity of CD1219 that was determined 
with KVFinder, (B) shows a detailed view of the docked GTP molecule and surrounding residues coordinating 
the GTP molecule. (C) shows a Ligplot illustration of the coordination of GTP by CD1219 residues. The color 
scheme was selected according to Fig. 39. 
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The conservation of the crystal structure of dimeric CD1219 and especially the region of the 
potential GTP-binding cavity was analyzed using ConSurf (Ashkenazy et al., 2016). The 
conservation score was calculated by comparing the CD1219 sequence with 150 homologous 
sequences. The structure and amino acid sequence of CD1219 was colored according to the 
calculated conservation score with 1 (cyan) indicating non-conserved residues and 9 (dark 
red) highlighting conserved residues (Fig. 41). The residues of the linker region and the region 
surrounding the potential ligand binding cavity of CD1219 are highly conserved. This shows 
that the residues surrounding the potential ligand binding region, especially these of the P-
loop, are conserved among homologous proteins of CD1219. This indicates that these proteins 
probably use a similar mechanism of ligand binding. 
 
Figure 41: Conservation of CD1219 residues. (A) and (B) The surface of CD1219 is colored according to its 
conservation score of the respective residues. The color code is shown in (C) together with the amino acid 
sequence of CD1219 colored according to the score. (D) shows the potential GTP-binding cavity and the CD1219 
structure in cartoon representation colored according to conservation score. 
 
7.2.8. The genomic environment of CD1219 
Analysis of the genomic environment of a gene can reveal clues about the function of its 
encoded protein, as proteins involved in one metabolic pathway are often encoded by genes 
arranged in the same gene operon (Huynen et al., 2000). 
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DOOR (Dam et al., 2007) prediction and PhyreBug analysis of the genetic environment of 
CD1219 revealed that the gene CD630_12190 is arranged in a gene operon encoding several 
other proteins (Fig. 42). The first gene organized in this operon encodes a putative thiamine 
diphosphokinase (CD630_12150, E2.7.6.2) with ATP-binding and kinase activity. This enzyme 
is involved in the central thiamine metabolism and catalyzes the conversion of thiamine and 
ATP to AMP and thiamine diphosphate. The neighboring gene CD630_12170 encodes a 
putative glucosyltransferase (E2.4.1.117), which catalyzes the conversion of UDP-glucose and 
dolichylphosphate to UDP and dolichyl-β-D-glucosylphosphate. CD630_12180 also encodes 
a putative glucosyltransferase, but the exact molecular function of this protein is not annotated. 
The gene CD630_12200 (nudF) encodes a putative hydrolase, involved in the reaction of ADP-
D-ribose and water to AMP and D-ribose-5-phosphate (E3.6.1.13). The other genes encoded 
in this operon, CD630_12160 and CD630_12190, are uncharacterized proteins. It is hence 
obvious that all genes that are encoded in this operon together with CD1219 are involved in 
central molecular processes, e.g. thiamine metabolism. This, together with the fact that 
CD1219 is essential for C. difficile growth in vitro, indicates that also CD1219 could be involved 
in this central metabolic pathway. 
 
Figure 42: Operon structure of CD630_12190 (for simplification abbreviated with CD1219). Genes are shown as 
arrows with arrow length illustrating gene length. The line under the respective genes summarizes the annotated 
function of the encoded proteins. 
 
A STRING (Szklarczyk et al., 2017) analysis of the interaction of the surrounding genes of 
CD1219 illustrates that probably also genes of the neighboring operon interact with CD1219 
(Fig. 43). CD630_12210 encodes a protein of unknown function, whereas CD630_12220 
(xerD1) encodes a tyrosine recombinase and CD630_12230 (deoB) a phosphopentomutase. 
These proteins are also involved in central carbon metabolic pathways, further indicating a role 
of CD1219 in the central metabolism of Clostridium difficile. 
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Figure 43: Interaction of CD1219 and neighboring genes. Individual genes are illustrated as nods. Interacting 
genes are connected by a colored line with the respective color indicating the type of interaction. The scheme 
was generated by STRING database. 
 
 
7.3. The uncharacterized protein CD1823 of Clostridium difficile 
The 29 kDa protein CD1823 is a structurally and functionally uncharacterized protein of 
Clostridium difficile 630. Dembek et al. (2015) showed that its homologue of Ribotype 20291, 
CD1717, is essential for sporulation of C. difficile in vitro. The aim of this work was to 
structurally characterize CD1823 and thereby derive ideas about its molecular function. 
 
7.3.1. Structure determination of CD1823 
As secondary structure prediction of CD1823 by PSIPRED (Buchan et al., 2013) revealed that 
the protein does not contain any unstructured flexible termini, full-length DNA of codon-
optimized CD1823 (LifeTechnologies, Darmstadt, Germany) was cloned in various expression 
vectors (p10$, pET-Sumo) by SLIC cloning. The fusion protein His6-T7-Lysozyme-CD1823 
(expression plasmid p10$-CD1823) was expressed in E. coli BL21-CodonPlus(DE3)-RIL in 
TB medium. Protein expression was induced by addition of 1 mM IPTG and expression was 
performed at 20 °C overnight. The recombinant CD1823 construct carries an N-terminal His6-
tag, followed by T7-Lysozyme and a cleavage site for S3C-protease. 
His6-T7-Lysozyme-CD1823 was purified by Ni-IMAC, tag cleavage was performed by S3C 
protease overnight and was followed by a reverse Ni-IMAC. A final size exclusion 
chromatography of CD1823 was performed to isolate pure CD1823 and to remove potential 
aggregates. An additional analytical size exclusion chromatography was performed to analyze 
the molecular weight of CD1823 by comparison to standard proteins, but the oligomeric state 
of CD1823 could not be determined by analytical size exclusion chromatography. The 
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chromatogram of the analytical size exclusion chromatography and the corresponding SDS-
PAGE for analysis of the final protein purity are depicted in Fig. 44. 
 
Figure 44: Chromatogram of an analytical size exclusion chromatography (S75 10/300 HR) of pure CD1823 (left) 
and the corresponding SDS-PAGE (right). The protein fractions that were pooled after size exclusion 
chromatography are marked with a pink bar. A protein standard was loaded in the first lane of the SDS-PAGE to 
estimate the size of the purified protein. The theoretical molecular weight of CD1823 is 29.2 kDa. 
 
Pure CD1823 was used for crystallization experiments in concentrations of 20, 10 and 5 mg/ml 
using commercially available crystallization screens in sitting-drop vapour-diffusion set-ups. 
Crystal growth was observed in several conditions already after one day. Some crystals were 
fished, cryoprotected with 2,3-butanediol and immediately flash-cooled in liquid nitrogen until 
data were collected at beamline P11 at DESY (Deutsches Elektronen-Synchrotron, Hamburg; 
Burkhardt et al., 2016). Exemplary CD1823 crystals are shown in Fig. 45A and the quality of 
the electron density of the final CD1823 structure is illustrated in Fig. 45B. 
 
Figure 45: (A) Exemplary CD1823 crystals that were used for data collection in the crystallization condition 
25% (w/v) PEG 3350, 0.1 M Tris pH 8.5, 0.2 M ammonium acetate, 5 mg/ml CD1823. (B) Exemplary 2Fo-Fc-
electron density of CD1823 at sigma contour level 1.2. 
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At the start of this thesis, the structure of CD1823 could not be predicted by structure prediction 
servers due to the lack of homologous protein structures. During the course of this thesis, the 
crystal structure of YaaA from E. coli (PDB-Code 5CAJ) was deposited in the PDB, which 
served as a model for MR to solve the structure of CD1823. The sequence identity of YaaA 
and CD1823 is 36% and MR was performed using Phenix Phaser (McCoy et al., 2007). Coot 
(Emsley et al., 2010) was used for manual model building and phenix.refine (Afonine et al., 
2012) for refinement of the structure. Data collection and refinement statistics are summarized 
in table 24 and table 25. CD1823 crystallized with two monomers in the asymmetric unit, 
indicated by a Matthews coefficient of 2.45 and a solvent content of 49.75% (calculated using 
the CCP4 suite). An exemplary region of 2F0Fc-electron density at sigma level 1.2 is shown in 
Fig. 45B. 
 
Table 24: Data collection statistics for CD1823 
Dataset CD1823_native 
Wavelength (Å) / beamline 1.033 / DESY, P11 
Resolution range (Å) 49.45-1.90 (1.97-1.90) 
Space group P 1 21 1 
Unit cell parameters (Å) 
                                 (°) 
57.79   75.64   65.54 
  90         94        90 
Mosaicity (°) 0.32 
Total No. of measured reflections 296502 (19021) 
Unique reflections 44441 (2861) 
Multiplicity 6.7 (6.6) 
Mean I/σ(I) 13.4 (1.5) 
Completeness (%) 100.0 (99.9) 
Rmeas (%) 9.8 (133.4) 
Rp.i.m. (%) 3.8 (51.3) 
CC1/2 99.9 (90.3) 
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Table 25: Refinement statistics for CD1823 
Dataset CD1823_native 
Resolution Range (Å) 49.45-1.90 (1.97-1.90) 
Rwork (%) 19.9 (48.7) 
Rfree (%) 24.7 (51.8) 
No. of non-H atoms  
   Protein 4036 
   Ion - 
   Ligand 2 (Cl-) 
   Water 503 
R.m.s. deviation  
   Bonds (Å) 0.004 
   Angles (°) 0.72 
Average B factors (Å2)  
   Protein 34 
   Ion - 
   Ligand 12 
   Water 40 
Ramachandran plot  
   Favored regions (%) 98 
   Outliers (%) 0 
MolProbity score 1.02 
 
 
7.3.2. SAXS experiments of CD1823 
The oligomeric state of CD1823 in solution could not be determined by analytical size exclusion 
chromatography, as the elution volume could not be clearly assigned to monomeric or dimeric 
CD1823. To determine the oligomeric state of CD1823 in solution, additional SAXS 
experiments were performed. 
The SAXS experiments for CD1823 (in 20 mM Tris/HCl pH 8.0, 100 mM NaCl) were performed 
at BM29 ESRF (Grenoble, France; Pernot et al., 2013) with different protein concentrations. 
Best data were measured for 2.5 mg/ml CD1823. The experimental scattering data were 
compared with theoretically calculated curves for monomeric and dimeric CD1823, while a 
crystallographic dimer was selected for fitting the data (Fig. 46). The X-value of 1.8 indicates 
a good fit of the experimental data with the theoretical curve for monomeric CD1823. As the fit 
of the experimental data and theoretical data for dimeric CD1823 yielded a higher X-value of 
94.6, SAXS analysis of CD1823 revealed that CD1823 is present as a monomer in solution. 
The SAXS envelope was calculated for monomeric CD1823 and the crystal structure of 
monomeric CD1823 was fitted into the SAXS envelope using Chimera (Fig. 46C). 
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Figure 46: SAXS analysis of CD1823. The fit of the experimental data (black dots) and theoretical SAXS curves 
(magenta curves) for monomeric (A) and dimeric CD1823 (B) is shown in the top panel. The crystal structure of 
monomeric and dimeric CD1823 is shown as cartoon representation with chain A in magenta and chain B in 
grey. (C) The fit of the calculated SAXS envelope for monomeric CD1823 and the crystal structure of monomeric 
CD1823 in magenta cartoon representation is shown in the bottom panel of the figure in different orientations. 
 
7.3.3. Crystal structure of CD1823 
CD1823 crystallized with two monomers in the asymmetric unit. As the CD1823 dimer is only 
a crystallographic and no functional dimer, the structural analysis of the protein will be 
performed with monomeric CD1823 in the following chapters. 
Monomeric CD1823 consists of one protein domain with a central β-sheet composed of five 
parallel β-strands that are flanked by additional five antiparallel strands, while strand β7 is 
significantly longer compared to the other strands. Many α-helices are located around the 
central β-strands on each side. CD1823 does not contain any conserved and characteristic 
secondary structure motifs that are conserved among traditional protein families. The crystal 
structure of CD1823 and the corresponding two-dimensional topology diagram are depicted in 
Fig. 47 with β-strands in magenta and α-helices in grey.  
Analysis of the electrostatic surface of monomeric CD1823 shows a large positively charged 
patch present on two neighboring sides of CD1823, which is illustrated in blue color in Fig. 47. 
The other sides of CD1823 show an even distribution of positive and negative charge without 
any special peculiarities. 
A small cavity can be found in CD1823 with a volume of ~230 Å3. The surface of the region 
surrounding this cavity is positively charged, indicating potential binding of a negatively 
charged ligand in this cavity. In the crystal structure that was determined in this thesis, this 
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cavity is occupied by several water molecules and a chloride ion, but is large enough to 
accommodate a small ligand instead of water molecules.  
 
Figure 47: (A) Crystal structure and electrostatic surface charge distribution of monomeric CD1823 of Clostridium 
difficile. Central β-strands are colored in magenta, surrounding α-helices in grey. The top panel illustrates the 
crystal structure of CD1823 and the bottom panel the electrostatic surface in the respective orientation of the 
structure in the panel above. The right panel is a 90° turned representation of the left orientation. Blue patches 
of the surface indicate positive charged, red patches indicate negative charged parts of the surface. (B) Topology 
diagram of monomeric CD1823. β-strands are simplified as arrows and α-helices as cylinders. The secondary 
structure elements are numbered consecutively. (C) Potential ligand binding cavity of CD1823 shown as cyan 
surface with bound Cl- ion (shown as blue sphere). 
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The conservation of CD1823 was calculated between CD1823 and 150 homologous 
sequences using ConSurf (Ashkenazy et al., 2016). The structure and amino acid sequence 
of CD1823 was colored according to conservation score from 1 to 9 with 1 showing variable 
and 9 the highly conserved regions (Fig. 48). Variable regions are colored in cyan, conserved 
regions are highlighted in dark red. Especially the region surrounding the potential ligand 
binding cavity of CD1823 including the bound chloride ion is surrounded by highly conserved 
residues. This indicates that this region is conserved among homologous proteins and could 
indeed depict a potential ligand binding region. Based on the homologous proteins that were 
selected for calculation of the conservation score, no hypothesis about the potential function 
of CD1823 could be derived, as the function of these proteins has also not been annotated so 
far. 
  
 
Figure 48: Conservation of CD1823. The structure of CD1823 is colored according to the conservation color code 
in (C) with 1 (cyan) showing variable and 9 (dark red) showing conserved residues. The structure of CD1823 is 
shown in cartoon representation in different orientations in (A) and (B) and as surface representation in (D). The 
bound chloride ion is shown as blue sphere. 
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7.3.4. Comparison of CD1823 and homologous proteins 
The structure of CD1823 was determined by MR using the structure of YaaA as search model. 
YaaA from E. coli and CD1823 from C. difficile share a sequence identity of 36% and an 
identical protein fold. Both structures can be aligned with an r.m.s.d. of 1.23 Å over 248 
residues. A structure-based sequence alignment is shown in Fig. 49A and a structural 
alignment of both structures is illustrated in Fig. 49B with CD1823 in magenta and YaaA in 
light cyan. Both proteins show almost identical three-dimensional structures, with only minor 
differences. YaaA contains two short β-strands (β2 and β4) that are not present in CD1823. 
Latter, on the other hand, possesses a short C-terminal α-helix (η5) that can’t be found in 
YaaA. 
The electrostatic surface distribution of YaaA is similar to that of CD1823 (Fig. 47 and Fig. 50). 
Both proteins contain a highly negative charged, continuous patch on one side of the protein 
structure, while the rest of the surface shows an even distribution of positive and negative 
charge. Similar to CD1823, YaaA has a bound chloride ion in the same position as in CD1823, 
which is surrounded by a highly positive charged surface. 
 
Figure 49: (A) Structure-based sequence alignment of CD1823 from Clostridium difficile and YaaA from 
Escherichia coli (PDB-ID 5CAJ, unpublished). Conserved residues are shown in bold and the secondary 
structure elements of YaaA are shown above the alignment, CD1823 elements are depicted below the alignment. 
α-helices are depicted as spirals, β-strands as arrows. Secondary structure elements are numbered 
consecutively. (B) Structural alignment of the crystal structures of CD1823 (purple) and YaaA (light cyan). 
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Figure 50: Electrostatic surface of YaaA. The crystal structure of YaaA is shown in cartoon representation in two 
orientations and as electrostatic surface in the same orientations. The second orientation (right panel) is turned 
by 270° around the x-axis with respect to the first one (left panel). 
 
Due to the high structural similarity between YaaA and CD1823, hypotheses about the 
molecular function of CD1823 could be derived based on the function of YaaA. YaaA from 
E. coli is annotated as a protein involved in peroxide stress response (Liu et al., 2011). Upon 
peroxide stress response, reactive oxygen species (ROS) can be generated intracellularly 
under aerobic conditions or extracellularly upon inflammation processes in the gut. They can 
enter cells due to membrane penetration and can cause severe damage by disturbing several 
central metabolic biomolecules. H2O2 is typically produced after reaction of oxygen with metals 
or thiols. Under normal conditions, iron and hydrogen peroxide undergo the so-called Fenton 
reaction (Fenton, 1894) and ROS are produced, which can cause DNA lesions and inactivation 
of iron enzymes or iron-sulfur enzymes (Liu et al., 2011).  
Upon peroxide stress response, YaaA is expressed under control of the OxyR regulon in H2O2 
presence. The OxyR regulon is activated when an activated thiolate residue of the OxyR 
transcription factor is oxidized by H2O2 to a sulfenic acid. This activated transcription factor 
then directly triggers expression of peroxide stress response proteins, e.g. YaaA (Lee et al., 
2004; Zheng et al., 1998). YaaA, together with Dps and Fur, lowers the intracellular levels of 
unincorporated iron and thereby helps to attenuate the Fenton reaction and to prevent DNA 
damage caused by reactive oxygen species (ROS), e.g. H2O2 (Liu et al., 2011). The exact 
molecular mechanism of YaaA and its potential role in iron metabolism is still unknown. Several 
potential mechanisms how YaaA might lower unincorporated iron levels inside the cell have 
been postulated. On one hand, it could slow down the import of iron into the cell and could on 
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the other hand also prevent release of iron from H2O2-damaged enzymes. Furthermore, it is 
possible that YaaA could accelerate the transfer of free iron to target proteins or increase its 
efflux out of the cell (Liu et al., 2011).   
In anaerobic bacteria, such as C. difficile, peroxide stress response is initiated in presence of 
oxygen. C. difficile expresses several proteins upon peroxide stress response, among these 
are manganese superoxide dismutase (CD1631), several putative manganese catalases 
(CD1567, CD0598, and CD2401) and a putative thioredoxin-dependent thiol peroxidase 
(CD1822) (Janoir et al., 2013). 
The high similarity between YaaA and CD1823 indicates a similar function of both proteins. As 
YaaA is involved in peroxide stress response, it can be assumed that also CD1823 is involved 
in this process. Because the exact molecular function of YaaA and its role during peroxide 
stress response are currently unknown, no hypotheses about the molecular function of 
CD1823 can be derived from its E. coli homologue. 
YaaA and CD1823 belong to the UPF0246 protein family, which has not been functionally 
characterized so far. Computational analysis using InterPro (Finn et al., 2017) showed that 
over 8700 other proteins from various organisms (archaea, aerobic and anaerobic bacteria, 
eukaryota) belong to this protein family. Sequence comparison of some of these protein family 
members showed several conserved amino acid patches (Fig. 51). However, as the exact 
molecular function of proteins of the UPF0246 family is not known, no ideas about the function 
of CD1823 can be derived from this homology. 
 
Figure 51: Sequence alignment of CD1823 from Clostridium difficile and other proteins of the UPF0246 protein 
family. Amino acids that are conserved in > 80% of the aligned proteins are colored in dark blue, a conservation 
in > 60% of the selected proteins is illustrated by mid blue and a conservation in > 40% in light blue. 
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The structure of CD1823 was submitted to online structural alignment servers such as DALI 
(Holm, et al., 2016) and PDBeFold (Krissinel & Henrick, 2004) to search for structurally 
homologous proteins. A search with PDBeFold revealed the structural homologue YaaA from 
E. coli (PDB-Code 5CAJ) that was already discussed above. DALI search also revealed YaaA 
of E. coli as the best hit, but also showed some proteins with lower sequential and structural 
similarity to CD1823 with a dramatic decrease in the alignment Z-score and r.m.s.d. compared 
to YaaA. The second-best hit was ManxA from Thermoanaerobacter tengcongensis (PDB-ID 
3LFH, Fu & Su, 2010, unpublished), part of a phosphotransferase system, which could be 
aligned with 42% CD1823 residues with an r.m.s.d. of 3.1 Å and showed an overall Z-score of 
only 4.8. A small part of the central core of CD1823 could be aligned with ManxA, but despite 
the similar topology of this small region, no hypothesis about the function of CD1823 could be 
derived based on the structural comparison with ManxA. 
 
7.3.5. Genetic environment of CD1823 
To get ideas about the potential function of CD1823, its genomic context was analyzed. The 
gene CD630_18230 is located at position 2,112,409 in the genome of Clostridium difficile 
strain 630. Gene operon analysis by DOOR (Mao et al., 2009) predicted that the gene 
CD630_18230 is organized in an operon together with the neighboring gene CD630_18220 
(bcp), which encodes a thioredoxin-dependent thiol peroxidase (E1.11.1.15). This protein is 
actively involved in peroxide stress response, as it is expressed upon peroxide stress, shows 
peroxidase activity and catalyzes the reduction of H2O2 (Janoir et al., 2013). 
Another gene, CD630_18240, which is not organized in the same operon as CD1823, encodes 
a p-type calcium transport ATPase. It flanks the predicted CD1823 operon upstream. 
Downstream to the CD630_18230 operon is another operon, including the genes 
CD630_18200 and CD630_18210. These genes encode an adenine deaminase (ade) and a 
transposase-like protein B (tlpB), respectively. The operon organization and genetic 
environment of CD630_18230 is illustrated in Fig. 52. 
 
Figure 52: Genomic context of CD630_18230. According to simplification, gene names are abbreviated with 
CD18230 instead of CD630_18230. Arrows of the same color indicate genes belonging to one operon. 
 
Analysis of the genomic context and operon organization of homologous genes of CD1823 in 
other bacterial strains, e.g. Pseudomonas aeruginosa and Legionella pneumophila, showed 
no conservation of the CD1823 operon structure. Thus, no potential function of CD1823 could 
be derived based on comparison of its operon structure with the operon structure of 
homologous genes of related bacterial strains. 
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The genetic context of CD1823 was additionally analyzed using the STRING database 
(Szklarczyk et al., 2017). The result is shown in Fig. 53. Due to gene neighborhood, it is 
assumed that CD1823 interacts with gene CD1824 (a cations-transporting ATPase), CD1822 
(bcp, a thiol peroxidase), CD1820 (ade_2, an adenine deaminase), CD0049 (proS1, a prolyl 
tRNA-synthetase), CD0050 (proS2, a prolyl tRNA-synthetase), CD2275 (topB2, a DNA 
topoisomerase III), CD1701 (recQ, an ATP-dependent DNA helicase) and CD1700 (ribD, a 
riboflavin biosynthesis protein). 
 
Figure 53: Analysis of the genetic context of CD1823 using the STRING database. The genes are depicted as 
colored nods and the line between two genes illustrates an interaction of the respective genes. The line color 
illustrates the type of interaction. 
 
The gene neighborhood of CD1823 and the putative thiol peroxidase CD1822, as well as the 
structural similarity between CD1823 and YaaA from E. coli, a peroxide resistance protein, 
indicates that CD1823 could also be involved in peroxide stress response. However, the exact 
molecular function of CD1823 needs still to be determined. 
 
7.4. Other essential proteins of Clostridium difficile 
Besides CD1219 and CD1823, three other essential, uncharacterized proteins of Clostridium 
difficile were selected for structural and functional analysis (table 18). While the structures of 
CD1219 and CD1823 could be determined by X-ray crystallography, the structural analysis of 
the other three proteins was more complicated. All proteins were cloned in expression vectors 
and test expression was performed analogous to CD1219 and CD1823. All cloned constructs 
are listed in table 38 in the supplement. 
The fusion constructs of CD1067 with an N-terminal His6-MBP, His6-T7-Lysozyme or His6-
Sumo-tag, respectively, could be solubly expressed in E. coli, but tag cleavage was not 
successful, as the recombinant protein precipitated after tag removal. An optimization of the 
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construct boundaries and attached tags is essential to find a suitable construct for protein 
expression and purification. A TDSA might help to find a buffer composition that is better suited 
for protein purification and tag cleavage of CD1067. Another option could be to perform 
crystallization experiments without cleaving off the affinity tag.  
The uncharacterized essential protein CD2589 of C. difficile was successfully purified in this 
thesis and pure protein was used for initial crystallization screens. Several crystals were 
subjected to diffraction experiments, but diffraction (resolution > 20 Å) was not sufficient for 
data collection. Optimization of the crystallization conditions using random screens and grid 
screens resulted in an improvement of the resolution to 10 Å. Crystals of SeMet-labeled 
CD2589 diffracted to 6 Å, but this resolution was still not sufficient for structure determination. 
A CD spectrum of native CD2589 was collected and is shown in Fig. 84 in the supplement. 
This spectrum reveals that the protein is properly folded in the buffer that was used for protein 
purification. To further improve diffraction quality of the crystals, a surface entropy reduction 
(SER) mutant of CD2589 was cloned. Therefore, three flexible residues (Glu121, Lys122 and 
Glu123), which are predicted to be located on the surface of the protein, were mutated to rigid 
alanine residues. Expression and purification of the SER mutant was performed analogous to 
native CD2589. However, the SER-mutant of CD2589 eluted in a single peak with small 
shoulders during size exclusion chromatography, indicating that the SER-mutant is not stable, 
but rather present in several oligomeric states. The SER-mutant of CD2589 was hence not 
used for crystallization setups. An optimization of buffer composition for purification of the SER 
mutant has to be performed to yield a stable protein sample that can be used for crystallization 
experiments. Further optimization of the crystal conditions, together with limited proteolysis of 
native CD2589 and SER-CD2589 might also help to improve the diffraction quality of CD2589 
crystals. 
The essential protein CD2752 was cloned in various expression vectors and all fusion proteins 
could be soluble expressed in E. coli. Purification of the protein yielded a stable protein sample 
of CD2752, but several impurities were still present in the sample after a 4-step purification. 
An optimization of the purification protocol and buffer is hence necessary to obtain pure protein 
that can be used for crystallization experiments. 
Overall, the structure of two essential proteins of Clostridium difficile, CD1219 and CD1823, 
could be determined in this thesis and could pave the way for further experiments for a 
functional analysis of these proteins. The structure of the other three selected proteins of this 
project could not be determined due to purification and diffraction problems. The general 
workflow and success of the structural and functional analysis is summarized in Fig. 54. 
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Figure 54: Overview of the workflow and progress of the structural and functional analysis of essential 
uncharacterized proteins of Clostridium difficile. 
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8. Diffocins 
The so-called diffocin proteins of Clostridium difficile are high-molecular weight, bacteriophage 
tail-like bacteriocins. Due to their killing activity towards related strains in their environment, 
they are treated as novel potential therapeutic agents for CDI. They are structurally related to 
other phage-tail like particles. 
 
8.1. Phage-tail like particles 
8.1.1. Contractile bacteriophage tails 
The architecture of bacteriophages is rather simple, as they consist in principle just of two 
parts: a phage capsid and a contractile tail. The capsid carries the genomic phage DNA that is 
transferred into the host cell during infection. The phage tail is involved in penetration of the 
host cell membrane and pore formation but it plays no active role in the DNA transfer. Upon 
host cell attachment, the bacteriophage tail undergoes large conformational changes that 
result in contraction of the tail envelope. Upon contraction, the inner tail part is pushed through 
the host cell membrane. The mechanism of action of the bacteriophage tail can hence be 
compared to a syringe (Leiman et al., 2004). 
According to their architecture, bacteriophage tails can be grouped into three different classes 
(Ackermann 2003):  
 Myoviridae:  long contractile tail 
 Siphoviridae:  long non-contractile tail 
 Podoviridae:  short non-contractile tail 
Bacteriophage tails consist of several structural elements (Fig. 55). The baseplate carries 
several tail fibers, also called receptor binding proteins (RBPs) that are involved in receptor 
binding and host cell attachment (Arisaka et al., 2016). A tube complex is attached to the 
baseplate that is surrounded by the contractile sheath, followed by the terminator complex, 
which connects the phage tail and capsid (Leiman & Shneider, 2012). The first step of the host-
cell infection involves receptor recognition and binding, which is supported by digestion of 
external polysaccharides present on the host cell surface due to the enzymatic activity of the 
RBPs. The peptidoglycan layer is then destroyed by a glycosidase present in the 
bacteriophage tail (Leiman et al. 2007, Walter et al. 2008). Upon contact to the host cell 
membrane, the baseplate undergoes a conformational change, which results in sheath 
contraction to half or even less of its original length. This pushes the inner part, the tail tube, 
through the host cell membrane, which creates a channel for transfer of the phage DNA 
(Leiman et al., 2010). It could be shown by cryo-EM studies (Leiman et al. 2004, Kostyuchenko 
et al. 2005) that the T4 sheath can be present in an elongated and a contracted state. 
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The tail of bacteriophage T4 is one of the best-studied bacteriophage tails (Leiman et al., 
2009). They are approximately 220 Å in diameter, but variable in their length (1.000 - 4.500 Å). 
Their structural organization is rather simple, as they are composed of only two components: 
the internal rigid tube (proteins with 15 - 21 kDa) and the external contractile sheath (proteins 
with 40 - 80 kDa) are both composed of copies of one single protein, respectively. The genes 
encoding the sheath and the tube protein are usually located adjacent to each other, with the 
sheath gene preceding the tube gene. Their transcription is usually regulated by other genes, 
transcription regulators (Leiman & Shneider, 2012). 
Besides bacteriophages, there are several homologous protein machineries that share a 
phage-tail like architecture, e.g. the pyocins from Pseudomonas aeruginosa, the bacterial Type 
VI secretion system (T6SS) or proteins encoded by the Photorhabdus virulence cassette. The 
function of these contractile tail systems differs between the individual systems, as they can 
be involved in transport of protein or DNA, but also in transfer of ions into the cytoplasm of the 
host cell. 
 
8.1.2. Pyocins from Pseudomonas aeruginosa 
Pyocins from Pseudomonas aeruginosa are high-molecular weight bacteriocins (Jacob 1954). 
According to their definition, bacteriocins are proteins or peptides that are produced by bacteria 
to kill other specific bacteria in their environment (Cotter et al., 2013). The pyocin genes are 
usually transcribed upon SOS response, e.g. after UV or mitomycin treatment (Matsui et al., 
1993). This leads to DNA damage and activation of RecA. RecA degrades the PrtR protein, a 
repressor of PrtN, which can then activate transcription of the pyocin genes (Michel-Bryand & 
Baysse, 2002). 
According to their architecture, pyocins are bacteriophage tail-like particles. The pyocin particle 
consists of 11 proteins that are encoded in the pyocin gene cluster, similar to bacteriophages. 
Based on their architecture, pyocin particles can be grouped into three different classes 
(Michel-Bryand & Baysse, 2002): 
 R-type pyocins:    non-flexible, contractile phage-tail like particles 
 F-type pyocins:    flexible, non-contractile phage-tail like particles 
 S-type pyocins:    colicin-like proteins 
R-type pyocins are one of the smallest contractile tail systems. One bacterium can produce up 
to 200 pyocin particles that are released into the environment upon lysis of the bacterial cell. 
However, one pyocin particle is enough to kill a bacterium. The bacterium that produces the 
pyocin particles is resistant against its own pyocin. It is assumed that production of pyocins is 
used to ensure survival of a bacterial species under stress conditions. One bacterial cell has 
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to sacrifice itself and lyse to release the pyocin particles to ensure the survival of its sister cells 
(Lee et al., 2016). 
Due to their structural similarity to contractile bacteriophage tails and to diffocin particles, the 
focus in this thesis will be on R-type pyocins; F- and S-type pyocins will not be discussed. 
 
8.1.3. Other phage-tail like particles 
Several other phage-tail like particles are known, e.g. the contractile tail of the bacterial T6SS 
or proteins encoded by the virulence cassette of Photorhabdus (Fig. 55). The bacterial T6SS 
is a complex macromolecular machine that is involved in pathogenesis. It consists of several 
proteins, among which several share a structural and sequence similarity to phage tail proteins 
(Leiman 2009). The contractile T6SS tail consists of the tube protein Hcp, while the sheath is 
composed of two proteins, VipA and VipB. The Hcp tube can be up to 1000 Å long with a 
diameter of 85 Å (Bönemann 2010). Similar to phages and pyocin particles, the T6SS uses its 
contractile tail to attack host cell membranes and to form a pore (Alteri & Mobley, 2016). In 
contrast to bacteriophages, this channel is used for the transfer of large proteins into the host 
cell cytoplasm. Other differences between T6SS and phage tails are e.g. that the T6SS 
baseplate consists of only three instead of five proteins, no tape measure protein is present in 
the T6SS and its sheath is build up by two proteins instead of only one protein. Furthermore, 
the bacterial T6SS has to act continuously and therefore has to be recycled (Leiman & 
Shneider, 2012). 
Photorhabdus sp. produces proteins encoded in the so-called Photorhabdus virulence 
cassettes (PVC) that are similar to R-type pyocins. In contrast to pyocins, the PVC proteins 
are not classified as bacteriocins, as they do not show any antibacterial activity (Yang et al., 
2006). Instead, they are toxic towards eukaryotic cells. The PVC proteins are encoded in a 
PVC gene operon that encodes tail sheath proteins and several other T6SS-related proteins, 
e.g. a VgrG-like protein (Hurst et al., 2004; Pukatzki et al., 2007). Similar to R-type pyocins, 
the PVC particle can be present in a contracted and an elongated state. It can therefore be 
assumed that the mechanism of pyocins and PVC proteins is similar and that also the PVC 
proteins drive the inner tube through the target cell membrane upon sheath contraction. 
 
8.1.4. Diffocin proteins as potential therapeutics for C. difficile infections 
Upon SOS-response, Clostridium difficile produces the so-called diffocin proteins (Gebhart et 
al., 2012). These proteins are high-molecular weight bacteriocins and their architecture is 
similar to tail proteins of the Myoviridae phages, R-type pyocins of Pseudomonas aeruginosa 
and the bacterial T6SS (Fig. 55). Due to their high selectivity for specific Clostridium difficile 
strains, the diffocin particles could be used as therapeutic agents for C. difficile infections, as 
they can also kill antibiotic-resistant strains (Sangster et al., 2014). The diffocin that is produced 
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by one specific C. difficile strain does not kill the same bacterial strain, but other specific strains 
of the same species. A strain producing diffocins is hence typically resistant against its own 
diffocins (Gebhart et al., 2012).  
The target specificity of the diffocin particle is determined by its receptor binding proteins (tail 
fibers), which differ between the individual diffocins (Gebhart et al., 2012). By swapping the 
RBPs and engineering new diffocin proteins, one could target the killing-activity to a certain 
C. difficile strain and use the diffocin proteins as a potential therapeutic. It could already be 
shown that engineered diffocin proteins stay active after oral admission and after passing the 
gastrointestinal tract of mice. They do also not damage the gut microbiota as compared to 
“traditional” antibiotic treatment (Gebhart et al., 2015).  
 
Figure 55: Schematic architecture of contractile bacteriophage tail-like systems. The figure is adapted with 
permission from Bönemann et al., 2010. 
 
In Clostridium difficile CD630, the diffocin proteins are encoded in an operon that contains 25 
predicted open reading frames (ORFs), including structural and regulatory proteins, as well as 
proteins with unknown function (CD13590-CD13760, Gebhart et al., 2012). The potential 
function of the respective proteins was derived from homology to known and well-characterized 
Myoviridae phage genes. The operon can be found in all sequenced C. difficile strains and the 
individual genes distribute a high homology among the individual strains, apart from the highly 
variable genes encoding the tail fibers and receptor binding proteins (CD1373 and CD1374) 
(Gebhart et al., 2012). The diffocin gene cluster is shown in Fig. 57 and the respective diffocin 
genes of CD630 encoded in this operon are summarized in table 26. 
The diffocin tail is composed of a tube surrounded by a contractile, non-flexible sheath, which 
is arranged on a baseplate, followed by six tail fibers and a spike protein. Upon SOS-response, 
these diffocin particles are produced inside the bacterium. At a certain time point, the bacterial 
cells lyse and release the diffocin particles into the environment. Upon binding of the tail fibers 
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to unique receptors on the host cell surface, the sheath contracts and pushes the inner tube 
through the bacterial membrane, thereby creating a pore (Gebhart et al., 2015). Due to 
homology to phage tail proteins, it is assumed that the baseplate changes its conformation, 
which causes sheath contraction and insertion of the tube through the membrane 
(Kostyuchenko et al., 2003). The created pore is big enough for transfer of ions, but its size is 
still small enough that no larger molecules such as proteins or toxins can get out of the host 
cell. This leads to disturbance of the membrane potential and depolarization of the cytoplasmic 
membrane, which kills the target bacterium. The architecture of the diffocin particle in its pre- 
and post-contraction state and the proposed diffocin mechanism is shown in Fig. 56. As the 
structure of the main components of contractile systems (T6SS, T4 phage tails, pyocin particle) 
are conserved, it is assumed that they also share a similar mechanism. 
However, the origin of bacteriophage-like tails has not been discovered, yet. As the structure 
of the core elements of the contractile tails is quite conserved without a clear homology at the 
level of the amino acid sequence, it is still unclear whether they have emerged from phages or 
bacteria (Leiman & Shneider, 2012). 
 
Figure 56: Overview of the schematic architecture of the diffocin particle in its pre- (left) and post-contraction 
state (right) and the diffocin mechanism. Upon binding to receptors on the host cell surface, the diffocin sheath 
contracts, which pushes the inner tube through the target membrane. A pore is formed, through which ions can 
be transferred out of the bacterial cell. The host cell is then killed due to disturbance of the membrane potential. 
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Figure 57: Gene clusters of different phage-tail like particles. The diffocin gene cluster is shown in (A), the pyocin 
gene cluster in (B) and the gene operon of bacteriophage T4 tail components in (C). Genes are illustrated as 
arrows with the gene name above the arrow. The arrow color indicates the annotated function (green for 
regulatory proteins, yellow for proteins with unknown function and blue for structural proteins). The gene cluster 
of bacteriophage T4 tail components is reduced severely to its basic components for simplification. Several 
regulatory and phage capsid genes were left out for clarity. 
 
 
Table 26: Genes of the diffocin operon with size of the respective encoded protein and their annotated function 
Gene Size (aa) Info 
CD13590 168 Putative phage protein, regulatory 
CD13600 106 Transcriptional regulator, Phage-type, regulatory 
CD13601 65 Transcriptional regulator, Phage-type, regulatory 
CD13610 146 Putative phage protein, regulatory 
CD13620 147 Uncharacterized protein, unknown function 
CD13630 354 Putative phage XkdK-like protein, structural (sheath) 
CD13640 142 Putative phage XkdM-like protein, structural (core) 
CD13650 148 Putative phage XkdN-like protein, structural 
CD13651 55 Uncharacterized protein, structural 
CD13660 817 Putative phage tail protein, structural (tape measure) 
CD13670 140 Putative phage XkdP-like protein, structural 
CD13680 509 Putative phage cell wall XkdQ-like hydrolase, structural (baseplate) 
CD13690 108 Putative phage protein, structural 
CD13700 142 Putative phage XkdS-like protein 
CD13710 350 Putative baseplate assembly predicted J-like, structural (baseplate) 
CD13720 232 Putative phage XkdT-like protein, structural 
CD13730 328 Putative phage tail fiber protein, structural (tail fiber) 
8 Diffocins  115 
CD13740 1743 Putative beta-lactamase-inhibitor protein II, structural (receptor binding) 
CD13750 39 Putative phage protein, unknown function 
CD13760 86 Putative phage protein, unknown function 
CD13770 151 Putative membrane protein, unknown function 
CD13780 139 Transcriptional regulator, Phage-type, regulatory 
CD13781 69 Transcriptional regulator, Phage-type, regulatory 
CD13782 73 Uncharacterized protein, regulatory 
CD13790 132 Transcriptional regulator, Phage-type, regulatory 
 
 
8.2. Aim of this project 
At the beginning of this project, the diffocin proteins of Clostridium difficile were structurally 
uncharacterized. Negative stain images of the diffocin particles are available (Sangster et al., 
2014), but crystal structures of diffocin proteins have not been determined, yet. Cryo-EM 
structures of the homologue R-type pyocins of Pseudomonas aeruginosa were published in 
2015 (Ge et al., 2015; PDB-Codes 3J9R and 3J9Q) in the pre- and post-contraction state at 
3.5 and 3.9 Å, respectively. These structures illustrate the overall shape of the pyocin sheath 
complex and highlight the interaction of the individual monomers in the assembled particle. 
Due to the lack of a high-resolution crystal diffocin structure, a detailed atomic structural 
characterization was not possible so far. 
To get insight into the structural details of the individual diffocin proteins, the structures of the 
non-oligomerized sheath and tube protein have been investigated by X-ray crystallography 
and SAXS experiments in this thesis. Comparison with homologous structures, e.g. pyocins 
and phage tail proteins reveals potential similarities and differences between diffocin and other 
phage-tail like particles and provides an opportunity to obtain insight into the assembly of the 
contractile apparatus of diffocins and other R-type bacteriocins as well as construction of a 
model of the diffocin particle in its assembled state. 
 
8.3. Structural analysis of the diffocin sheath protein CD1363 
The 39 kDa protein CD1363 from Clostridium difficile is a structural protein encoded in the 
diffocin gene operon. It is annotated as a putative phage XkdK-like protein building the sheath 
envelope of the diffocin particle (UniProt-Code Q18BN0), but its exact molecular function and 
structure were unknown at the start of this project. 
 
8.3.1. Structure determination of CD1363 
The gene encoding CD1363 (CD630_13630) was amplified from genomic Clostridium difficile 
CD630 DNA (provided by Prof. Dr. Ralf Gerhard, MHH, Germany) and was cloned in a 
116  8 Diffocins 
pOPIN-M expression vector by SLIC-cloning. The fusion construct His6-MBP-S3C-CD1363 
was solubly expressed in E. coli BL21-CodonPlus(RIL) cells by autoinduction at 25 °C for 24 h. 
Purification of CD1363 was achieved by affinity chromatography (MBP-tag), followed by tag 
cleavage by S3C-protease overnight, another step of affinity chromatography (reverse 
Ni(II)-IMAC) and final size exclusion chromatography. Pure protein was used for crystallization 
setups using commercially available screens. Crystal growth was obtained in several 
conditions already after one day. As no suitable model was available for structure solution by 
molecular replacement, SeMet-labeled CD1363 was expressed in M9 minimal medium in 
E. coli BL21-CodonPlus(RIL) cells in TB-medium at 20 °C overnight. Purification and 
crystallization setups were performed analogous to native CD1363. The chromatogram of the 
final size exclusion chromatography step of SeMet-labeled CD1363 and the corresponding 
SDS-PAGE illustrating the final protein purity is depicted in Fig. 58A and B. Exemplary crystals 
of native and SeMet-labeled CD1363 are shown in Fig. 58C and D. 
 
Figure 58: Chromatogram (A) and corresponding SDS-PAGE of the final size exclusion chromatography of 
SeMet-labeled CD1363. A protein standard is loaded in the first lane of the SDS-PAGE for comparison of the 
molecular weight of CD1363 (theoretical MW CD1363 = 39 kDa) with standard proteins. Protein fractions that 
were pooled and used for crystallization setups are marked with an orange bar. Exemplary crystals of SeMet-
labeled CD1363 (C) and native CD1363 (D). Crystallization condition (C): 1.0 M Lithium chloride, 0.1 M Tris 
pH 8.0, 20% (w/v) PEG 6000, 20 mg/ml CD1363; Crystallization condition (D): 0.1 M BIS-TRIS pH 5.5, 25% (w/v) 
PEG 3350, 20 mg/ml CD1363. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
Crystals were fished directly from the crystallization screens, 2,3-Butanediol was used as 
cryoprotectant and data were collected at beamline PXII at SLS (PSI, Villigen, Switzerland; 
Fuchs et al., 2014). Statistics of the dataset collection of SeMet-labeled CD1363 crystals are 
summarized in table 27. The crystal structure was solved using Autosol (Adams et al., 2010) 
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from the Phenix suite, initial model building was performed using Autobuild (Terwilliger et al., 
2008), followed by iterative refinement cycles (using Phenix.Refine (Afonine et al., 2012)) and 
manual model building using Coot (Emsley & Cowtan, 2004; Emsley et al., 2010). Refinement 
statistics are shown in table 28.  
Table 27: Dataset collection statistics for SeMet-labeled CD1363. 
Dataset   CD1363 SeMet 
Wavelength (Å) / beamline   0.97945/ SLS, PXII 
Resolution range (Å)   38.36-1.90 (1.97-1.90) 
Space group   C121 
Unit cell parameters (Å) 
                                  (°) 
  75.94   47.88   112.51 
  90.00   92.25     90.00 
Mosaicity (°)   0.23 
Total No. of measured reflections   432693 (27784) 
Unique reflections   32089 (3199) 
Multiplicity   13.5 (13.3) 
Mean I/σ(I)   21.8 (1.8) 
Completeness (%)   99.8 (99.6) 
Rmeas (%)   9.2 (159.3) 
Rp.i.m. (%)   2.5 (43.0) 
CC1/2 (%)   100 (70) 
Table 28: Refinement statistics for CD1363. 
Dataset CD1363 SeMet 
Resolution Range (Å) 38.36-1.90 (1.96-1.90) 
Rwork (%) 21.11 
Rfree (%) 24.57 
No. of non-H atoms  
Protein 2689 
Water 183 
R.m.s. deviation  
Bonds (Å) 0.004 
Angles (°) 0.57 
Average B factors (Å2)  
Protein 51 
Water 46 
Atoms 51 
Ramachandran plot  
Favored regions (%) 97.4 
Outliers (%) 0 
MolProbity score 1.64 
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8.3.2. Crystal structure of CD1363 
CD1363 crystallized in space group C121 with one molecule in the asymmetric unit. The 
solvent content is approximately 53% with a Matthews coefficient of 2.61 (calculated with 
CCP4_Matthews_coef). The crystal structure of monomeric CD1363 and the corresponding 
two-dimensional topology diagram is shown in Fig. 59. 
 
Figure 59: (A) Crystal structure of monomeric CD1363 from Clostridium difficile in cartoon representation. 
Individual domains are colored in orange and yellow, respectively. (B) Topology diagram of monomeric CD1363. 
The domains are colored analogous to the cartoon representation of CD1363 in (A). Secondary structure 
elements are numbered consecutively; α-helices are illustrated as cylinders and β-sheets as arrows. The figure 
was prepared using Topdraw (Bond, 2003). Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
Monomeric CD1363 is composed of two domains, domain I (residues 4-25 and 226-354) and 
domain II (residues 26-225), colored in yellow and orange in Fig. 59, respectively. It is 
important to note that domain II is an insertion into domain I. Domain I starts with a long α-helix 
at the N-terminus, followed by domain II, which folds back into domain I at the C-terminus. 
Domain I is composed of a central three-stranded β-sheet with two parallel and one antiparallel 
β-strand. The β-sheet is sandwiched between six α-helices. Domain II (colored in orange) 
contains a central six-stranded β-sheet with five parallel and one antiparallel β-strand, flanked 
by four α-helices. The β-sheet is followed by five additional smaller β-strands and two α-
helices.  
The surface of CD1363 shows an equal distribution of alternating negative and positive 
charged patches (Fig. 60). This allows an interaction of CD1363 monomers due to attraction 
of opposite surface charges and could favor the assembly of the individual monomers into the 
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diffocin particle. CD1363 contains several negatively charged “fingers” and small positively 
charged cavities on its surface that could interact with each other due to electrostatic attraction. 
Figure 60: Electrostatic surface of the crystal structure of CD1363 from Clostridium difficile in different 
orientations. Red patches illustrate negatively charged surface regions, blue patches indicate positive charge. 
Each orientation is shown in cartoon representation (top panel), as well as electrostatic surface (bottom panel). 
Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
A large cavity flanked by several residues of both domains and with a volume of ~ 580 Å3 is 
present in the interface between domain I and II (Fig. 61). The outer part of this cavity, which 
is directly accessible from the solvent, is surrounded by several positively charged amino acids, 
e.g. lysine and arginine. The inner part is mainly negatively charged due to the presence of 
several glutamate residues. 
The conservation of CD1363 was analyzed using the ConSurf server (Ashkenazy et al., 2016). 
The crystal structure of CD1363 was colored according to the calculated conservation score 
and is illustrated in Fig. 62. Cyan patches depict non-conserved residues, dark red patches 
indicate conserved residues. The amino acids of the central β-sheet of domain II as well as 
the helical parts of domain I are highly conserved. In contrast to this, the central β-sheet of 
domain I and the helices of domain II are highly variable in their amino acid composition. 
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Figure 61: A cavity is present in the interface between domain I and II of CD1363 from Clostridium difficile. The 
cavity is shown as light grey surface representation in the top panel with the crystal structure of CD1363 in 
cartoon representation. Domain I is colored in yellow and domain II in orange. The bottom panel illustrates the 
electrostatic charge distribution of the cavity in two orientations with flanking residues in stick representation. 
Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
Figure 62: Crystal structure and amino acid sequence of CD1363 colored according to the calculated 
conservation score. A score of 1 illustrates variable residues, a score of 9 depicts conserved amino acids. The 
scores were calculated by the Consurf server. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 
2018). 
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8.3.3. SAXS analysis of CD1363 
SAXS experiments of CD1363 were performed at BM29 ESRF (Grenoble, France; Pernot et 
al., 2013) to analyze the oligomeric state of the diffocin sheath protein in solution. The best 
data were obtained for 0.63 mg/ml CD1363 in 20 mM HEPES pH 7.5, 150 mM NaCl. 
Experimental SAXS data are shown as black dots in Fig. 63. These experimentally measured 
data were fit against theoretically calculated scattering curves for monomeric and dimeric 
CD1363. A crystallographic dimer of CD1363 was selected for this purpose. The fit for 
monomeric CD1363 is shown in Fig. 63A and is described by a X-value of 1.8. The fit of dimeric 
CD1363 yielded a X-value of 25.7 and is shown in Fig. 63B. Due the low X-value of the fit for 
monomeric CD1363, SAXS experiments showed that CD1363 is monomeric in solution. The 
SAXS envelope was hence calculated for monomeric CD1363 and the crystal structure of the 
monomer was fit into the envelope using Crysol (Fig. 63C). 
Figure 63: Fit of experimental SAXS data of CD1363 (black dots) and theoretical SAXS data (orange curves) for 
monomeric (A) and dimeric (B) CD1363. (C) Fit of the crystal structure of monomeric CD1363 (orange, cartoon 
representation) into the calculated SAXS envelope (surface representation) in different orientations (turned by 
90° around x- and y-axis, respectively). Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
8.3.4. Comparison of CD1363 and homologous phage-tail like proteins 
Phage-tail like particles are usually composed of an outer part, the contractile sheath, and an 
inner part, the rigid tube. Based on their structural organization, sheath proteins of phage-tail 
like particles share several similarities. They are large macromolecules that can be divided into 
individual domains. One of the best-characterized sheath proteins is that of bacteriophage T4: 
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protein gp18. It is composed of four domains that are inserted into each other like a Russian 
doll. Domain IV is inserted between two β-strands of domain III, domain III itself is an insertion 
into a loop region of domain II and so on. The only crystal structure of gp18 that was published 
so far is that of a deletion mutant of gp18 (gp18M), which lacks domain I (PDB-ID 3FOA, 
Aksyuk et al., 2009). The structure and the corresponding topology diagram of gp18M is shown 
in the top left panel of Fig. 64.  
The domain architecture of homologous phage-tail like sheath proteins was compared to that 
of gp18M (Fig. 64). Several other phage sheath proteins show a similar domain architecture 
as gp18, but there are some sheath proteins that lack particular domains. They all have in 
common that their domains are arranged as insertions into the prior domain like a Russian doll. 
The phage sheath proteins LIN1278 (PDB-ID 3LML, Forouhar et al., 2010, unpublished) and 
DYS3957 (PDB-ID 3HXL, Forouhar et al., 2010, unpublished) are for example only composed 
of domains I, II and III and lack domain IV. They seem to depict a truncated form of the 
bacteriophage sheath protein gp18 and could have evolved from gp18 upon deletion of 
domain IV. The diffocin sheath protein CD1363 and its homologue, the pyocin sheath protein 
FIR2 from Pseudomonas aeruginosa (PDB-ID 3J9R, Ge et al., 2015), are only composed of 
domains I and II. As the pyocin sheath protein FIR2 can still assemble into a sheath particle 
(shown by Cryo-EM studies; Ge et al., 2015), it can be assumed that domains I and II are the 
minimal part of bacteriophage-like sheath proteins that are essential for particle formation. 
As the diffocin sheath protein CD1363 is only composed of domains I and II, only domains I 
and II of homologous sheath proteins were used for further analysis. The other domains (III 
and IV) were neglected for simplification. A structure-based sequence alignment of CD1363, 
the homologous sheath protein of Pseudomonas aeruginosa and the bacteriophage sheath 
proteins LIN1278 and DSY3957 is shown in Fig. 65 to illustrate sequence similarities. Bold 
residues indicate conserved amino acids and it can be shown that especially these residues 
that are organized in secondary structure elements, are conserved among the selected 
homologous sheath proteins, whereas loop residues are quite variable. 
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Figure 64: Domain organization of bacteriophage-tail like sheath proteins. Sheath proteins are in general 
composed of four separate domains, here highlighted by different colors (domain I in yellow, domain II in orange, 
domain III in green and domain IV in blue). The crystal structure and the corresponding topology diagram of six 
selected sheath proteins is shown: CD1363 from Clostridium difficile, FIR2 from Pseudomonas aeruginosa (PDB-
ID 3J9R, Ge et al., 2015), T4 Bacteriophage sheath protein gp18 (PDB-ID 3FOA, Aksyuk et al., 2009), sheath 
protein from bacteriophage PhiKZ (PDB-ID 3SPE, Aksyuk et al., 2011), LIN1278 from Listeria innocua (PDB-ID 
3LML, unpublished) and DSY3957 from Desulfitobacterium hafniense (PDB-ID 3HXL, unpublished). The crystal 
structures and secondary structure elements are colored according to the domain organization shown at the top 
of the figure. The domain organization of the full-length amino acid sequence is shown above the respective 
crystal structure. A white box indicates that this part of the protein is not resolved in the crystal structure or was 
not included in the crystallized protein construct. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 
2018). 
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Figure 65: Structure-based sequence alignment of the homologous sheath proteins FIR2 from Pseudomonas 
aeruginosa (PDB-ID 3J9R, Ge et al., 2015), DSY3957 from Desulfitobacterium hafniense (PDB-ID 3HXL, 
unpublished), LIN1278 from Listeria innocua (PDB-ID 3LML, unpublished) and CD1363 from Clostridium difficile. 
Only domains I and II were used for this alignment. Domain III of LIN1278 and DSY3957 was left out for clarity. 
Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
8.3.5. Similarities between the diffocin and pyocin sheath monomer 
Among homologous sheath proteins, CD1363 from Clostridium difficile shares highest 
sequence and structural homology to FIR2 from Pseudomonas aeruginosa, the component of 
the contractile sheath of the Pseudomonas pyocin particle. Both proteins share a sequence 
identity of almost 19% and a sequence similarity of 33%. Their structures can be aligned with 
an r.m.s.d. of 3.9 Å. Although the r.m.s.d. of the structural alignment is quite high, the general 
topology of CD1363 and FIR2 is highly similar. The three-dimensional structures of both 
proteins and the corresponding topology diagrams are shown in Fig. 66. Both proteins can be 
subdivided into two domains, colored in yellow and orange, respectively. Domain II of both 
sheath proteins contains a central β-sheet composed of six β-strands β1-β6 (one antiparallel 
and five parallel strands). The long helix α4 of CD1363 that flanks the central β-sheet is divided 
in two small α-helices α4 and α4* in FIR2. The pyocin sheath protein further possesses an 
additional helix α5* that is not present in CD1363. The C-terminal part of domain II of CD1363 
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consists of five short β-strands and two α-helices, similar to that of FIR2 with one β-strand (β9) 
missing in its structure compared to CD1363. Domain II of CD1363 and FIR2 is hence almost 
identical with only minor differences in the secondary structure composition.  
The main differences between the two homologous sheath proteins can be found in the 
structural organization of domain I, especially at their N- and C-terminus. The N-terminus of 
CD1363 is arranged as a long α-helix (α1) that is tightly packed against the rest of the protein. 
The C-terminus of CD1363 is organized as a β-strand (β14) that interacts with the neighboring 
β-strand β13. This structural assembly of the CD1363 termini results in a compact packing of 
the whole protein structure. In contrast to CD1363, both termini of FIR2 are unstructured with 
two long loops protruding from the rest of the protein. This results in a rather elongated 
architecture of the FIR2 protein compared to CD1363.   
The unstructured protruding terminal regions of FIR2 are essential for the interaction and 
assembly of the individual FIR2 monomers into the sheath of the pyocin particle. Upon 
assembly, the termini of FIR2 form short β-strands. The terminal β-strands of the individual 
monomers interact with each other to form a stable mesh-like interwoven sheath structure of 
the pyocin particle (Fig. 67). The interaction of the strands is stabilized by π-interactions of 
neighboring aromatic side chains and hydrogen bonds of neighboring side chains. The 
assembled pyocin particle is further stabilized by electrostatic attraction of neighboring FIR2 
monomers. FIR2 shares a similar electrostatic surface charge distribution as CD1363 (cp. 
Fig. 60 and Fig. 68). The protruding terminal arms of FIR2 possess a complementary charge, 
which enables the interaction of the respective arms of FIR2 monomers due to attraction of 
opposite electrostatic charge. By interaction of several FIR2 monomers, the contractile sheath 
of the pyocin particle is formed. 
The assembly of the pyocin sheath is hence stabilized due to the interaction of the protruding 
arms of neighboring monomers, the atomic interaction (hydrogen bonds) between adjacent 
side chains and due to electrostatic attraction of the terminal arms. As these protruding arms 
are not present in CD1363 monomers, it is unclear how the interaction of the individual 
monomers upon assembly of the diffocin sheath particle is achieved. One explanation could 
be that parts of the diffocin sheath protein CD1363 change their conformation upon particle 
assembly, suggesting that the form crystallized here represents a pre-assembly state with 
organization of the termini in secondary structure motifs. As the structure of the pyocin sheath 
monomer FIR2 was solved by cryo-EM studies of the assembled pyocin particle, the structure 
of the FIR2 monomer depicts the structure and orientation in the assembled form. The obvious 
structural differences between the termini of both monomers could hence reveal the 
conformational changes that might be essential for particle assembly. The terminal regions of 
the diffocin sheath monomer that are tightly packed against the rest of the protein could 
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therefore undergo conformational changes upon particle assembly and change into protruding 
arms that interact with each other to form the diffocin sheath, similar to the pyocin particle. 
 
Figure 66: Comparison of the structure and topology of the sheath proteins CD1363 of Clostridium difficile and 
FIR2 of Pseudomonas aeruginosa (PDB-ID 3J9R, Ge et al., 2015). The individual domains are colored in yellow 
and orange, respectively, the central β-sheet of domain II is highlighted in pink, the N-terminus in blue and the 
C-terminus in green. The topology diagrams are colored according to the crystal structures. α-helices are 
depicted as cylinders, β-strands as arrows. The secondary structure motifs of CD1363 are numbered 
consecutively. The elements of FIR2 are numbered according to the homologous parts of CD1363. Helices and 
strands of FIR2 that are marked with an asterisk (*) confer to secondary structure motifs that are not present in 
the CD1363 structure. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
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Figure 67: Interaction of FIR2 sheath monomers in the assembled pyocin particle in the elongated form. Six 
monomers are shown in cartoon representation in light color with the termini in the respective bright color. The 
right panel illustrates side chains and respective distances between the amino acids that are involved in the 
interaction of neighboring sheath monomers upon particle assembly. Figure is adapted from Schwemmlein et al. 
(Front. Microbiol., 2018). 
 
Figure 68: Electrostatic surface of FIR2 from Pseudomonas aeruginosa. Individual orientations turned by 90° 
relative to the prior orientation. The electrostatic surface potential was calculated by Pymol. Figure is adapted 
from Schwemmlein et al. (Front. Microbiol., 2018). 
 
8.3.6. Model of the diffocin sheath particle 
Due to the structural similarity of CD1363 and FIR2, it can be assumed that CD1363 monomers 
interact similar to the pyocin sheath monomers to form a contractile sheath of the diffocin 
particle. The crystal structure of monomeric CD1363 was aligned on top of the FIR2 monomers 
of the assembled pyocin sheath (PDB-Codes 3J9Q and 3J9R, Ge et al., 2015) by the Cα-align 
command in Pymol to generate a theoretical model of the assembled diffocin sheath in the 
contracted as well as in the elongated state. Due to the structural similarity of pyocin and 
diffocin sheath monomers, the overall architecture of the modelled diffocin particle is therefore 
almost identical to the assembled pyocin sheath. The individual CD1363 monomers do not 
clash with each other in the elongated, as well as in the contracted diffocin model. The final 
models of the diffocin particle in the pre- and post-contraction state are shown in Fig. 69. 
Because CD1363 was most probably crystallized in its “pre-assembly form”, no interaction of 
the individual CD1363 monomers can be observed in the model of the diffocin particle. 
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Figure 69: A model of the diffocin particle in its pre- (bottom) and post-contraction state (top) based on the pyocin 
structure in pre- (PDB-Code 3J9R) and post-contraction state (PDB-Code 3J9Q). The diffocin sheath in the post-
contraction state (top panel) is colored in light orange and shown from the top (left) and from the side (right). The 
diffocin sheath in the pre-contraction state (lower panel) is colored in light yellow and shown from the top (left) 
and the side perspective (right). Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
The assembled pyocin particle as well as the model of the diffocin particle are arranged in a 
six-start helix, which is composed of six sheath monomers. The sheath particle is composed 
of several discs of each six CD1363 monomers that are packed on top of each other. It is 
assumed that the individual CD1363 monomers in the pre- and post-contraction state of the 
diffocin particle share the same conformation as compared to the pyocin particle (Ge et al., 
2015). Upon contraction, the pyocin sheath monomers are tilted relative to their pre-contraction 
orientation. Therefore, the distance between the individual discs is decreased and the diameter 
of the sheath particle is increased. The monomers in the assembled pyocin particle are 
oriented in a way that domain I points to the inside of the sheath particle and domain II is 
directed to the outside of the particle. Due to the structural similarity between CD1363 and 
homologous sheath proteins, it is assumed that CD1363 monomers are arranged in the same 
orientation as e.g. in the pyocin particle and that the mechanism of contraction of the diffocin 
sheath is similar to that of the pyocin sheath. 
Similar to the pyocin particle, the model of the diffocin sheath particle shows a predominantly 
negatively charged surface on both the outside and on the inside (Ge et al., 2015; Fig. 70B). 
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Figure 70: The model of the contracted diffocin sheath is colored according to its electrostatic potential and is 
depicted from the side view (A) and from the inside (B) in a clipped representation. Red patches illustrate negative 
charge, blue patches indicate positive charge. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 
2018). 
 
 
8.4. The diffocin tube protein CD1364 
The diffocin tube protein CD1364 is a 16 kDa protein and is annotated as a putative phage 
XkdM-like protein. Due to homology to phage tail-like tube proteins and its genetic context, it 
is assumed that it is the tube component of the diffocin particle. 
 
8.4.1. From gene to structure 
The gene encoding CD630_13640 (short CD1364) was amplified from genomic C. difficile 
CD630 DNA and was cloned in a pOPIN-M vector. Expression and purification was performed 
analogously to CD1363 (chapter 8.3.1). The final size exclusion chromatography 
chromatogram and the corresponding SDS-PAGE of pure CD1364 are shown in Fig. 71. Pure 
protein was used for crystallization experiments using commercially available screens. 
Crystals were obtained in some conditions after a few days and exemplary crystals of native 
CD1364 are depicted in Fig. 72. Native datasets were collected at BESSY (Berlin, Germany; 
Müller et al., 2015) and the structure was solved by Molecular Replacement using a truncated 
model of chain A of P54332 from Bacillus subtilis (PDB-Code 2GUJ) to 1.5 Å resolution. The 
protein was crystallized by Dr. Emerich-Mihai Gazdag, structure solution was performed with 
the help of Dr. Jan Pippel. CD1364 crystallized in space group P43212 with one molecule in 
the asymmetric unit (solvent content 44.86%, Matthews coefficient 2.23). Statistics of data 
collection and refinement are shown in table 29 and table 30, respectively. The overall 
structure of monomeric CD1364 in cartoon representation and the corresponding topology 
diagram are illustrated in Fig. 73. 
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Figure 71: Size exclusion chromatography of CD1364 (A) and corresponding SDS-PAGE (B) of eluted fractions. 
A protein standard is shown in the first lane of the SDS-PAGE for molecular weight comparison of CD1364 
(theoretical molecular weight 16 kDa). The green bar indicates the protein fractions that were used for 
crystallization setups. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
Figure 72: Exemplary protein crystals of native CD1364 (Crystallization 
condition: 20% (w/v) PEG3350, 0.2 M ammoniumchloride, 20 mg/ml 
CD1364). Figure is adapted from Schwemmlein et al. (Front. Microbiol., 
2018). 
  
 
Table 29: Data collection statistics for native CD1364 crystal. 
Dataset CD1364 
Wavelength (Å) / beamline   0.918 Å / BESSY 14.1 
Resolution range (Å)   34.42-1.50 (1.55-1.50) 
Space group   P43212 
Unit cell parameters (Å) 
                                  (°) 
  36.3   36.3   216.7 
    90      90       90 
Mosaicity (°)   0.10 
Total No. of measured reflections   611841 (30831) 
Unique reflections   24674 (1193) 
Multiplicity   24.8 (25.8) 
Mean I/σ(I)   19.6 (1.5) 
Completeness (%)   100 (100) 
Rmeas (%)   8.5 (257.2) 
Rp.i.m. (%)   2.3 (68.7) 
CC1/2   100 (62.8) 
 
 
Table 30: Refinement statistics for native CD1364. 
Dataset   CD1364 
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Resolution Range (Å)   35.83-1.50 (1.57-1.50) 
Rwork (%)   19.86 
Rfree (%)   21.91 
No. of non-H atoms  
   Protein   1079 
   Water   128 
R.m.s. deviation  
   Bonds (Å)   0.006 
   Angles (°)   0.698 
Average B factors (Å2)  
   Protein   36 
   Water   41 
All atoms   37 
Ramachandran plot  
Favored regions (%)   98.5 
Outliers (%)   1.5 
MolProbity score   1.28 
 
8.4.2. The crystal structure of CD1364 
Monomeric CD1364 consists of a central seven-stranded β-barrel with alternating parallel and 
antiparallel β-strands. The barrel is flanked by two α-helices on each side, which cap the top 
and the bottom part of the central β-barrel.  
Analysis of the CD1364 crystal structure regarding conservation of amino acids reveals that 
especially the residues of the central β-barrel are highly conserved among homologous 
proteins. The flanking α-helices are more variable in their amino acid composition (Fig. 74). 
The central β-barrel is conserved among bacteriophage-like tube proteins (chapter 8.4.4 for 
further analysis), while the helices surrounding the β-barrel of CD1364 are unique in the 
diffocin tube protein and cannot be found in homologous tube proteins. 
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Figure 73: Crystal structure of monomeric CD1364 in cartoon representation (A) and as topology diagram (B). 
The central β-barrel is colored in dark green, surrounding α-helices are shown in light green. In (B), α-helices 
are illustrated as cylinders and β-strands as arrows. The secondary structure elements are numbered 
consecutively. The dashed line indicates a region that could not be built due to unresolved electron density. 
Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
Figure 74: Conservation of CD1364. The crystal structure of monomeric CD1364 (top) and its amino acid 
sequence (bottom) is depicted colored according to conservation score with 1 (cyan) highlighting variable and 9 
(dark red) illustrating conserved residues. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
8.4.3. SAXS analysis of CD1364 
The oligomeric state of CD1364 in solution was analyzed by SAXS experiments. Best data 
were measured at BM29, ESRF (Grenoble, France; Pernot et al., 2013) for 1.25 mg/ml 
CD1364 in 20 mM HEPES pH 7.5, 150 mM NaCl. The fit of the experimental SAXS data and 
theoretical data for monomeric CD1364 is shown in Fig. 75. The fit with theoretical data for 
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monomeric CD1364 is characterized by a lower X-value (0.71) compared to the fit for dimeric 
CD1364 (X-value of 21.33; fit not shown). Due to the lower X-value and hence the better fit of 
experimental and theoretical data, it could be shown by SAXS experiments that CD1364 is 
monomeric in solution. The SAXS envelope was calculated for monomeric CD1364 and the 
crystal structure was fit into the envelope (Fig. 76). 
 
Figure 75: Fit of experimental SAXS data (black dots) with calculated curves for monomeric (A) and dimeric 
CD1364 (B) (green curves). Figure is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
 
Figure 76: Crystal structure of monomeric CD1364 (green cartoon representation) fitted into the calculated SAXS 
envelope for monomeric CD1364. Individual figures are turned by 90° around x- and y-axis respectively. Figure 
is adapted from Schwemmlein et al. (Front. Microbiol., 2018). 
 
The fit of the crystal structure into the SAXS envelope reveals that most of the protein in the 
crystal state is arranged in the same orientation as in solution. One exception is the region 
involving the small helix α1 of the crystal structure of CD1364, which could not be fit into the 
SAXS envelope. This, together with the lack of electron density in this region, indicates that 
this part of the protein is highly flexible and can adopt different orientations in the crystal, as 
well as in solution. The high flexibility of this region is further indicated by high B-factors in the 
crystal structure. 
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8.4.4. Comparison of CD1364 with homologous tube proteins 
Homologous proteins of the diffocin tube protein CD1364 are e.g. the pyocin tube protein FIIR2 
from Pseudomonas aeruginosa, the T4 bacteriophage tube protein gp19 or the Hcp tube 
protein of the T6SS system of Vibrio cholera. A comparison of the topology and three-
dimensional structure of these proteins is illustrated in Fig. 77. Secondary structure motifs that 
are homologous to CD1364 are colored in the same color as in the CD1364 structure, which 
is depicted in the top panel of the figure. 
All of these selected tube proteins have in common that they are arranged as a central β-
barrel, which is composed of antiparallel β-strands. The number of strands involved in barrel 
formation differs between the individual tube proteins, together with the secondary structure 
elements that surround the β-barrel. 
Based on the architecture of the monomer, CD1364 shows highest similarity to the monomer 
of XkdM of Bacillus subtilis/bacteriophage phi812K1-420 (PDB-ID 5LI2, Novacek et al., 2016), 
as both monomers can be aligned with an r.m.s.d. of 1.895 Å. The only difference in their 
secondary structure composition are two additional short α-helices (α1 and α3) in the CD1364 
structure that are not present in XkdM. Some parts of the XkdM structure are not resolved due 
to low resolution and high flexibility, which is indicated by a dashed line in the topology diagram 
in Fig. 77. The other homologous tube proteins share a similar topology as CD1364, but have 
several missing or additional secondary structure elements compared to CD1364. The 
alignment of these tube proteins with CD1364 was hence not as good as the alignment with 
the XkdM tube protein.  
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Figure 77: Structural comparison of the diffocin 
tube protein CD1364 from Clostridium difficile, 
tube protein XkdM (PDB-ID 5LI2, Novacek et al., 
2016) from bacteriophage phi812K-420, T6SS 
tube protein Hcp (PDB-ID 5MXN, Wang et al., 
2017) from Vibrio cholerae, pyocin tube protein 
FIIR2 (PDB-ID 5W5E, Zheng et al., 2017) from 
Pseudomonas aeruginosa and tube protein gp19 
(PDB-ID 5W5F, Zheng et al., 2017) from 
bacteriophage T4. The crystal structure of the tube 
proteins is shown in the left panel, the 
corresponding topology diagram in the right panel. 
Each structure was colored according to the color 
code of CD1364. Here, the central β-barrel is 
colored in dark green and surrounding α-helices in 
pale green. Secondary structure elements that 
could be aligned to CD1364 were colored 
accordingly to CD1364. Additional elements that 
are not present in the CD1364 structure were 
colored in light orange. In the topology diagrams, 
α-helices are depicted as cylinders and β-sheets 
as arrows. The secondary structure elements of 
CD1364 were numbered consecutively. The 
elements of the other tube proteins were 
numbered according to the respective aligned 
secondary structure element of CD1364. 
Additional elements that are not present in 
CD1364 were marked with a star. Regions that are 
not resolved in the crystal structure are indicated 
by a dashed line in the topology diagram. Figure is 
adapted from Schwemmlein et al. (Front. 
Microbiol., 2018). 
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8.4.5. Model of the diffocin tube particle 
All tube proteins shown in Fig. 77 have in common that they assemble in several hundred 
copies into a hollow tube particle. These tube particles are arranged as a six-start helix with 
six tube monomers arranged in a circular manner. Several of such discs are packed on top of 
each other to build the tube particle similar to the sheath particle. The diffocin tube protein 
CD1364 was aligned on top of the homologous tube particles to compare their structural 
arrangement and to derive an idea about the orientation of the CD1364 monomer in the 
assembled diffocin particle. 
Cryo-EM studies revealed the orientation and architecture of the bacteriophage phi812K1-420 
(PDB-ID 5LI2, Novacek et al., 2016) sheath-tube complex at low resolution (6.8 Å). The crystal 
structure of the CD1364 monomer was aligned on top of the tube monomers, but the aligned 
CD1364 monomers clash with each other due to the presence of the two additional α-helices 
of CD1364. In detail, the CD1364 helix α4 clashes with strand β1 of the neighboring CD1364 
monomer. CD1364 monomers were also aligned on top of the other assembled tube particles, 
but in each model, some secondary structure elements of CD1364 monomers clashed with 
each other (α3 and α4 for the fit with Hcp from Vibrio cholerae, α2 and α3 for the model based 
on FIIR2 from Pseudomonas aeruginosa). 
A model of the diffocin tube particle without serious clashes could be generated by alignment 
of the CD1364 monomers on top of the assembled tube proteins gp19 of bacteriophage T4 
(PDB-ID 5W5F, Zheng et al., 2017). The central β-barrel is arranged in a way that the axis of 
the barrel lies perpendicular to the assembled tube plane. The additional β-strands of the T4 
tube protein gp19, which are not present in the CD1364 structure, are located on top of the 
barrel and point to the inside of the tube. They could be involved in stabilization of the 
interaction between the neighboring monomers. The additional short α-helix of gp19, which 
cannot be found in the CD1364 structure, is located on the other side opposite of the two 
additional β-strands and could hence facilitate the interaction with the neighboring disc that is 
packed on top of the prior one. As these secondary structure elements are not present in 
CD1364, the interaction of CD1364 monomers and the stabilization of the assembled diffocin 
tube remains unclear. All tube particles of the other homologous bacteriophage-like proteins 
share the same orientation of the central β-barrel, which lies perpendicular to the tube axis 
with flanking secondary structure elements that stabilize the interaction between neighboring 
tube monomers. The diffocin tube model (Fig. 78) based on alignment on top of the 
bacteriophage T4 tube shows that the CD1364 helices α1 and α2 (colored in orange and yellow 
in the diffocin model) point away from the rest of the protein and could hence be involved in 
interaction of the neighboring discs. Thus, these helices could stabilize the assembly of the 
tube particle. One disc of the diffocin tube model is shown in the left and middle panel of Fig. 78 
from the top and side view, respectively. Helices that could be involved in interaction of the 
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individual discs are highlighted in yellow and orange. The model of a diffocin tube composed 
of three discs is shown in the right panel of Fig. 78. 
 
Figure 78: Diffocin tube model (one disc) based on homology to the assembled tube particle of bacteriophage 
T4 (PDB-ID 5W5F, Zheng et al., 2017). Diffocin CD1364 monomers are shown in green with helices that are 
possibly involved in interaction with neighboring discs in yellow and orange, respectively. The diffocin tube disc 
is shown from the top (left panel) and from the side view (middle panel). A model of an assembled diffocin tube 
composed of three discs is shown in the right panel. Figure is adapted from Schwemmlein et al. (Front. Microbiol., 
2018). 
 
Similar to the sheath protein CD1363, the CD1364 monomer shows a complementary 
distribution of positively and negatively charged surface patches. A positively charged patch 
on one side of the monomer lies opposite to a negatively charged patch on the other side of 
the protein (Fig. 79A). This enables the interaction of CD1364 monomers due to electrostatic 
attraction. In the diffocin tube model, these oppositely charged regions interact with each other, 
creating a stable interaction of the tube monomers and could also be involved in self-assembly 
of the monomers into the diffocin particle. The outside of the tube model shows an even 
distribution of positive and negative charge. These charged patches could interact with 
oppositely charged patches of the sheath particle to facilitate a stable interaction between the 
sheath and tube particle. The inside of the diffocin tube model also shows an even distribution 
of positively and negatively charged patches. It is assumed that the diffocin particle is a channel 
used for ion transport similar to the pyocin particle (Ge et al., 2015). Due to the even charge 
distribution, ions could easily be transported across this channel.  
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Figure 79: Electrostatic surface charge distribution of CD1364. The surface charge of the CD1364 monomer is 
shown in two different orientations (A) projected by 180° rotation around the illustrated axis. The electrostatic 
surface charge of the modelled diffocin tube particle is illustrated in (B) from the outside (left) and from the inside 
(right). Red color indicates negative charge, blue color illustrates positive charge. Figure is adapted from 
Schwemmlein et al. (Front. Microbiol., 2018). 
  
 
8.4.6. Model of the assembled diffocin particle 
The homologous pyocin particle was analyzed by Cryo-EM studies in its elongated as well as 
in the contracted state. In the elongated state, the electron density for sheath and tube was 
resolved to 3.5 Å and the structure of the individual sheath and tube monomers could be 
modelled into the density map. In contrast, the density for the pyocin tube was not resolved in 
the contracted state of the pyocin particle. Only the structure of the sheath monomers could 
be modelled into the density map of the contracted particle to 3.9 Å resolution (Ge et al., 2015). 
A model of the fully assembled diffocin particle composed of sheath and tube was therefore 
generated based on the pyocin particle in its elongated form. This model is shown in Fig. 80. 
Some minor clashes are present between the diffocin sheath and tube particle, i.e. the clash 
of the loop between β1 and β2 of CD1364 (tube) with helix α10 of CD1363 (sheath). 
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Figure 80: Model of the diffocin particle in the elongated state based on the architecture of the pyocin particle 
(PDB-ID 3J9Q, Ge et al., 2015). The diffocin particle is composed of an outer sheath (orange) and an inner tube 
(green). It is shown from the side (left) and from the top (middle panel). The right figure illustrates the clashes 
between sheath and tube monomer in the diffocin particle model. Figure is adapted from Schwemmlein et al. 
(Front. Microbiol., 2018). 
 
In summary, the models of the assembled diffocin particle shown above are only theoretical 
models based on homology of the crystal structures of the monomeric diffocin sheath and tube 
protein to homologous bacteriophage tail-like proteins. Due to some clashes in the prepared 
models of the diffocin particle, it is probable that the diffocin monomers have to undergo slight 
conformational changes upon particle assembly. The exact structure and architecture of the 
assembled diffocin particle needs additional experiments, such as cryo-EM studies similar to 
the pyocin particle to reveal the orientation and assembly of the diffocin particle in nature. 
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9. Conclusions and Outlook 
This thesis was subdivided into three different projects: the toxins of Clostridium difficile, 
essential proteins involved in growth or sporulation of the pathogen and the diffocin proteins. 
Aim of all projects was the structural analysis of the respective virulence factors and essential 
proteins to gain a deeper understanding of their structure and function. The detailed structural 
characterization of the so far uncharacterized proteins should reveal ideas about their potential 
molecular function and facilitate the comparison with structurally homologous proteins. 
The main virulence factor TcdB from Clostridium difficile was already characterized to some 
extent by other groups regarding structure and molecular function of its individual domains. 
The only domain that was not characterized so far was the intermediate domain, which is 
involved in translocation and pore formation. SAXS analysis of this domain was performed in 
this thesis and revealed that the TcdB translocation domain shares the same overall shape 
and oligomeric state as the TcdA translocation domain. Nevertheless, determination of a 
crystal structure of the TcdB translocation domain is necessary to analyze its molecular 
structure and to draw a detailed comparison to the TcdA translocation domain at atomic level. 
The exact mechanism of pore formation and translocation of both homologous toxins across 
the endosomal membrane are also not completely understood. Hence, further analysis of toxin 
translocation has to be performed to understand this part of the toxin mechanism, especially 
in terms of designing potential drugs targeting this process of toxin translocation. 
The second project involved the characterization of two essential proteins involved in growth 
or sporulation of Clostridium difficile. Although the structural analysis of CD1219 and CD1823 
by X-ray crystallography and SAXS revealed some ideas about their molecular function, these 
hypotheses have to be validated by further experiments. A comparison with structurally 
homologous proteins revealed that CD1219 (determined by X-ray crystallography to 1.8 Å 
resolution) shows strong similarity to GTPases and that CD1823 (determined by X-ray 
crystallography to 1.9 Å resolution) could possibly be involved in H2O2 stress response. Future 
investigations will include a detailed biochemical analysis of CD1219 regarding ligand binding 
and potential GTPase activity. Several potential ligands have to be tested towards their binding 
specificity for CD1219. A broad TDSA of CD1219 could be performed to test the stabilizing or 
destabilizing effect of several potential ligands on the protein. Ligands that show a stabilizing 
effect can then be subjected to binding studies by MST or ITC measurements. Furthermore, 
soaking or co-crystallization experiments can be performed with potential ligands to determine 
ligand-bound structures of CD1219. Such ligand structures aid to understand the binding 
mechanism of CD1219. Additional biochemical analysis should be performed to reveal the 
molecular function of CD1823 and its potential role in H2O2 stress response. Transcriptomic or 
metabolomics analysis can thereby help to identify the molecular function of CD1823. 
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A third project dealt with the characterization of diffocin proteins, bacteriophage tail-like 
bacteriocins of Clostridium difficile. The determination of the first crystal structure of the diffocin 
sheath protein CD1363 (1.9 Å resolution) and of the tube protein CD1364 (1.5 Å resolution) in 
this thesis revealed important details about the molecular components of the diffocin tail. 
Comparison with homologous phage-tail like particles led to a generation of a theoretical model 
of the diffocin particle. Nevertheless, an analysis of the assembled native diffocin particle is 
essential to understand its molecular organization and architecture. Cryo-EM analysis of the 
diffocin particle would be an important technique to yield a structure of the assembled particle. 
To summarize, it could be shown in this thesis that structural analysis of proteins using X-ray 
crystallography can reveal ideas about the potential function of these proteins, but structural 
analysis alone is not sufficient to characterize the molecular function of a protein. Further 
additional biochemical and biophysical experiments always have to be performed to prove the 
exact function of the respective proteins. Nevertheless, the novel protein structures that have 
been determined in this thesis revealed important structural details of the analyzed proteins 
and serve as a basis for the design of future experiments for a functional analysis of these 
proteins. 
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Table 31: Overview of oligonucleotides used for SLIC cloning of uncharacterized proteins in this study. 
Oligonucleotide Sequence 5’ → 3’ 
p10$-10670fw-Nde GTTTCAGGGCCCGCATATGCAGGACTACAAAAAAACA 
p10$-10670rv-Xho TTAGCAGCCGGATCCCTCGAGTTAACGATGACAGC 
pMal-10670-fwNde CTTTATTTTCAGGGCCATATGCAGGACTACAAAAAAAAC 
pMal-10670-rvXho CAAGCTTGAATTCCTCGAGTTAACGATGACAGCT 
pET19-10670fwNde GAATCTTTATTTTCAGGGCCATATGCAGGACTACAAAAAAAAC 
pET19-10670rvXho 
pETSumo-1067rvXho 
GCAGCCGGATCCCTCGAGTTAACGATGACAGCT 
Sumo-10670-fwNde CGAACAGATCGGTGGTCATATGCAGGACTACAAAAAAAAC 
p10$-12190-fwNde GTTTCAGGGCCCGCATATGATTAGCAAACGTGTGGGTAT 
p10$-12190-rvXho 
pET19-12190rvXho 
pETSumo-12190rvXho 
AGCCGGATCCCTCGAGTTAAACTTCCATCAGATA 
pET19-12190fwNde TCTTTATTTTCAGGGCCATATGATTAGCAAACGTGTGGG 
pMal-12190-fwNde CTTTATTTTCAGGGCCATATGATTAGCAAACGTGTGG 
pMal-12190-rvXho CAAGCTTGAATTCCTCGAGTTAAACTTCCATCAGATAAT 
Sumo-12190-fwNde CGAACAGATCGGTGGTCATATGATTAGCAAACGTGT 
p10$-18230-fwNde GTTTCAGGGCCCGCATATGATCATTATGCTGAGCCC 
p10$-18230-rvXho 
pET19-18230rvXho 
pETSumo-18230rvXho 
TTAGCAGCCGGATCCCTCGAGTTACTCTTTCACAAAGATG 
pET19-18230fwNde GAATCTTTATTTTCAGGGCCATATGATCATTATGCTGAGCCC 
pMal-18230-fwNde CTTTATTTTCAGGGCCATATGATCATTATGCTGAGCC 
pMal-18230-rvXho CAAGCTTGAATTCCTCGAGTTACTCTTTCACAAAGATG 
Sumo-18230-fwNde GAACAGATCGGTGGTCATATGATCATTATGCTGAGCCC 
p10$-25890-fwNde GTTTCAGGGCCCGCATATGGCAATTAGCATGACCG 
p10$-25890-rvXho 
pET19-25890rvXho 
pETSumo-25890rvXho 
TTAGCAGCCGGATCCCTCGAGTTATTCGATGTTCTGGATC 
pET19-25890fwNde GAATCTTTATTTTCAGGGCCATATGGCAATTAGCATGACCG 
pMal-25890-fwNde CTTTATTTTCAGGGCCATATGGCAATTAGCATGACC 
pMal-25890-rvXho CAAGCTTGAATTCCTCGAGTTATTCGATGTTCTGGATC 
Sumo-25890-fwNde CGAACAGATCGGTGGTCATATGGCAATTAGCATGACAGG 
p10$-27520-fwNde TTCAGGGCCCGCATATGAAAGGCAACATCGTGCAG 
p10$-27520-rvXho 
Sumo-27520-rvXho 
TTAGCAGCCGGATCCCTCGAGTTAGTTCAGGTTACCGG 
pET19-27520fwNde GAATCTTTATTTTCAGGGCCATATGAAGGGCAACATCGTGCAG 
pET19-27520rvXho CAGCCGGATCCCTCGAGTTAGTTCAGGTTACC 
pMal-27520-fwNde CTTTATTTTCAGGGCCATATGAAGGGAAACATCGTGCAG 
pMal-27520-rvXho CAAGCTTGAATTCCTCGAGTTAGTTCAGGTTACCGGCT 
Sumo-27520-fwNde CGAACAGATCGGTGGTCATATGAAAGGCAACATCGTG 
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Table 32: Overview of oligonucleotides used for traditional cloning of uncharacterized proteins in this study. 
Oligonucleotide Sequence 5’ → 3’ 
1067-Nde-fwd CGCGCCCATATGCAAGATTATAAAAAAAAT 
1067-Xho-rev CTCGAGCTATCTGTGGCAACTTG 
1823-Nde-fwd CGCGCCCATATGATTATAATGTTATCACCAGC 
1823-Xho-rev CGCGCCCTCGAGCTACTCTTTTACAAATATG 
2589-Nde-fwd CCATATGGCAATTAGCATGACCGG 
2589-Xho-rev GCCCTCGAGTTATTCTATGTTCTGGATC 
2752-Nde-fwd GCCCATATGAAAGGCAACATCGTGC 
2752-Xho-rev CGCCTCGAGTTAGTTCAGGTTACC 
 
Table 33: Overview of oligonucleotides used for mutation in this study. 
Oligonucleotide Sequence 5’ → 3’ 
2589QC-fw1 CGGACATTGTGAAAATCGAAGCGGCAGAAGAGGACGAAGATCTGC 
2589QC-rev1 GCAGATCTTCGTCCTCTTCTGCCGCTTCGATTTTCACAATGTCCG 
2589QC-fw2 GAAAATCGAAGCGGCAGCGGAGGACGAAGATCTGCTGTG 
2589QC-rev2 CACAGCAGATCTTCGTCCTCCGCTGCCGCTTCGATTTTC 
QCp10$-1067-1-fw GGCCCGCATATGCAGGACTACAAAAAAAACAAACGTCGC 
QCp10$-1067-1-rv GCGACGTTTGTTTTTTTTGTAGTCCTGCATATGCGGGCC 
 
Table 34: Overview of oligonucleotides used for SLIC cloning of diffocin proteins during DPF campaign in this 
study 
Oligonucleotide Sequence 5’ → 3’ 
pOPIN-His-MBP-CD1363_fwd GAAGTTCTGTTTCAGGGTCCCATGGCTATAGGATTACCAAGTATCAACA
TATCATTTAAG 
pOPIN-His-MBP-CD1363_rev TAAACTGGTCTAGAAAGCTTATATTTCTATTGATAAATCTATATCTTCCAT
AGCATCAAGTACTTTTATTTTTG 
pOPIN-His-MBP-CD1364_fwd GAAGTTCTGTTTCAGGGTCCCATGGCAAATATGGAAGCTAGAAATGTAA
TGAGT 
pOPIN-His-MBP-CD1364_rev TAAACTGGTCTAGAAAGCTTAAATTATATCAAGAAAATCATACTCAGTAA
ATGTGAAAGGTGC 
pOPIN-His-MBP-CD1365_fwd GAAGTTCTGTTTCAGGGTCCCATGAGTGAAAATGGATTATTAAAAAATAT
AAACATAGTAGATTTACTTTT 
pOPIN-His-MBP-CD1365_rev TAAACTGGTCTAGAAAGCTTAGTTTTTTACCTCTTCTATCACTGCATTTTT
ACCATAAC 
pOPIN-His-MBP-CD1366_fwd GAAGTTCTGTTTCAGGGTCCCATGGGAAATGTGAGAGAAGAAGGTATAA
ATATGTAC 
pOPIN-His-MBP-CD1366_rev TAAACTGGTCTAGAAAGCTTATAAGACACCCCCTAACTGTGCC 
pOPIN-His-MBP-CD1367_fwd GAAGTTCTGTTTCAGGGTCCCATGGAAATGTGGCTTAGACAAGCTGAA 
pOPIN-His-MBP-CD1367_rev TAAACTGGTCTAGAAAGCTTATTGTTTTGGAGTTACTTTTGGTATCTTTAT
TCTTTTATACTC 
pOPIN-His-MBP-CD1368_fwd GAAGTTCTGTTTCAGGGTCCCATGATAATTAATAGGTCTAAAGATTCAAG
CAGTAATGAAATTAGTT 
pOPIN-His-MBP-CD1368_rev TAAACTGGTCTAGAAAGCTTATAATACTCTCCTAGCTGTGTTAAAATCTC
TTCTACT 
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pOPIN-His-MBP-CD1369_fwd GAAGTTCTGTTTCAGGGTCCCATGGCTAATCCAATAAATGAATTTATAGG
AATAATAAGAGAAGAAG 
pOPIN-His-MBP-CD1369_rev TAAACTGGTCTAGAAAGCTTATAAGCTCACCAACTTACTTACAACAGCA 
pOPIN-His-MBP-CD1370_fwd GAAGTTCTGTTTCAGGGTCCCATGAGTACAATATTTCCTTTTATAGGTGT
CCCAGA 
pOPIN-His-MBP-CD1370_rev TAAACTGGTCTAGAAAGCTTATACATTTATTTCCACCTCCCCATAGATAG
TGG 
pOPIN-His-MBP-CD1371_fwd GAAGTTCTGTTTCAGGGTCCCATGTATAGTGACCAGACATATGAAGTAA
TAAAAAATAGAACTCT 
pOPIN-His-MBP-CD1371_rev TAAACTGGTCTAGAAAGCTTATTGATTTTCCACCTCACTAAAATTAACAG
TTGTTAC 
pOPIN-His-MBP-CD1372_fwd GAAGTTCTGTTTCAGGGTCCCATGAAGCTAATTGATAAACTACCATCATT
TGATAGAAATTACA 
pOPIN-His-MBP-CD1372_rev TAAACTGGTCTAGAAAGCTTATACCACCTCCGATTTAGGATAAACTACTA
C 
pOPIN-His-MBP-CD1373_fwd GAAGTTCTGTTTCAGGGTCCCTTGGAAGAAAAATTTTATATAATATTAAC
CAAAATTGGTAGAGAA 
pOPIN-His-MBP-CD1373_rev TAAACTGGTCTAGAAAGCTTATCTTATTTCATACGAATACTTATTTAGAGT
TATATCTTTTTGTTC 
pOPIN-His-MBP-CD1374_85-
536_fwd 
GAAGTTCTGTTTCAGGGTCCCTATGTATCTTGTGGTTCAAAACACAGTGT
AGC 
pOPIN-His-MBP-CD1374_85-
536_rev 
TAAACTGGTCTAGAAAGCTTAACCCCACCCATATAATTCCTTTGAATGAT
TTAATG 
pOPIN-His-MBP-
CD1374_911-1420_fwd 
GAAGTTCTGTTTCAGGGTCCCAGTATAGATGGTAACACAACATTTGCAA
TTAGAAATGA 
pOPIN-His-MBP-
CD1374_911-1420_rev 
TAAACTGGTCTAGAAAGCTTATGTAGTTACTACTAATGTATAGTTTTTACC
ACAATGTAC 
pOPIN-His-MBP-
CD1374fl_fwd 
GAAGTTCTGTTTCAGGGTCCCATGAAGCAAAATAAACTTTTACAGCGTG
GTG 
pOPIN-His-MBP-CD1374fl_rev TAAACTGGTCTAGAAAGCTTAAGCTTGTGGCTCGTTGTTTTCAGC 
 
 
Table 35: Overview of oligonucleotides used for SLIC cloning of TcdB constructs during DPF campagne in this 
study. 
Oligonucleotide Sequence 5’ → 3’ 
pOPIN-His-MBP-
NIS1000-1300_fwd 
GAAGTTCTGTTTCAGGGTCCCACTATTACAGATGCAGCCAAAGTTGTTGA 
pOPIN-His-MBP-
NIS1000-1300_rev 
TAAACTGGTCTAGAAAGCTTATATAAAACTTCTAGTATTACTATCTAAATTTATTC
TTATATTAGTATCTTCATATCTTGGT 
pOPIN-His-MBP-
NIS1300-1600_fwd 
GAAGTTCTGTTTCAGGGTCCCGTTCCAATAATAACTACAGAATATATAAGAGAA
AAATTATCATATTCTTTCTATGG 
pOPIN-His-MBP-
NIS1300-1600_rev 
TAAACTGGTCTAGAAAGCTTATTGTAAGAAATTAACGAAAATACTTTTTATATTCA
TACTTTCTAAAAAGC 
pOPIN-His-MBP-
NIS1400-1700_fwd 
GAAGTTCTGTTTCAGGGTCCCGGATTTGTTTCTTTAACATTTTCAATTTTAGAAG
GAATAAATGC 
pOPIN-His-MBP-
NIS1400-1700_rev 
TAAACTGGTCTAGAAAGCTTATGTATAAATATTTGGTGAAATTACAACTTTATTAA
CACAACTGT 
pOPIN-His-SUMO-
NIS1000-1300_fwd 
GCGAACAGATCGGTGGTACTATTACAGATGCAGCCAAAGTTGTTGA 
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pOPIN-His-SUMO-
NIS1000-1300_rev 
TAAACTGGTCTAGAAAGCTTATATAAAACTTCTAGTATTACTATCTAAATTTATTC
TTATATTAGTATCTTCATATCTTGGT 
pOPIN-His-SUMO-
NIS1300-1600_fwd 
GCGAACAGATCGGTGGTGTTCCAATAATAACTACAGAATATATAAGAGAAAAAT
TATCATATTCTTTCTATGG 
pOPIN-His-SUMO-
NIS1300-1600_rev 
TAAACTGGTCTAGAAAGCTTATTGTAAGAAATTAACGAAAATACTTTTTATATTCA
TACTTTCTAAAAAGC 
pOPIN-His-SUMO-
NIS1400-1700_fwd 
GCGAACAGATCGGTGGTGGATTTGTTTCTTTAACATTTTCAATTTTAGAAGGAAT
AAATGC 
pOPIN-His-SUMO-
NIS1400-1700_rev 
TAAACTGGTCTAGAAAGCTTATGTATAAATATTTGGTGAAATTACAACTTTATTAA
CACAACTGT 
pOPIN-NHis-3C-
NIS1000-1300_fwd 
GAAGTTCTGTTTCAGGGTCCCACTATTACAGATGCAGCCAAAGTTGTTGA 
pOPIN-NHis-3C-
NIS1000-1300_rev 
CAAACTGGTCTAGAAAGCTTATATAAAACTTCTAGTATTACTATCTAAATTTATTC
TTATATTAGTATCTTCATATCTTGGT 
pOPIN-NHis-3C-
NIS1300-1600_fwd 
GAAGTTCTGTTTCAGGGTCCCGTTCCAATAATAACTACAGAATATATAAGAGAA
AAATTATCATATTCTTTCTATGG 
pOPIN-NHis-3C-
NIS1300-1600_rev 
CAAACTGGTCTAGAAAGCTTATTGTAAGAAATTAACGAAAATACTTTTTATATTC
ATACTTTCTAAAAAGC 
pOPIN-NHis-3C-
NIS1400-1700_fwd 
GAAGTTCTGTTTCAGGGTCCCGGATTTGTTTCTTTAACATTTTCAATTTTAGAAG
GAATAAATGC 
pOPIN-NHis-3C-
NIS1400-1700_rev 
CAAACTGGTCTAGAAAGCTTATGTATAAATATTTGGTGAAATTACAACTTTATTA
ACACAACTGT 
pOPIN-NHis-3C-
NIS543-2366_fwd 
GAAGTTCTGTTTCAGGGTCCCCTTGGTGAAGATGATAATCTTGATTTTTCTCAAA
ATATAGTAGT 
pOPIN-NHis-3C-
NIS543-2366_rev 
CAAACTGGTCTAGAAAGCTTATTCACTAATCACTAATTGAGCTGTATCAGGATC
AAAAT 
pOPIN-CHis-NIS1400-
1834_fwd 
CAATCAAAGGAGATATACCATGGGATTTGTTTCTTTAACATTTTCAATTTTAGAA
GGAATAAA 
pOPIN-CHis-NIS1400-
1834_rev 
GATGGTGATGGTGGTGCTCGAGTCCAGATACCATCATTCCAAAGTTATTAATAT
AAAATTTCTCA 
pOPIN-CHis-NIS800-
1400_fwd 
CAATCAAAGGAGATATACCATGTTATTACAAGAAATTAGAAATAATTCTAATTCA
AGTGATATTGAACTAGAAGAA 
pOPIN-CHis-NIS800-
1400_rev 
GATGGTGATGGTGGTGCTCGAGATTACTTCCATTTACCTCACCAGAAAAATTAA
TCTC 
pOPIN-CHis-NIS800-
1834_fwd 
CAATCAAAGGAGATATACCATGTTATTACAAGAAATTAGAAATAATTCTAATTCA
AGTGATATTGAACTAGAAGAA 
pOPIN-CHis-NIS800-
1834_rev 
GATGGTGATGGTGGTGCTCGAGTCCAGATACCATCATTCCAAAGTTATTAATAT
AAAATTTCTCA 
pOPIN-His-MBP-
NIS1100-1400_fwd 
GAAGTTCTGTTTCAGGGTCCCTCAGCAGGTATACCAAGCTTAGTAAACAATG 
pOPIN-His-MBP-
NIS1100-1400_rev 
TAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-His-MBP-
NIS1200-1500_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATCTATATATGACGTATTGGAAGTACAAAAA
GAAGAACTTG 
pOPIN-His-MBP-
NIS1200-1500_rev 
TAAACTGGTCTAGAAAGCTTACATATAAACCTTACTTATAAGAACTACATCAGGT
AATTCA 
pOPIN-His-MBP-
NIS1400-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCGGATTTGTTTCTTTAACATTTTCAATTTTAGAAG
GAATAAA 
pOPIN-His-MBP-
NIS1400-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-MBP-
NIS1500-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCGATGATAGTAAGCCTTCATTTGGATATTATAGT
AATAATTTGAAAGAT 
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pOPIN-His-MBP-
NIS1500-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-MBP-
NIS800-1100_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-His-MBP-
NIS800-1100_rev 
TAAACTGGTCTAGAAAGCTTAAATTCCTGCTAAAGGAACTAAAAGTATACTAAAT
CCA 
pOPIN-His-MBP-
NIS800-1400_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-His-MBP-
NIS800-1400_rev 
TAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-His-MBP-
NIS800-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-His-MBP-
NIS800-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-MBP-
NIS900-1200_fwd 
GAAGTTCTGTTTCAGGGTCCCTTTATTAATAAAGAAACTGGAGAATCTATATTTG
TAGAAACTGAAAAAAC 
pOPIN-His-MBP-
NIS900-1200_rev 
TAAACTGGTCTAGAAAGCTTAGTGTGGCTCTCTATATGTTATTGATGGTGCT 
pOPIN-His-SUMO-
NIS1100-1400_fwd 
GCGAACAGATCGGTGGTTCAGCAGGTATACCAAGCTTAGTAAACAATG 
pOPIN-His-SUMO-
NIS1100-1400_rev 
TAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-His-SUMO-
NIS1200-1500_fwd 
GCGAACAGATCGGTGGTTTATCTATATATGACGTATTGGAAGTACAAAAAGAAG
AACTTG 
pOPIN-His-SUMO-
NIS1200-1500_rev 
TAAACTGGTCTAGAAAGCTTACATATAAACCTTACTTATAAGAACTACATCAGGT
AATTCA 
pOPIN-His-SUMO-
NIS1400-1834_fwd 
GCGAACAGATCGGTGGTGGATTTGTTTCTTTAACATTTTCAATTTTAGAAGGAAT
AAA 
pOPIN-His-SUMO-
NIS1400-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-SUMO-
NIS1500-1834_fwd 
GCGAACAGATCGGTGGTGATGATAGTAAGCCTTCATTTGGATATTATAGTAATA
ATTTGAAAGAT 
pOPIN-His-SUMO-
NIS1500-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-SUMO-
NIS800-1100_fwd 
GCGAACAGATCGGTGGTTTATTACAAGAAATTAGAAATAATTCTAATTCAAGTGA
TATTGAACTAGAAGAA 
pOPIN-His-SUMO-
NIS800-1100_rev 
TAAACTGGTCTAGAAAGCTTAAATTCCTGCTAAAGGAACTAAAAGTATACTAAAT
CCA 
pOPIN-His-SUMO-
NIS800-1400_fwd 
GCGAACAGATCGGTGGTTTATTACAAGAAATTAGAAATAATTCTAATTCAAGTGA
TATTGAACTAGAAGAA 
pOPIN-His-SUMO-
NIS800-1400_rev 
TAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-His-SUMO-
NIS800-1834_fwd 
GCGAACAGATCGGTGGTTTATTACAAGAAATTAGAAATAATTCTAATTCAAGTGA
TATTGAACTAGAAGAA 
pOPIN-His-SUMO-
NIS800-1834_rev 
TAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-His-SUMO-
NIS900-1200_fwd 
GCGAACAGATCGGTGGTTTTATTAATAAAGAAACTGGAGAATCTATATTTGTAG
AAACTGAAAAAAC 
pOPIN-His-SUMO-
NIS900-1200_rev 
TAAACTGGTCTAGAAAGCTTAGTGTGGCTCTCTATATGTTATTGATGGTGCT 
pOPIN-NHis-3C-
NIS1100-1400_fwd 
GAAGTTCTGTTTCAGGGTCCCTCAGCAGGTATACCAAGCTTAGTAAACAATG 
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pOPIN-NHis-3C-
NIS1100-1400_rev 
CAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-NHis-3C-
NIS1200-1500_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATCTATATATGACGTATTGGAAGTACAAAAA
GAAGAACTTG 
pOPIN-NHis-3C-
NIS1200-1500_rev 
CAAACTGGTCTAGAAAGCTTACATATAAACCTTACTTATAAGAACTACATCAGGT
AATTCA 
pOPIN-NHis-3C-
NIS1400-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCGGATTTGTTTCTTTAACATTTTCAATTTTAGAAG
GAATAAA 
pOPIN-NHis-3C-
NIS1400-1834_rev 
CAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-NHis-3C-
NIS1500-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCGATGATAGTAAGCCTTCATTTGGATATTATAGT
AATAATTTGAAAGAT 
pOPIN-NHis-3C-
NIS1500-1834_rev 
CAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-NHis-3C-
NIS800-1100_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-NHis-3C-
NIS800-1100_rev 
CAAACTGGTCTAGAAAGCTTAAATTCCTGCTAAAGGAACTAAAAGTATACTAAAT
CCA 
pOPIN-NHis-3C-
NIS800-1400_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-NHis-3C-
NIS800-1400_rev 
CAAACTGGTCTAGAAAGCTTAATTACTTCCATTTACCTCACCAGAAAAATTAATC
TC 
pOPIN-NHis-3C-
NIS800-1834_fwd 
GAAGTTCTGTTTCAGGGTCCCTTATTACAAGAAATTAGAAATAATTCTAATTCAA
GTGATATTGAACTAGAAGAA 
pOPIN-NHis-3C-
NIS800-1834_rev 
CAAACTGGTCTAGAAAGCTTATCCAGATACCATCATTCCAAAGTTATTAATATAA
AATTTCTCA 
pOPIN-NHis-3C-
NIS900-1200_fwd 
GAAGTTCTGTTTCAGGGTCCCTTTATTAATAAAGAAACTGGAGAATCTATATTTG
TAGAAACTGAAAAAAC 
pOPIN-NHis-3C-
NIS900-1200_rev 
CAAACTGGTCTAGAAAGCTTAGTGTGGCTCTCTATATGTTATTGATGGTGCT 
 
 
Table 36: Overview of oligonucleotides used for traditional cloning of TcdB constructs in this study. 
Oligonucleotide Sequence 5’ → 3’ 
540-2366NdeI_fw GCCCGCCATATGCTTCTACTA 
540-2366BamHI_rv GTCCCGGGATCCCACTAATCA 
800-1834NdeI_fw GCCCGCCATATGAATAATGTT 
800-1834BamHI_rv GTCCTGGGATCCATCCAGATA 
fl_TcdB_Xho_rv GTCCCGCTCGAGATCCAGATA 
800-1400_Nde_fw CGCGCCCCGCATATGTTATTACAAGAA 
800-1400_Xho_rv CTGGTCCGCCTCGAGATTACTTCCATT 
1401-1834_Nde_fw GCCCCGCATATGGGATTTGTT 
1401-1834_Xho_rv GTCCTCCTCGAGATCCAGATA 
Nde_fw1349-1811 GCCGCGCATATGGATAATGTTGTGAGAGAT 
Xho_rv1349-1811 GCACCATAACTCGAGTTAATAGCCAATCAATCC 
TcdB_C698>Ala GAAATAAATTTATTAGGAGCGAATATGTTTAGCTACTCTATCAACGTA 
TcdB_C698>Ser GAAATAAATTTATTAGGAAGTAATATGTTTAGCTACTCTATCAACGTA 
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Table 37: Overview of oligonucleotides for SLIC cloning of synthetic TcdB constructs, prepared by Konrad 
Büssow (HZI, Brunswick, Germany). 
Oligonucleotide Sequence 5’ → 3’ 
TcdB-TDCP-fwd GAAGTTCTGTTTCAGGGTACCGAAGATGATAATCTGGATTTTAGCCAGAATATTG 
TcdB-TDCP-RevM TTAAACTGGTCTAGAAAGCTTCAACCGCTCACCATCATGCC 
TcdB-TDCP-RevF ACAAACTGGTCTAGAAAGCTTCAACCGCTCACCATCATGCC 
TcdB-TD-Fwd GAAGTTCTGTTTCAGGGTACCCTGCTGCAAGAAATTCGTAATAATAGC 
TcdB-fl-Fwd GAAGTTCTGTTTCAGGGTACCAGCCTGGTTAATCGTAAACAGC 
TcdB-fl-RevM TTAAACTGGTCTAGAAAGCTTCATTCACTAATCACCAGCTGTGCG 
TcdB-fl-RevF ACAAACTGGTCTAGAAAGCTTCATTCACTAATCACCAGCTGTGCG 
 
 
Table 38: Overview of plasmids used and created in this study. 
Plasmid Source Application 
pHIS1522-TcdB-543-2366 Ralf Gerhard, MHH, Hannover Protein production 
pHIS1522-TcdB-543-2366(C698A) Ralf Gerhard, MHH, Hannover Protein production 
pOPIN-M-TcdB-800-1100 this study (DPF) Protein production 
pOPIN-M-TcdB-800-1400 this study (DPF) Protein production 
pOPIN-M-TcdB-800-1834 this study (DPF) Protein production 
pOPIN-M-TcdB-900-1200 this study (DPF) Protein production 
pOPIN-M-TcdB-1000-1300 this study (DPF) Protein production 
pOPIN-M-TcdB-1100-1400 this study (DPF) Protein production 
pOPIN-M-TcdB-1200-1500 this study (DPF) Protein production 
pOPIN-M-TcdB-1300-1600 this study (DPF) Protein production 
pOPIN-M-TcdB-1400-1700 this study (DPF) Protein production 
pOPIN-M-TcdB-1400-1834 this study (DPF) Protein production 
pOPIN-M-TcdB-1500-1834 this study (DPF) Protein production 
pOPIN-S3C-TcdB-800-1100 this study (DPF) Protein production 
pOPIN-S3C-TcdB-800-1400 this study (DPF) Protein production 
pOPIN-S3C-TcdB-800-1834 this study (DPF) Protein production 
pOPIN-S3C-TcdB-900-1200 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1000-1300 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1100-1400 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1200-1500 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1300-1600 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1400-1700 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1400-1834 this study (DPF) Protein production 
pOPIN-S3C-TcdB-1500-1834 this study (DPF) Protein production 
pOPIN-F-TcdB-800-1100 this study (DPF) Protein production 
pOPIN-F-TcdB-800-1400 this study (DPF) Protein production 
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pOPIN-F-TcdB-800-1834 this study (DPF) Protein production 
pOPIN-F-TcdB-900-1200 this study (DPF) Protein production 
pOPIN-F-TcdB-1000-1300 this study (DPF) Protein production 
pOPIN-F-TcdB-1100-1400 this study (DPF) Protein production 
pOPIN-F-TcdB-1200-1500 this study (DPF) Protein production 
pOPIN-F-TcdB-1300-1600 this study (DPF) Protein production 
pOPIN-F-TcdB-1400-1700 this study (DPF) Protein production 
pOPIN-F-TcdB-1400-1834 this study (DPF) Protein production 
pOPIN-F-TcdB-1500-1834 this study (DPF) Protein production 
pOPIN-F-TcdB-543-2366 this study (DPF) Protein production 
pOPIN-G-TcdB-1400-1834 this study (DPF) Protein production 
pOPIN-G-TcdB-800-1400 this study (DPF) Protein production 
pOPIN-G-TcdB-800-1834 this study (DPF) Protein production 
p10$-TcdB-1349-1811 this study Protein production 
pOPIN-M-TcdB1490-1848 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-M-TcdB1-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU23-TcdB1490-1848 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU23-TcdB1-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-J-TcdB1490-1848 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-J-TcdB1-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-M-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-M-TcdB-543-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPIN-M-TcdB-800-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU10-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU10-TcdB-800-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU11-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU11-TcdB-543-1834 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU11-TcdB-800-1834 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU23-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU23-TcdB-543-1834 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pPEU23-TcdB-800-1834 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINJ-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINJ-TcdB-543-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINJ-TcdB-800-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINF-TcdB-1-2366 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINF-TcdB-543-1834 this study, Konrad Büssow (HZI) Protein production 
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(synthetic TcdB) 
pOPINF-TcdB-800-1834 
(synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINS3C-TcdB-1-2366 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINS3C-TcdB-800-1834 (synthetic TcdB) this study, Konrad Büssow (HZI) Protein production 
pOPINM-CD1363 this study (DPF) Protein production 
pOPINM-CD1364 this study (DPF) Protein production 
pOPINM-CD1365 this study (DPF) Protein production 
pOPINM-CD1366 this study (DPF) Protein production 
pOPINM-CD1367 this study (DPF) Protein production 
pOPINM-CD1368 this study (DPF) Protein production 
pOPINM-CD1369 this study (DPF) Protein production 
pOPINM-CD1370 this study (DPF) Protein production 
pOPINM-CD1371 this study (DPF) Protein production 
pOPINM-CD1372 this study (DPF) Protein production 
pOPINM-CD1373 this study (DPF) Protein production 
pOPINM-CD1374_85-536 this study (DPF) Protein production 
pOPINM-CD1374_911-1420 this study (DPF) Protein production 
pOPINM-CD1374fl this study (DPF) Protein production 
p10$-CD10670 this study Protein production 
pMal-CD10670 this study Protein production 
pET-Sumo-CD10670 this study Protein production 
pET-Sumo-CD12190 this study Protein production 
p10$-CD18230 this study Protein production 
pET-Sumo-CD18230 this study Protein production 
p10$-CD25890 this study Protein production 
pET-Sumo-CD25890 this study Protein production 
pET-Sumo-CD25890-SER1 this study Protein production 
pMal-CD27520 this study Protein production 
pET-Sumo-CD27520 this study Protein production 
 
Table 39: Overview of produced constructs in E. coli with expression conditions used in this study. 
Protein E. coli strain Expression conditions Plasmid 
His6-Sumo-TcdB800-1834 BL21CodonPlus(DE3)RIL 4L LB medium, 0.5 mM IPTG, 20 °C, 16 h 
pOPINS3C-TcdB800-
1834 
His6-Sumo-TcdB800-1400 BL21CodonPlus(DE3)RIL 4L LB medium, 0.5 mM IPTG, 20 °C, 16 h 
pOPINS3C-TcdB800-
1400 
His6-Sumo-TcdB1500-1834 BL21CodonPlus(DE3)RIL 4L LB medium, 0.5 mM IPTG, 20 °C, 16 h 
pOPINS3C-
TcdB1500-1834 
His6-MBP-TcdB800-1100 BL21CodonPlus(DE3)RIL 4L autoinduction medium, 25 °C, 24 h 
pOPINM-TcdB800-
1100 
His6-MBP-TcdB1500-1834 BL21CodonPlus(DE3)RIL 4L autoinduction medium, 25 °C, 24 h 
pOPINM-TcdB1500-
1834 
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His6-T7-Lysozyme-
TcdB1349-1811 BL21CodonPlus(DE3)RIL 
8L LB medium, 0.5 mM 
IPTG, 20 °C, 16 h p10$-TcdB1349-1811 
His6-MBP-CD1363 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1363 
His6-MBP-CD1364 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1364 
His6-MBP-CD1367 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1367 
His6-MBP-CD1368 Rosetta2(DE3) 2L TB medium, 20 °C, 16 h, 0.5 mM IPTG pOPINM-CD1368 
His6-MBP-CD1369 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1369 
His6-MBP-CD1370 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1370 
His6-MBP-CD1371 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1371 
His6-MBP-CD1372 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1372 
His6-MBP-CD1373 BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h pOPINM-CD1373 
His6-MBP-CD1374 (85-536) BL21CodonPlus(DE3)RIL 2L autoinduction medium, 25 °C, 24 h 
pOPINM-CD1374 
(85-536) 
His6-MBP-CD1374 (911-
1420) Rosetta2(DE3) 
2L TB medium, 20 °C, 
16h, 1 mM IPTG 
pOPINM-CD1374 
(911-1420) 
His6-MBP-TcdB800-1834 
(synthetic TcdB) Rosetta2(DE3) 
4L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINM-TcdB800-
1834 (synthetic TcdB) 
His6-MBP-TcdB543-1834 
(synthetic TcdB) Rosetta2(DE3) 
8L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINM-TcdB543-
1834 (synthetic TcdB) 
His6-MBP-TcdB1490-1848 
(synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINM-TcdB1490-
1848 (synthetic TcdB) 
Strep-TcdB1490-1848 
(synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pPEU23-TcdB1490-
1848 (synthetic TcdB) 
His6-GST-TcdB1490-1848 
(synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINJ-TcdB1490-
1848 (synthetic TcdB) 
His6-MBP-TcdB1-1834 
(synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L LB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINM-TcdB1-1834 
(synthetic TcdB) 
Strep-TcdB1-1834 
 (synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L TB medium, 1 mM 
IPTG, 37 °C, 16 h 
pPEU23-TcdB1-1834 
(synthetic TcdB) 
His6-GST-TcdB1-1834 
(synthetic TcdB) BL21CodonPlus(DE3)RIL 
8L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pOPINJ-TcdB1-1834 
(synthetic TcdB) 
His6-T7-Lysozyme-CD2589 BL21CodonPlus(DE3)RIL 4L TB medium, 1 mM IPTG, 20 °C, 16 h p10$-CD2589 
His6-Sumo-CD1067 Rosetta2(DE3) 4L TB medium, 1 mM IPTG, 20 °C, 3 h pET-Sumo-CD1067 
His6-Sumo-CD2752 BL21CodonPlus(DE3)RIL 4L TB medium, 1 mM IPTG, 20 °C, 16 h pET-Sumo-CD2752 
His6-MBP-CD2752 Rosetta2(DE3) 4L TB medium, 1 mM IPTG, 20 °C, 16 h pMal-CD2752 
His6-MBP-CD1067 Rosetta2(DE3) 4L TB medium, 1 mM IPTG, 20 °C, 16 h pMal-CD1067 
His6-Sumo-CD1219 Rosetta2(DE3) 4L TB medium, 1 mM IPTG, 20 °C, 16 h pET-Sumo-CD1219 
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His6-Sumo-CD1823 BL21CodonPlus(DE3)RIL 4L TB medium, 1 mM IPTG, 20 °C, 16 h pET-Sumo-CD1823 
His6-Sumo-CD2589 
His6-Sumo-CD2589-SER1 Rosetta2(DE3) 
4L TB medium, 1 mM 
IPTG, 20 °C, 16 h 
pET-Sumo-CD2589 
pET-Sumo-CD2589-
SER1 
His6-T7-Lysozyme-CD1823 BL21CodonPlus(DE3)RIL 4L TB medium, 1 mM IPTG, 20 °C, 16 h p10$-CD1823 
His6-T7-Lysozyme-CD1067 Rosetta2(DE3) 4L TB medium, 1 mM IPTG, 20 °C, 16 h p10$-CD1067 
His6-T7-Lysozyme-CD2752 BL21CodonPlus(DE3)RIL 8L TB medium, 1 mM IPTG, 20 °C, 16 h p10$-CD2752 
 
 
Figure 81: Structure-based sequence alignment of the glucosyltransferase domain of TcdA (PDB-Code 3SRZ) 
and TcdB (PDB-Code 2BVL). Secondary structure elements of TcdA-GTD are depicted under the alignment, 
TcdB-GTD structure is illustrated above the alignment. Conserved residues are highlighted by a black box. α-
helices are depicted by spirals, β-strands by arrows. The secondary structure elements are numbered 
consecutively. 
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Figure 82: Structure-based sequence alignment of the autoprotease domain of TcdA (PDB-Code 3HO6) and 
TcdB (PDB-Code 3PEE). Secondary structure elements of TcdA-APD are depicted above the alignment, TcdB-
APD structure is illustrated under the alignment. Conserved residues are highlighted by a black box. α-helices 
are depicted by spirals, β-strands by arrows. The secondary structure elements are numbered consecutively. 
 
 
Figure 83: Structural alignment of the intermediate translocation domain of TcdA (PDB-Code 4R04, in blue) and 
the Phyre model of the TcdB translocation domain (yellow). 
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Figure 84: CD spectrum of native CD2589 in 20 mM Tris/HCl pH 8.0, 150 mM NaCl 
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